Package Rates

BARIATRIC SURGERY
எடை குறைப்பு அறுவை சிகிச்சை 		CARDIOLOGY
இருதய நோய் சிகிச்சை 		CARDIOTHORACIC SURGERIES
இருதய நோய் அறுவை சிகிச்சை 		DERMATOLOGY
தோல் நோய் சிகிச்சை 		E N T
காது மூக்கு தொண்டை சிகிச்சை 		Emergency Room Packages (Care requiring less than 12 hrs stay)
#N/A 		ENDOCRINE SURGERY
நாளமில்லா சுரப்பி அறுவை சிகிச்சை
ENDOCRINOLOGY
உட்சுரப்பி சிகிச்சை 		FOLLOW-UP
பின் தொடர் செயல்முறை 		GASTROENTEROLOGY
இரைப்பை குடல் சிகிச்சை 		GENERAL MEDICINE
பொது மருத்துவ சிகிச்சை 		GENERAL SURGERY
பொது அறுவை சிகிச்சை 		GENITOURINARY SURGERY
இருபாலார் சிறுநீரக நோய் சிகிச்சை 		GYNAECOLOGY OBSTETRIC SURGERY
இரத்தவகை சிகிச்சை
HEMATOLOGY
இரத்தவகை சிகிச்சை 		HEPATOLOGY
கல்லீரல் நோய் சிகிச்சை 		INFECTIOUS DISEASES - GENERAL MEDICINE
தொற்று நோய் சிகிச்சை 		INTERVENTIONAL CARDIOLOGY
இடையீடு இருதயவியல் 		INTERVENTIONAL RADIOLOGY
இடையீடு கதிர்வீச்சு இருதய சிகிச்சை 		MEDICAL GASTROENTROLOGY
இரைப்பை குடல் சிகிச்சை 		MEDICAL ONCOLOGY
புற்றுநோய் மருத்துவ சிகிச்சை
NEONATOLOGY
பச்சிளம் குழந்தைகள் சிகிச்சை 		NEPHROLOGY
சிறுநீரக சிகிச்சை 		NEUROLOGY
நரம்பியல் சிகிச்சை 		NEUROSURGERY
நரம்பியல் அறுவை சிகிச்சை 		OFMS
வாய் வழி மற்றும் தாடை அறுவை சிகிச்சை 		OPHTHALMOLOGY SURGERIES
கண் நோய் அறுவை சிகிச்சை 		ORTHOPEDIC TRAUMA
#N/A
ORTHOPEDICS
எலும்பியல் காயம் 		PAEDIATRIC INTENSIVE CARE
இளம் குழந்தைகள் தீவிர சிகிச்சை 		PAEDIATRIC SURGERIES
குழந்தை அறுவை சிகிச்சை 		PAEDIATRICS
குழந்தைகள் சிகிச்சை 		PLASTIC SURGERY
ஒட்டுறுப்பு அறுவை சிகிச்சை 		PMR
PSYCHIATRY
மனநல மருத்துவ சிகிச்சை
PULMONLOGY
நுரையீரல் சிகிச்சை 		RADIATION ONCOLOGY
கதிர்வீச்சு புற்றுநோய் சிகிச்சை 		REHABILITATION
மறுவாழ்வு 		RHEUMATOLOGY
முடக்கு வாதம் சிகிச்சை 		SPINE
தண்டுவடம் சிகிச்சை 		SURGICAL GASTRO ENTEROLOGY
இரைப்பை குடல் அறுவை சிகிச்சை 		SURGICAL ONCOLOGY
புற்றுநோய் அறுவை சிகிச்சை
THORACIC MEDICINE
நெஞ்சக நோய் சிகிச்சை 		VASCULAR SURGERIES
இரத்தநாள அறுவை சிகிச்சை

SNOPackage NameCategoryA1A2A3A4 A5A6S1S2
123 CMU0106 : BREAST CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
124 CMU0106 -a : BREAST CANCER - COMBINED REGIMEN AC & T MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
125 CMU0106 -a-I : BREAST CANCER - DOSE DENSE AC (ADRIAMYCIN/CYCLOPHOSPHAMIDE) ; (DAY 1 - DOXORUBICIN 60MG/M2 IV, CYCLOPHOSPHAMIDE 600MG/M2 IV) ; REPEAT CYCLE - EVERY 14 DAYS FOR 4 CYCLES; FOLLOWED BY PACLITAXEL FOR 4 CYCLES MEDICAL ONCOLOGY 3200 3200 3200 3200 3200 3200 3200 3200
126 CMU0106 -a-II : BREAST CANCER - PACLITAXEL (PRECEEDED BY DOSE DENSE AC - 4 CYCLES) ; (DAY 1 - PACLITAXEL 175MG/M2) REPEAT CYCLE - EVERY 14 DAYS FOR 4 CYCLES MEDICAL ONCOLOGY 7400 7400 7400 7400 7400 7400 7400 7400
127 CMU0106 -a-III : BREAST CANCER - PACLITAXEL (PRECEEDED BY DOSE DENSE AC - 4 CYCLES) ; (DAY 1 - PACLITAXEL 175MG/M2) REPEAT CYCLE - EVERY 21 DAYS FOR 4 CYCLES MEDICAL ONCOLOGY 7400 7400 7400 7400 7400 7400 7400 7400
128 CMU0106 -a-IV : BREAST CANCER - PACLITAXEL (PRECEEDED BY DOSE DENSE AC - 4 CYCLES) ; (DAY 1 - PACLITAXEL 80MG/M2) REPEAT CYCLE - WEEKLY FOR 12 CYCLES MEDICAL ONCOLOGY 3700 3700 3700 3700 3700 3700 3700 3700
129 CMU0106 -b : BREAST CANCER - TC (DOECTAXEL & CYCLOPHOSPHAMIDE) ; DAY 1 - DOCETAXEL 75MG/M2 IV, CYCLOPHOSPHAMIDE 600MG/M2 IV ; REPEAT CYCLE - EVERY 21 DAYS FOR 4 CYCLES MEDICAL ONCOLOGY 6300 6300 6300 6300 6300 6300 6300 6300
130 CMU0106 -c : BREAST CANCER - CMF (CYCLOPHOSPHAMIDE/METHOTREXATE/FLUOROURACIL) - (INCLUDES DAY 1 & DAY 8) ; DAYS 1-14 - CYCLOPHOSPHAMIDE 100MG/M2 ORALLY ; DAYS 1 AND 8 - METHOTREXATE 40MG/M2 IV ; DAYS 1 AND 8 - 5-FLUOROURACIL 600MG/M2 IV. ; REPEAT CYCLE - EVERY 28 DAYS FOR 6 CYCLES MEDICAL ONCOLOGY 2900 2900 2900 2900 2900 2900 2900 2900
131 CMU0106 -d : BREAST CANCER - EC (EPIRUBICIN/CYCLOPHOSPHAMIDE) ; DAY 1 - EPIRUBICIN 100MG/M2 IV ; DAY 1 - CYCLOPHOSPHAMIDE 830MG/M2 IV. ; REPEAT CYCLE - EVERY 21 DAYS FOR 8 CYCLES MEDICAL ONCOLOGY 5400 5400 5400 5400 5400 5400 5400 5400
132 CMU0106 -e : BREAST CANCER - FEC + T MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
133 CMU0106 -e-I : BREAST CANCER - FEC/CEF FOLLOWED BY T (FLUOROURACIL/EPIRUBICIN/CYCLOPHOSPHAMIDE) - FOLLOWED BY DOCETAXEL OR FOLLOWED BY WEEKLY PACLITAXEL) ; DAY 1 - 5-FLUOROURACIL 500MG/M2 IV ; DAY 1 - EPIRUBICIN 100MG/M2 IV ; DAY 1 - CYCLOPHOSPHAMIDE 500MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 3 CYCLES MEDICAL ONCOLOGY 5400 5400 5400 5400 5400 5400 5400 5400
134 CMU0106 -e-II : BREAST CANCER - DOCETAXEL - (PRECEEDED BY FEC/CEF ) ; DAY 1 - DOCETAXEL 100MG/M2 IV. ; REPEAT CYCLE - EVERY 21 DAYS FOR 3 CYCLES MEDICAL ONCOLOGY 5800 5800 5800 5800 5800 5800 5800 5800
135 CMU0106 -e-III : BREAST CANCER - PACLITAXEL - WEEKLY - (PRECEEDED BY FEC/CEF ) ; PACLITAXEL 100MG/M2 IV ; REPEAT CYCLE - ONCE WEEKLY FOR 8 WEEKS MEDICAL ONCOLOGY 3700 3700 3700 3700 3700 3700 3700 3700
136 CMU0106 -f : BREAST CANCER - FAC + T MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
137 CMU0106 -f-I : BREAST CANCER - FAC FOLLOWED BY T (FLUOROURACIL/ADRIAMYCIN/CYCLOPHOSPHAMIDE) - FOLLOWED BY WEEKLY PACLITAXEL ; 5-FLUOROURACIL 500MG/M2 IV DAYS 1 AND 8 OR 1 AND 4 - ; DAY 1 - DOXORUBICIN 50MG/M2 IV ; DAY 1 - CYCLOPHOSPHAMIDE 500MG/M2 IV. ; REPEAT CYCLE - EVERY 21 DAYS FOR 6 CYCLES MEDICAL ONCOLOGY 3400 3400 3400 3400 3400 3400 3400 3400
138 CMU0106 -f-II : BREAST CANCER - PACLITAXEL - WEEKLY - PRECEEDED BY FAC ; PACLITAXEL 80MG/M2 IV ; REPEAT CYCLE WEEKLY FOR 12 WEEKS. MEDICAL ONCOLOGY 3700 3700 3700 3700 3700 3700 3700 3700
139 CMU0106 -g : BREAST CANCER - TAC (DOCETAXEL/ADRIAMYCIN/CYCLOPHOSPHAMIDE) ; DAY 1 - DOXORUBICIN 60MG/M2 IV ; DAY 1 - CYCLOPHOSPHAMIDE 600MG/M2 IV. ; DAY 1 - DOCETAXEL 100MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 4 CYCLES, MEDICAL ONCOLOGY 5900 5900 5900 5900 5900 5900 5900 5900
140 CMU0106 -h : BREAST CANCER - AC FOLLOWED BY T + TRASTUZUMAB MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
141 CMU0106 -h-I : BREAST CANCER - AC - FOLLOWED BY PACLITAXEL + TRASTUZUMAB +/- PERTUZUMAB ; DAY 1 - DOXORUBICIN 60MG/M2 IV ; DAY 1 - CYCLOPHOSPHAMIDE 600MG/M2 IV. ; REPEAT CYCLE - EVERY 21 DAYS FOR 4 CYCLE MEDICAL ONCOLOGY 3200 3200 3200 3200 3200 3200 3200 3200
142 CMU0106 -h-II : BREAST CANCER - PACLITAXEL (PRECEEDED BY AC) ; (TO BE CHOOSEN ALONG WITH TRASTUZUMAB PACKAGE) ; PACLITAXEL 80MG/M2 IV. ; REPEAT CYCLE WEEKLY FOR 12 WEEKS. MEDICAL ONCOLOGY 3700 3700 3700 3700 3700 3700 3700 3700
143 CMU0106 -h-III : BREAST CANCER - TRASTUZUMAB (6MG) ; (TO BE CHOOSEN ALONG WITH PACLITAXEL PACKAGE) ; DAY 1 - TRASTUZUMAB 6MG/KG IV ; REPEAT CYCLE EVERY 21 DAYS TO COMPLETE 1 YEAR. ; (TO BE APPROVED WITH PACLITAXEL CYCLE 1, 4, 7, 10 AND STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS) MEDICAL ONCOLOGY 26000 26000 26000 26000 26000 26000 26000 26000
144 CMU0106 -h-IV : BREAST CANCER - TRASTUZUMAB 4MG (FOLLOWED BY TRASTUZUMAB 2MG SUBSEQUENT WEEKS) ; (TO BE CHOOSEN ALONG WITH PACLITAXEL PACKAGE) ; DAY 1 - TRASTUZUMAB 4MG/KG IV WITH FIRST DOSE OF PACLITAXEL. ; (FIRST DOSE - ONLY TO BE APPROVED WITH PACLITAXEL CYCLE 1. SUBSEQUENT CYCLES - 2MG PACKAGE ONLY) MEDICAL ONCOLOGY 26000 26000 26000 26000 26000 26000 26000 26000
145 CMU0106 -h-V : BREAST CANCER - TRASTUZUMAB 2MG (SUBSEQUENT DOSES) ; (TO BE CHOOSEN ALONG WITH PACLITAXEL PACKAGE) ; DAY 1 - TRASTUZUMAB 2MG/KG IV WEEKLY TILL ONE YEAR FROM DAY 1 OF AC. ; (TO BE APPROVED WITH PACLITAXEL CYCLES 2 - 12 AND STANDALONE FOR THE UPTO 1 YEAR EVERY WEEK) MEDICAL ONCOLOGY 9800 9800 9800 9800 9800 9800 9800 9800
146 CMU0106 -i : BREAST CANCER - TCH MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
147 CMU0106 -i-I : BREAST CANCER - TC (DOCETAXEL/CARBOPLATIN) ; (TO BE CHOOSEN ALONG WITH TRASTUZUMAB PACKAGE) ; DAY 1 - DOCETAXEL 75MG/M2 IV; CARBOPLATIN AUC 6MG PER MIN/ML IV. ; EVERY 21 DAYS FOR 6 CYCLES MEDICAL ONCOLOGY 7500 7500 7500 7500 7500 7500 7500 7500
148 CMU0106 -i-II : BREAST CANCER - TRASTUZUMAB (6MG) ; (TO BE CHOOSEN ALONG WITH TC PACKAGE) ; TRASTUZUMAB 6MG/KG IV ; REPEAT CYCLE EVERY 21 DAYS TO COMPLETE 1 YEAR. ; (TO BE APPROVED WITH TC CYCLE 1 TO 6 AND STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS (OR) AFTER COMPLETION OF WEEKLY TRASTUZUMAB FOR 18 WEEKS AS STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS) MEDICAL ONCOLOGY 26000 26000 26000 26000 26000 26000 26000 26000
149 CMU0106 -i-III : BREAST CANCER - TRASTUZUMAB 4MG (FIRST DOSE - ONLY) - FOLLOWED BY 2MG ; (TO BE CHOOSEN ALONG WITH TC PACKAGE) ; DAY 1 - TRASTUZUMAB 4MG/KG IV ; (FIRST DOSE - ONLY TO BE APPROVED WITH TC CYCLE 1. SUBSEQUENT CYCLES - 2MG PACKAGE ONLY) MEDICAL ONCOLOGY 26000 26000 26000 26000 26000 26000 26000 26000
150 CMU0106 -i-IV : BREAST CANCER - TRASTUZUMAB 2MG (SUBSEQUENT DOSES - WEEKLY) ; TRASTUZUMAB 2MG/KG IV ; (TO BE APPROVED WEEKLY FOR 17 WEEEKS MAY OVERLAP WITH TC CYCLES 2 - 6. TO BE FOLLOWED BY TRASTUZUMAB (6MG) PACKAGE UPTO 1 YEAR MEDICAL ONCOLOGY 9800 9800 9800 9800 9800 9800 9800 9800
151 CMU0106 -j : BREAST CANCER - AC FOLLOWED BY DOCETAXEL + TRASTUZUMAB MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
152 CMU0106 -j-I : BREAST CANCER - AC - FOLLOWED BY DOCETAXEL + TRASTUZUMAB ; DAY 1 - DOXORUBICIN 60MG/M2 IV; DAY 1 - CYCLOPHOSPHAMIDE 600MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 4 CYCLES, MEDICAL ONCOLOGY 3200 3200 3200 3200 3200 3200 3200 3200
153 CMU0106 -j-II : BREAST CANCER - DOCETAXEL (PRECEEDED BY AC) + TRASTUZUMAB ; (TO BE CHOOSEN ALONG WITH TRASTUZUMAB PACKAGE) ; DAY 1 - DOCETAXEL 100MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 4 CYCLES MEDICAL ONCOLOGY 5700 5700 5700 5700 5700 5700 5700 5700
154 CMU0106 -j-III : BREAST CANCER - TRASTUZUMAB (6MG) ; (TO BE CHOOSEN ALONG WITH DOCETAXEL PACKAGE) ; DAY 1 - TRASTUZUMAB 6MG/KG IV ; REPEAT EVERY 21 DAYS TILL 1 YEAR ; (TO BE APPROVED WITH DOCETAXEL CYCLE 1 TO 4 AND STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS (OR) OR FROM 13 TH WEEK AFTER COMPLETION OF 12 WEEKS OF WEEKLY TRASTUZUMAB - UPTO 1 YEAR EVERY 21 DAYS) MEDICAL ONCOLOGY 26000 26000 26000 26000 26000 26000 26000 26000
155 CMU0106 -j-IV : BREAST CANCER - TRASTUZUMAB 4MG (FIRST DOSE - ONLY) - FOLLOWED BY 2MG ; (TO BE CHOOSEN ALONG WITH DOCETAXEL PACKAGE) ; TRASTUZUMAB 4MG/KG IV ; (FIRST DOSE - ONLY TO BE APPROVED WITH DOCETAXEL CYCLE 1. SUBSEQUENT CYCLES - 2MG PACKAGE ONLY) MEDICAL ONCOLOGY 26000 26000 26000 26000 26000 26000 26000 26000
156 CMU0106 -j-V : BREAST CANCER - TRASTUZUMAB 2MG (SUBSEQUENT DOSES) ; TRASTUZUMAB 2MG/KG IV ; (TO BE APPROVED WEEKLY FOR 11 WEEEKS MAY OVERLAP WITH DOCETAXEL CYCLES 2 - 4. TO BE FOLLOWED BY TRASTUZUMAB (6MG) PACKAGE UPTO 1 YEAR) MEDICAL ONCOLOGY 9800 9800 9800 9800 9800 9800 9800 9800
157 CMU0106 -k : BREAST CANCER - DOCETAXEL + CYCLOPHOSPHAMIDE + TRASTUZUMAB MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
158 CMU0106 -k-I : BREAST CANCER - DOCETAXEL + CYCLOPHOSPHAMIDE - WITH TRASTUZUMAB ; (TO BE CHOOSEN ALONG WITH TRASTUZUMAB PACKAGE) ; DAY 1 - DOCETAXEL 75MG/M2 IV; CYCLOPHOSPHAMIDE 600MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 4 CYCLES, MEDICAL ONCOLOGY 5300 5300 5300 5300 5300 5300 5300 5300
159 CMU0106 -k-II : BREAST CANCER - TRASTUZUMAB (6MG) ; (TO BE CHOOSEN ALONG WITH DOCETAXEL + CYCLOPHOSPHAMIDE PACKAGE) ; DAY 1 - TRASTUZUMAB 6MG/KG IV ; (TO BE APPROVED WITH DOCETAXEL + CYCLOPHOSPHAMIDE CYCLE 1 TO 4 AND STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS (OR) AFTER COMPLETION OF WEEKLY TRASTUZUMAB FOR 12 WEEKS AS STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS) MEDICAL ONCOLOGY 26000 26000 26000 26000 26000 26000 26000 26000
160 CMU0106 -k-III : BREAST CANCER - TRASTUZUMAB 4MG (FIRST DOSE - ONLY) - FOLLOWED BY 2MG ; (TO BE CHOOSEN ALONG WITH DOCETAXEL + CYCLOPHOSPHAMIDE PACKAGE) ; TRASTUZUMAB 4MG/KG IV ; (FIRST DOSE - ONLY TO BE APPROVED WITH DOCETAXEL + CYCLOPHOSPHAMIDE CYCLE 1. SUBSEQUENT CYCLES - 2MG PACKAGE ONLY) MEDICAL ONCOLOGY 26000 26000 26000 26000 26000 26000 26000 26000
161 CMU0106 -k-IV : BREAST CANCER - TRASTUZUMAB 2MG (SUBSEQUENT DOSES) ; TRASTUZUMAB 2MG/KG IV ; (TO BE APPROVED WEEKLY FOR 11 WEEEKS MAY OVERLAP WITH DOCETAXEL + CYCLOPHOSPHAMIDE CYCLES 2 - 4. TO BE FOLLOWED BY TRASTUZUMAB (6MG) PACKAGE UPTO 1 YEAR) MEDICAL ONCOLOGY 9800 9800 9800 9800 9800 9800 9800 9800
162 CMU0106 -L : BREAST CANCER - PACLITAXEL + TRASTUZUMAB MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
163 CMU0106 -L-I : BREAST CANCER - PACLITAXEL - (WITH TRASTUZUMAB) ; (TO BE CHOOSEN ALONG WITH TRASTUZUMAB PACKAGE) ; PACLITAXEL 80MG/M2 IV. ; REPEAT CYCLE WEEKLY FOR 12 WEEKS. MEDICAL ONCOLOGY 3200 3200 3200 3200 3200 3200 3200 3200
164 CMU0106 -L-II : BREAST CANCER - TRASTUZUMAB (6MG) ; TRASTUZUMAB 6MG/KG IV ; REPEAT EVERY 21 DAYS ; (TO BE APPROVED AFTER COMPLETION OF WEEKLY TRASTUZUMAB FOR 12 WEEKS AS STANDALONE FOR THE UPTO 1 YEAR EVERY 21 DAYS) MEDICAL ONCOLOGY 26000 26000 26000 26000 26000 26000 26000 26000
165 CMU0106 -L-III : BREAST CANCER - TRASTUZUMAB 4MG (FIRST DOSE - ONLY) - FOLLOWED BY 2MG ; (TO BE CHOOSEN ALONG WITH PACLITAXEL PACKAGE) ; TRASTUZUMAB 4MG/KG IV WITH FIRST DOSE OF PACLITAXEL. ; (FIRST DOSE - ONLY TO BE APPROVED WITH PACLITAXEL CYCLE 1. SUBSEQUENT CYCLES - 2MG PACKAGE ONLY) MEDICAL ONCOLOGY 26000 26000 26000 26000 26000 26000 26000 26000
166 CMU0106 -L-IV : BREAST CANCER - TRASTUZUMAB 2MG (SUBSEQUENT DOSES) ; (TO BE CHOOSEN ALONG WITH PACLITAXEL PACKAGE) ; DAY 1 - TRASTUZUMAB 2MG/KG IV WEEKLY ; (TO BE APPROVED WITH PACLITAXEL CYCLES 2 - 12. MAY BE APPROVED AS STANDALONE FOR THE UPTO 1 YEAR EVERY WEEK OR TRASTUZUMAB 6MG PACKAGE MAY BE USED ONCE EVERY 21 DAYS UPTO 1 YEAR) MEDICAL ONCOLOGY 9800 9800 9800 9800 9800 9800 9800 9800
167 CMU0106 -N : BREAST CANCER - TAMOXIFEN MEDICAL ONCOLOGY 100 100 100 100 100 100 100 100
168 CMU0106 -O : BREAST CANCER - AROMATASE INHIBITORS MEDICAL ONCOLOGY 1100 1100 1100 1100 1100 1100 1100 1100
169 CMU0106 -P : BREAST CANCER - ZOLEDRONIC ACID FOR SKELETAL METASTASIS MEDICAL ONCOLOGY 2900 2900 2900 2900 2900 2900 2900 2900
170 CMU0107 : BLADDER CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
171 CMU0107 -a-I : BLADDER CANCER - DDMVAC ; DAY 1 - METHOTREXATE 30MG/M2 IV; DAY 2 - VINBLASTINE 3MG/M2 IV, DOXORUBICIN 30MG/M2 IV, CISPLATIN 70MG/M2 IV; ; REPEAT EVERY 2 WEEKS FOR 3-4 CYCLES MEDICAL ONCOLOGY 4000 4000 4000 4000 4000 4000 4000 4000
172 CMU0107 -a-II : BLADDER CANCER - GEMCITABINE + CISPLATIN ; DAYS 1, 8, AND 15 - GEMCITABINE 1, 000MG/M2 IV; DAY 2 - CISPLATIN 70MG/M2. ; REPEAT EVERY 4 WEEKS FOR 4 CYCLES. MEDICAL ONCOLOGY 6700 6700 6700 6700 6700 6700 6700 6700
173 CMU0107 -a-III : BLADDER CANCER - CISPLATIN + METHOTREXATE + VINBLASTINE (CMV) ; DAY 1 - METHOTREXATE 30MG/M2 IV, VINBLASTINE 4MG/M2 IV; DAY 2 - CISPLATIN 100MG/M2 IV, LEUCOVORIN 15MG ORAL OR IV EVERY 6 HOURS FOR 4 DOSES; DAY 8 - METHOTREXATE 30MG/M2 IV, VINBLASTINE 4MG/M2 IV DAY 9 - LEUCOVORIN 15MG ORAL EVERY 6 HOURS FOR 4 DOSES ; REPEAT EVERY 3 WEEKS FOR 3 CYCLES. MEDICAL ONCOLOGY 5100 5100 5100 5100 5100 5100 5100 5100
174 CMU0107 -a-IV : BLADDER CANCER - RADIOSENSITIZING - CISPLATINC + 5-FU ; DAYS 1, 2, 3, 15, 16, AND 17 - IV HYDRATION AT A RATE OF 500ML/HOUR; FOLLOWED BY 5-FU 400MG/M2 IV PUSH; FOLLOWED BY CISPLATIN 15MG/M2 IV OVER 1 HOUR AS INDUCTION AND CONSOLIDATION THERAPY MEDICAL ONCOLOGY 10300 10300 10300 10300 10300 10300 10300 10300
175 CMU0107 -a-V : BLADDER CANCER -RADIOSENSITIZING - CISPLATIN + PACLITAXEL ; DAYS 1, 8, AND 15 - PACLITAXEL 50MG/M2 ; DAY 1-3, 8-10, 15-17 - CISPLATIN 15MG/M2; FOLLOWED BY TWICE-DAILY RADIOTHERAPY FOR 8 DAYS MEDICAL ONCOLOGY 19300 19300 19300 19300 19300 19300 19300 19300
176 CMU0107 -a-VI : BLADDER CANCER -RADIOSENSITIZING - 5-FU + MITOMYCIN32 ; DAY 1 OF RADIOTHERAPY - MITOMYCIN 12MG/M2 IV BOLUS, PLUS ; WEEK 1 (FRACTIONS 1-5) AND WEEK 4 (FRACTIONS 16-20) OF RADIOTHERAPY - 5-FU 500MG/M2 CONTINUOUS IV INFUSION (10 DAYS TOTAL) MEDICAL ONCOLOGY 15900 15900 15900 15900 15900 15900 15900 15900
177 CMU0107 -c : BLADDER CANCER - CONCURRENT CISPLATIN; CISPLATIN 40MG/M2 IV ONCE WEEKLY FOR UP TO 5 CYCLES MEDICAL ONCOLOGY 1900 1900 1900 1900 1900 1900 1900 1900
178 CMU0108 : LUNG CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
179 CMU0108 -i : LUNG CANCER - MESOTHELIOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
180 CMU0108 -i-a : LUNG CANCER - MESOTHELIOMA - PEMETREXED + CISPLATIN ; DAY 1 - PEMETREXED 500MG/M2 IV, CISPLATIN 75MG/M2 ; REPEAT EVERY 21 DAYS UP TO 12 CYCLES. MEDICAL ONCOLOGY 15200 15200 15200 15200 15200 15200 15200 15200
181 CMU0108 -i-b : LUNG CANCER - MESOTHELIOMA - PEMETREXED + CARBOPLATIN ; DAY 1 - PEMETREXED 500MG/M2 IV, CARBOPLATIN AUC 5MG/MIN/ML IV. ; REPEAT EVERY 21 DAYS FOR A MAX OF 9 CYCLES. MEDICAL ONCOLOGY 17300 17300 17300 17300 17300 17300 17300 17300
182 CMU0108 -i-c : LUNG CANCER - MESOTHELIOMA - CISPLATIN & GEMCITABINE ; DAY 1 - CISPLATIN 80-100MG/M2 IV ; DAYS 1, 8, AND 15 - GEMCITABINE 1000-1250MG/M2 IV ; REPEAT EVERY 21 - 28 DAYS FOR 6 CYCLES. MEDICAL ONCOLOGY 8000 8000 8000 8000 8000 8000 8000 8000
183 CMU0108 -i-d : LUNG CANCER - MESOTHELIOMA - VINORELBINE ; VINORELBINE 25-30MG/M2 (MAX 60MG) IV ; REPEAT EVERY WEEK FOR 12 WEEKS. MEDICAL ONCOLOGY 9500 9500 9500 9500 9500 9500 9500 9500
184 CMU0108 -i-e : LUNG CANCER - MESOTHELIOMA - PEMETREXED ; DAY 1 - PEMETREXED 500MG/M2 IV. ; REPEAT EVERY 21 DAYS FOR 4 CYCLES (IF FIRST LINE) OR REPEAT EVERY 21 DAYS FOR 8 CYCLES (IF SECOND LINE) MEDICAL ONCOLOGY 15200 15200 15200 15200 15200 15200 15200 15200
185 CMU0108 -i-f : LUNG CANCER - MESOTHELIOMA - GEMCITABINE ; DAYS 1, 8, AND 15 - GEMCITABINE 1250MG/M2 IV. ; REPEAT EVERY 28 DAYS FOR A MAX OF 10 CYCLES. MEDICAL ONCOLOGY 8000 8000 8000 8000 8000 8000 8000 8000
186 CMU0108 -ii : LUNG CANCER - NSCLC MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
187 CMU0108 -ii-a : LUNG CANCER - NSCLC - CISPLATIN & VINORELBINE - (I) ; DAYS 1 AND 8 - CISPLATIN 50MG/M2 IV AND DAYS 1, 8, 15 AND 22 - VINORELBINE 25MG/M2 IV ; (OR) ; DAY 1 - CISPLATIN 100MG/M2 IV AND DAYS 1, 8, 15 AND 22 - VINORELBINE 30MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES. MEDICAL ONCOLOGY 35300 35300 35300 35300 35300 35300 35300 35300
188 CMU0108 -ii-b : LUNG CANCER - NSCLC - CISPLATIN & VINORELBINE - (II) ; DAY 1 - CISPLATIN 75-80MG/M2 ; DAYS 1 AND 8 - VINORELBINE 25-30MG/M2. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES MEDICAL ONCOLOGY 18800 18800 18800 18800 18800 18800 18800 18800
189 CMU0108 -ii-c : LUNG CANCER - NSCLC - CISPLATIN & ETOPOSIDE ; DAY 1 - CISPLATIN 100MG/M2 IV ; DAYS 1-3 - ETOPOSIDE 100MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES MEDICAL ONCOLOGY 5200 5200 5200 5200 5200 5200 5200 5200
190 CMU0108 -ii-d : LUNG CANCER - NSCLC - CISPLATIN & DOCETAXEL ; DAY 1 - DOCETAXEL 75MG/M2 IV, CISPLATIN 75MG/M2 IV. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES. MEDICAL ONCOLOGY 6600 6600 6600 6600 6600 6600 6600 6600
191 CMU0108 -ii-e : LUNG CANCER - NSCLC - CISPLATIN & GEMCITABINE ; DAY 1 - CISPLATIN 75MG/M2 IV ; DAYS 1 AND 8 - GEMCITABINE 1, 250MG/M2 IV. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES MEDICAL ONCOLOGY 6400 6400 6400 6400 6400 6400 6400 6400
192 CMU0108 -ii-f : LUNG CANCER - NSCLC - PEMETREXED + CISPLATIN (FOR NON SQUAMOUS CELL CA) ; DAY 1 - CISPLATIN 75MG/M2 IV, PEMETREXED 500MG/M2 IV. ; REPEAT EVERY - 21 DAYS FOR 4 CYCLES. MEDICAL ONCOLOGY 15200 15200 15200 15200 15200 15200 15200 15200
193 CMU0108 -ii-g : LUNG CANCER - NSCLC - PACLITAXEL/CARBOPLATIN ; DAY 1 - PACLITAXEL 200MG/M2 IV, CARBOPLATIN AUC 6MG PER MIN/ML IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 4 CYCLES. MEDICAL ONCOLOGY 8500 8500 8500 8500 8500 8500 8500 8500
194 CMU0108 -ii-h : LUNG CANCER - NSCLC - CISPLATIN & ETOPOSIDE ; DAYS 1, 8, 29 AND 36 - CISPLATIN 50MG/M2 IV ; DAYS 1-5 AND 29-33 - ETOPOSIDE 50MG/M2 IV ; CONCURRENT THORACIC RADIOTHERAPY 1.8GY/DAY FOR 5 DAYS/WEEK (TOTAL DOSE, 61GY). MEDICAL ONCOLOGY 8900 8900 8900 8900 8900 8900 8900 8900
195 CMU0108 -iii : LUNG CANCER - SCLC MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
196 CMU0108 -ii-i : LUNG CANCER - NSCLC - CISPLATIN & VINBLASTINE ; DAYS 1 AND 29 - CISPLATIN 100MG/M2 IV ; DAYS 1, 8, 15, 22 AND 29 - VINBLASTINE 5MG/M2 IV ; CONCURRENT THORACIC RADIOTHERAPY (TOTAL DOSE, 60GY). MEDICAL ONCOLOGY 8600 8600 8600 8600 8600 8600 8600 8600
197 CMU0108 -iii-a : LUNG CANCER - SCLC - CISPLATIN & ETOPOSIDE ; DAY 1 - CISPLATIN 60MG/M2 IV, DAYS 1-3 - ETOPOSIDE 120MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR AT LEAST 4 CYCLES. ;(OR) ; DAY 1 - CISPLATIN 80MG/M2 IV, DAYS 1-3 - ETOPOSIDE 100MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4-6 CYCLES. MEDICAL ONCOLOGY 5200 5200 5200 5200 5200 5200 5200 5200
198 CMU0108 -iii-b : LUNG CANCER - SCLC - CARBOPLATIN & ETOPOSIDE ; DAY 1 - CARBOPLATIN AUC 5-6MG PER MIN/ML IV ; DAYS 1-3 - ETOPOSIDE 100MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS OR 28 DAYS FOR 4 - 6 CYCLES MEDICAL ONCOLOGY 6800 6800 6800 6800 6800 6800 6800 6800
199 CMU0108 -iii-c : LUNG CANCER - SCLC - CISPLATIN + IRINOTECAN ; DAY 1 - CISPLATIN 60MG/M2 IV. ; DAYS 1, 8, AND 15 - IRINOTECAN 60MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES. MEDICAL ONCOLOGY 6100 6100 6100 6100 6100 6100 6100 6100
200 CMU0108 -iii-d : LUNG CANCER - SCLC - CISPLATIN + IRINOTECAN ; DAY 1 AND 8 - CISPLATIN 30MG/M2 IV, IRINOTECAN 65MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 4-6 CYCLES. MEDICAL ONCOLOGY 6000 6000 6000 6000 6000 6000 6000 6000
201 CMU0108 -iii-e : LUNG CANCER - SCLC - CARBOPLATIN & IRINOTECAN ; DAY 1 - CARBOPLATIN AUC 5MG PER MIN/ML IV ; DAYS 1, 8, AND 15 - IRINOTECAN 50MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES MEDICAL ONCOLOGY 8100 8100 8100 8100 8100 8100 8100 8100
202 CMU0108 -ii-j : LUNG CANCER - NSCLC - CARBOPLATIN + PEMETREXED ; DAY 1 - CARBOPLATIN AUC 5MG PER MIN/ML IV ; DAY 1 - PEMETREXED 500 MG/M2 IV ; WITH CONCURRENT THORACIC RADIOTHERAPY. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES. MEDICAL ONCOLOGY 17300 17300 17300 17300 17300 17300 17300 17300
203 CMU0108 -ii-k : LUNG CANCER - NSCLC - CISPLATIN + PEMETREXED ; DAY 1 - CISPLATIN 75 MG/M2 IV. ; DAY 1 - PEMETREXED 500 MG/M2 IV ; WITH CONCURRENT THORACIC RADIOTHERAPY. ; REPEAT EVERY 3 WEEKS FOR 3 CYCLES. MEDICAL ONCOLOGY 15700 15700 15700 15700 15700 15700 15700 15700
204 CMU0108 -ii-l : LUNG CANCER - NSCLC - PACLITAXEL + CARBOPLATIN ; PACLITAXEL 45MG/M2 IV + CARBOPLATIN AUC 2MG PER MIN/ML IV ; WITH CONCURRENT THORACIC RADIOTHERAPY (TOTAL DOSE, 60GY) ; REPEAT WEEKLY FOR 6 WEEKS MEDICAL ONCOLOGY 3500 3500 3500 3500 3500 3500 3500 3500
205 CMU0109 : OESOPHAGEAL CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
206 CMU0109 -i : ESOPHAGEAL CANCER - NEO ADJUVANT MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
207 CMU0109 -i-a : ESOPHAGEAL CANCER - NEO ADJUVANT - PACLITAXEL + CARBOPLATIN ; DAY 1 - PACLITAXEL 50MG/M2 IV + CARBOPLATIN AUC 2MG/MIN/ML IV. ; REPEAT WEEKLY FOR 5 WEEKS MEDICAL ONCOLOGY 3500 3500 3500 3500 3500 3500 3500 3500
208 CMU0109 -i-b : ESOPHAGEAL CANCER - NEO ADJUVANT - FLUOROURACIL & CISPLATIN ; DAYS 1 AND 29 - CISPLATIN 75-100MG/M2 IV ; DAYS 1-4 AND 29-32 - 5-FU 750-1, 000MG/M2 IV. MEDICAL ONCOLOGY 12600 12600 12600 12600 12600 12600 12600 12600
209 CMU0109 -i-c : ESOPHAGEAL CANCER - NEO ADJUVANT - FLUOROURACIL & CISPLATIN ; DAYS 1-5 - CISPLATIN 15MG/M2 IV DAILY ; DAYS 1-5 AND DAYS 22-26 - 5-FU 800 MG/M2 IV ; REPEAT EVERY 21 DAYS FOR 2 CYCLES MEDICAL ONCOLOGY 7500 7500 7500 7500 7500 7500 7500 7500
210 CMU0109 -i-d : ESOPHAGEAL CANCER - NEO ADJUVANT - FLUOROURACIL + OXALIPLATIN + LEUCOVORIN ; DAY 1 - OXALIPLATIN 85MG/M2, LEUCOVORIN 200MG/M2 AND 5-FU 400MG/M2 BOLUS, WITH 1, 600MG/M2 INFUSION; ; REPEAT EVERY 14 DAYS FOR 6 CYCLES MEDICAL ONCOLOGY 4800 4800 4800 4800 4800 4800 4800 4800
211 CMU0109 -i-e : ESOPHAGEAL CANCER - NEO ADJUVANT - CISPLATIN + CAPECITABINE ; DAY 1 - CISPLATIN 30MG/M2 IV ; DAYS 1-5 - CAPECITABINE 800MG/M2 ORALLY TWICE DAILY ; REPEAT CYCLE WEEKLY FOR 5 WEEKS MEDICAL ONCOLOGY 2600 2600 2600 2600 2600 2600 2600 2600
212 CMU0109 -i-f : ESOPHAGEAL CANCER - NEO ADJUVANT - FLUOROURACIL & OXALIPLATIN ; DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-33 - 5-FU 180MG/M2/DAY IV MEDICAL ONCOLOGY 27100 27100 27100 27100 27100 27100 27100 27100
213 CMU0109 -i-g : ESOPHAGEAL CANCER - NEO ADJUVANT - OXALIPLATIN + CAPECITABINE ; DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY FOR 5 WEEKS. MEDICAL ONCOLOGY 9400 9400 9400 9400 9400 9400 9400 9400
214 CMU0109 -i-h : ESOPHAGEAL CANCER - NEO ADJUVANT - IRINOTECAN & CISPLATIN ; DAYS 1, 8, 22, AND 29 - IRINOTECAN 65MG/M2 IV, CISPLATIN 30MG/M2 IV. MEDICAL ONCOLOGY 10200 10200 10200 10200 10200 10200 10200 10200
215 CMU0109 -ii : ESOPHAGEAL CANCER - PERI-OPERATIVE MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
216 CMU0109 -i-i : ESOPHAGEAL CANCER - NEO ADJUVANT - FLUOROURACIL & PACLITAXEL ; DAY 1 - PACLITAXEL 45MG/M2 IV ; DAYS 1-5 - 5-FU 300MG/M2/DAY IV INFUSION. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS. MEDICAL ONCOLOGY 5800 5800 5800 5800 5800 5800 5800 5800
217 CMU0109 -ii-a : ESOPHAGEAL CANCER - PERI-OPERATIVE - ECF (EPIRUBICIN/CISPLATIN/FLUOROURACIL) ; DAY 1 - EPIRUBICIN 50MG/M2 IV; CISPLATIN 60MG/M2 IV ; DAYS 1-21 - 5-FU 200MG/M2 IV CONTINUOUS INFUSION ONCE DAILY; ; REPEAT EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY MEDICAL ONCOLOGY 17600 17600 17600 17600 17600 17600 17600 17600
218 CMU0109 -ii-b : ESOPHAGEAL CANCER - PERI-OPERATIVE - EOF (EPIRUBICIN/CISPLATIN/FLUOROURACIL) ; DAY 1 - EPIRUBICIN 50MG/M2 IV; OXALIPLATIN 130MG/M2 IV ; DAYS 1-21 - 5-FU 200MG/M2 IV; ; REPEAT EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY. MEDICAL ONCOLOGY 19700 19700 19700 19700 19700 19700 19700 19700
219 CMU0109 -ii-c : ESOPHAGEAL CANCER - PERI-OPERATIVE - EOC (EPIRUBICIN/CISPLATIN/FLUOROURACIL) ; DAY 1 - EPIRUBICIN 50MG/M2 IV; OXALIPLATIN 130MG/M2 IV ; DAYS 1-21 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY. ; REPEAT EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY. MEDICAL ONCOLOGY 8200 8200 8200 8200 8200 8200 8200 8200
220 CMU0109 -ii-d : ESOPHAGEAL CANCER - PERI-OPERATIVE - FLUOROURACIL & CISPLATIN ; DAYS 1 AND 29 - CISPLATIN 75-100MG/M2 IV ; DAYS 1-4 AND 29-32 - 5-FU 750-1, 000MG/M2 IV ; REPEAT CYCLE EVERY 28 DAYS FOR 2-4 CYCLES MEDICAL ONCOLOGY 12600 12600 12600 12600 12600 12600 12600 12600
221 CMU0109 -ii-e : ESOPHAGEAL CANCER - PERI-OPERATIVE - FLUOROURACIL & CISPLATIN ; DAYS 1-5 - CISPLATIN 15MG/M2 IV DAILY ; DAYS 1-5 - 5-FU 800 MG/M2 IV CONTINUOUS INFUSION OVER 24 HOURS. ; CYCLED EVERY 21 DAYS FOR 2 CYCLESCYCLED EVERY 21 DAYS FOR 2 CYCLES MEDICAL ONCOLOGY 7500 7500 7500 7500 7500 7500 7500 7500
222 CMU0109 -iii : ESOPHAGEAL CANCER - POST-OPERATIVE MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
223 CMU0109 -iii-a : ESOPHAGEAL CANCER - POST-OPERATIVE - FLUOROURACIL + LEUCOVORIN (I) ; DAYS 1-5 - 5-FU 425MG/M2/DAY IV AND LEUCOVORIN 20MG/M2/DAY IV, FOLLOWED BY 4 WEEKS BREAK AND CCRT ; RT DAYS 1-4 AND 23-25 - 5-FU 400MG/M2/DAY IV AND LEUCOVORIN 20MG/M2/DAY IV FOLLOWED BY ONE MONTH BREAK AND ; DAYS 1-5 - 5-FU 425MG/M2/DAY IV AND LEUCOVORIN 20MG/M2/DAY IV FOLLOWED BY ONE MONTH BREAK AND ; DAYS 1-5 - 5-FU 425MG/M2/DAY IV AND LEUCOVORIN 20MG/M2/DAY IV. MEDICAL ONCOLOGY 26700 26700 26700 26700 26700 26700 26700 26700
224 CMU0109 -iii-b : ESOPHAGEAL CANCER - POST-OPERATIVE - FLUOROURACIL + LEUCOVORIN (II) ; DAYS 1, 2, 15, AND 16 - LEUCOVORIN 200MG/M2 IV, 5-FU 400MG/M2 IV PUSH AND 5-FU 600MG/M2 INFUSION MEDICAL ONCOLOGY 9500 9500 9500 9500 9500 9500 9500 9500
225 CMU0109 -iii-c : ESOPHAGEAL CANCER - POST-OPERATIVE - CAPECITABINE (I) ; DAYS 1-14 - CAPECITABINE 750-1000MG/M2 ORALLY TWICE DAILY; ; REPEAT EVERY 28 DAYS; 1 CYCLE BEFORE AND 2 CYCLES AFTER CHEMORADIATION MEDICAL ONCOLOGY 3300 3300 3300 3300 3300 3300 3300 3300
226 CMU0109 -iii-d : ESOPHAGEAL CANCER - POST-OPERATIVE - CAPECITABINE (II) ; DAYS 1-5 OR DAYS 1-7 - CAPECITABINE 625-825MG/M2 ORALLY TWICE DAILY, ; ONCE WEEKLY FOR 5 WEEKS. MEDICAL ONCOLOGY 1700 1700 1700 1700 1700 1700 1700 1700
227 CMU0109 -iii-e : ESOPHAGEAL CANCER - POST-OPERATIVE - FLUOROURACILDAYS 1-5 OR DAYS 1-7 - 5-FU 200-250MG/M2 IV CONTINUOUS INFUSION OVER 24 HOURS DAILY, ; ONCE WEEKLY FOR 5 WEEKS.ONCE WEEKLY FOR 5 WEEKS. MEDICAL ONCOLOGY 6900 6900 6900 6900 6900 6900 6900 6900
228 CMU0109 -i-j : ESOPHAGEAL CANCER - NEO ADJUVANT - PACLITAXEL + CAPECITABINE ; DAY 1 - PACLITAXEL 45-50MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625-825MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS. MEDICAL ONCOLOGY 12900 12900 12900 12900 12900 12900 12900 12900
229 CMU0109 -iv : ESOPHAGEAL CANCER - DEFINITIVE MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
230 CMU0109 -iv-a : ESOPHAGEAL CANCER - DEFINITIVE - FLUOROURACIL & CISPLATIN (I) ; DAYS 1 AND 29 - CISPLATIN 75-100MG/M2 IV ; DAYS 1-4 AND 29-32 - 5-FU 750-1, 000MG/M2 IV MEDICAL ONCOLOGY 12600 12600 12600 12600 12600 12600 12600 12600
231 CMU0109 -iv-b : ESOPHAGEAL CANCER - DEFINITIVE - FLUOROURACIL & CISPLATIN (II) ; DAYS 1-5 - CISPLATIN 15MG/M2 IV DAILY ; DAYS 1-5 - 5-FU 800 MG/M2 IV CONTINUOUS INFUSION OVER 24 HOURS. ; CYCLED EVERY 21 DAYS FOR 2 CYCLES MEDICAL ONCOLOGY 7500 7500 7500 7500 7500 7500 7500 7500
232 CMU0109 -iv-c : ESOPHAGEAL CANCER - DEFINITIVE - FLUOROURACIL & OXALIPLATIN ; DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-33 - 5-FU 180MG/M2/DAY CONTINUOUS IV INFUSION. MEDICAL ONCOLOGY 27100 27100 27100 27100 27100 27100 27100 27100
233 CMU0109 -iv-d : ESOPHAGEAL CANCER - DEFINITIVE - CISPLATIN + CAPECITABINE ; DAY 1 - CISPLATIN 30MG/M2 IV ; DAYS 1-5 - CAPECITABINE 800MG/M2 ORALLY TWICE DAILY ; REPEAT CYCLE WEEKLY FOR 5 WEEKS MEDICAL ONCOLOGY 2100 2100 2100 2100 2100 2100 2100 2100
234 CMU0109 -iv-e : ESOPHAGEAL CANCER - DEFINITIVE - OXALIPLATIN + CAPECITABINE ; DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY FOR 5 WEEKS MEDICAL ONCOLOGY 9400 9400 9400 9400 9400 9400 9400 9400
235 CMU0109 -iv-f : ESOPHAGEAL CANCER - DEFINITIVE - PACLITAXEL + CARBOPLATIN ; DAY 1 - PACLITAXEL 50MG/M2 IV AND CARBOPLATIN 2MG/MIN/ML IV ; REPEAT WEEKLY FOR 5 WEEKS. MEDICAL ONCOLOGY 3500 3500 3500 3500 3500 3500 3500 3500
236 CMU0109 -iv-g : ESOPHAGEAL CANCER - DEFINITIVE - CISPLATIN WITH DOCETAXEL (I) ; DAYS 1 AND 22 - DOCETAXEL 60MG/M2 IV ; DAYS 1 AND 22 - CISPLATIN 60-80MG/M2 IV GIVEN FOR 1 CYCLE MEDICAL ONCOLOGY 9400 9400 9400 9400 9400 9400 9400 9400
237 CMU0109 -iv-h : ESOPHAGEAL CANCER - DEFINITIVE - CISPLATIN WITH DOCETAXEL (II) ; DAY 1 - DOCETAXEL 20-30MG/M2 IV ; DAY 1 - CISPLATIN 20-30MG/M2 IV ; REPEAT WEEKLY FOR 5 WEEKS MEDICAL ONCOLOGY 3200 3200 3200 3200 3200 3200 3200 3200
238 CMU0109 -iv-i : ESOPHAGEAL CANCER - DEFINITIVE - CISPLATIN WITH PACLITAXEL ; DAYS 1, 8, 15, AND 22 - PACLITAXEL 60MG/M2 IV ; DAY 1 - CISPLATIN 75MG/M2 IV GIVEN FOR 1 CYCLE. MEDICAL ONCOLOGY 13800 13800 13800 13800 13800 13800 13800 13800
239 CMU0109 -iv-j : ESOPHAGEAL CANCER - DEFINITIVE - IRINOTECAN & CISPLATIN ; DAYS 1, 8, 22, AND 29 - IRINOTECAN 65MG/M2 IV ; DAYS 1, 8, 22, AND 29 - CISPLATIN 30MG/M2 IV. MEDICAL ONCOLOGY 10200 10200 10200 10200 10200 10200 10200 10200
240 CMU0109 -iv-k : ESOPHAGEAL CANCER - DEFINITIVE - FLUOROURACIL & PACLITAXEL ; DAY 1 - PACLITAXEL 45MG/M2 IV ; DAYS 1-5 - 5-FU 300MG/M2/DAY IV ; REPEAT CYCLE WEEKLY FOR 5 WEEKS. MEDICAL ONCOLOGY 5800 5800 5800 5800 5800 5800 5800 5800
241 CMU0109 -iv-l : ESOPHAGEAL CANCER - DEFINITIVE - PACLITAXEL + CAPECITABINE ; DAY 1 - PACLITAXEL 45-50MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625-825MG/M2 PO TWICE DAILY. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS. MEDICAL ONCOLOGY 12900 12900 12900 12900 12900 12900 12900 12900
242 CMU0109 -v : ESOPHAGEAL CANCER - CONCURRENT CISPLATIN; CISPLATIN 40MG/M2 IV ONCE WEEKLY FOR UP TO 5 CYCLES MEDICAL ONCOLOGY 1900 1900 1900 1900 1900 1900 1900 1900
243 CMU0110 : GASTRIC CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
244 CMU0110 -i : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
245 CMU0110 -i-a : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - PACLITAXEL + CARBOPLATIN ; DAY 1 - PACLITAXEL 50MG/M2 IV, CARBOPLATIN AUC 2MG/MIN/ML IV. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS. MEDICAL ONCOLOGY 3500 3500 3500 3500 3500 3500 3500 3500
246 CMU0110 -i-b : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - FLUOROURACIL & CISPLATIN (I) ; DAYS 1 AND 29 - CISPLATIN 75-100MG/M2 IV ; DAYS 1-4 AND 29-32 - 5-FU 750-1000MG/M2/DAY IV MEDICAL ONCOLOGY 12600 12600 12600 12600 12600 12600 12600 12600
247 CMU0110 -i-c : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - FLUOROURACIL & CISPLATIN (II) ; DAYS 1-5 - CISPLATIN 15MG/M2 IV ONCE DAILY, 5-FU 800MG/M2/DAY IV ; REPEAT CYCLE EVERY 21 DAYS FOR 2 CYCLES. MEDICAL ONCOLOGY 7500 7500 7500 7500 7500 7500 7500 7500
248 CMU0110 -i-d : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - FLUOROURACIL & OXALIPLATIN (I)DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-33 - 5-FU 180MG/M2/DAY IV. MEDICAL ONCOLOGY 27100 27100 27100 27100 27100 27100 27100 27100
249 CMU0110 -i-e : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - FLUOROURACIL & OXALIPLATIN (II)DAY 1 - OXALIPLATIN 85MG/M2 AND LEUCOVORIN 400MG/M2 FOLLOWED BY 5-FU 400MG/M2 BOLUS, THEN 800MG/M2 24-HOUR CONTINUOUS INFUSION OVER DAYS 1 AND 2; THE FIRST 3 CYCLES WERE DELIVERED DURING RADIOTHERAPY (RT), THE OTHER 3 AFTER RT; 6 BIMONTHLY (14 DAYS) CYCLES. MEDICAL ONCOLOGY 6500 6500 6500 6500 6500 6500 6500 6500
250 CMU0110 -i-f : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - CISPLATIN + CAPECITABINE ; DAY 1 - CISPLATIN 30MG/M2 IV ; DAYS 1-5 - CAPECITABINE 800MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS. MEDICAL ONCOLOGY 2100 2100 2100 2100 2100 2100 2100 2100
251 CMU0110 -i-g : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - OXALIPLATIN + CAPECITABINE ; DAYS 1, 15, AND 29 - OXALIPLATIN 85MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY FOR 5 WEEKS MEDICAL ONCOLOGY 9400 9400 9400 9400 9400 9400 9400 9400
252 CMU0110 -i-h : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - FLUOROURACIL & PACLITAXEL ; DAY 1 - PACLITAXEL 45-50MG/M2 IV WEEKLY ; DAYS 1-5 - 5-FU 300MG/M2 IV ; REPEAT CYCLE WEEKLY FOR 5 WEEKS MEDICAL ONCOLOGY 5800 5800 5800 5800 5800 5800 5800 5800
253 CMU0110 -ii : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
254 CMU0110 -i-i : GASTRIC CANCER - PREOPERATIVE CHEMORADIATION (ESOPHAGOGASTRIC JUNCTION AND GASTRIC CARDIA) - PACLITAXEL + CAPECITABINE ; DAY 1 - PACLITAXEL 45-50MG/M2 IV ; DAYS 1-5 - CAPECITABINE 625-825MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE WEEKLY FOR 5 WEEKS. MEDICAL ONCOLOGY 3300 3300 3300 3300 3300 3300 3300 3300
255 CMU0110 -ii-a : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION) - ECF (EPIRUBICIN/CISPLATIN/FLUOROURACIL) ; DAY 1 - EPIRUBICIN 50MG/M2 IV, CISPLATIN 60MG/M2 IV ; DAYS 1-21 - 5-FU 200MG/M2/DAY IV ; REPEAT CYCLE EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY MEDICAL ONCOLOGY 17600 17600 17600 17600 17600 17600 17600 17600
256 CMU0110 -ii-b : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION) - EOF (EPIRUBICIN/ OXALIPLATIN /FLUOROURACIL) ; DAY 1 - EPIRUBICIN 50MG/M2 IV; OXALIPLATIN 130MG/M2 IV ; DAYS 1-21 - 5-FU 200MG/M2 IV; ; REPEAT EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY. MEDICAL ONCOLOGY 19300 19300 19300 19300 19300 19300 19300 19300
257 CMU0110 -ii-c : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION) - EPIRUBICIN + CISPLATIN + CAPECITABINE ; DAY 1 - EPIRUBICIN 50MG/M2 IV + CISPLATIN 60MG/M2 IV ; DAYS 1-21 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY. MEDICAL ONCOLOGY 6200 6200 6200 6200 6200 6200 6200 6200
258 CMU0110 -ii-d : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION) - ECF MODIFICATION (EPIRUBICIN + OXALIPLATIN + CAPECITABINE) ; DAY 1 - EPIRUBICIN 50MG/M2 IV + OXALIPLATIN 130MG/M2 IV ; DAYS 1-21 - CAPECITABINE 625MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELYREPEAT CYCLE EVERY 21 DAYS FOR 3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY MEDICAL ONCOLOGY 8200 8200 8200 8200 8200 8200 8200 8200
259 CMU0110 -ii-e : GASTRIC CANCER - PERIOPERATIVE CHEMOTHERAPY (INCLUDING ESOPHAGOGASTRIC JUNCTION) - FLUOROURACIL & CISPLATIN ; DAY 1 - CISPLATIN 75-80MG/M2 IV ; DAYS 1-5 - 5-FU 800MG/M2 IV ; REPEAT CYCLE EVERY 28 DAYS FOR 2-3 CYCLES PREOPERATIVELY AND 3-4 CYCLES POSTOPERATIVELY FOR A TOTAL OF 6 CYCLES. MEDICAL ONCOLOGY 7300 7300 7300 7300 7300 7300 7300 7300
260 CMU0110 -iii : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
261 CMU0110 -iii-a : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - FLUOROURACIL + LEUCOVORIN (I) ; CYCLES 1, 3, AND 4 (BEFORE AND AFTER RADIATION) DAYS 1-5 - LEUCOVORIN 20MG/M2 IV, 5-FU 425MG/M2/DAY IV ; REPEAT CYCLE EVERY 28 DAYS. ; CYCLE 2 (WITH RADIATION) DAYS 1-4 AND 31-33 - LEUCOVORIN 20MG/M2 IVP ; DAYS 1-4 - 5-FU 400MG/M2/DAY IVP. ; REPEAT CYCLE EVERY 35 DAYS MEDICAL ONCOLOGY 26700 26700 26700 26700 26700 26700 26700 26700
262 CMU0110 -iii-b : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - FLUOROURACIL + LEUCOVORIN (II) ; DAYS 1, 2, 15, AND 16 - LEUCOVORIN 400MG/M2 IV, 5-FU 400MG/M2 IV AND 5-FU 1200MG/M2 INFUSION; ; 1 CYCLE BEFORE AND 2 CYCLES AFTER CHEMORADIATION. ; REPEAT CYCLE EVERY 28 DAYSREPEAT CYCLE EVERY 28 DAYS MEDICAL ONCOLOGY 15700 15700 15700 15700 15700 15700 15700 15700
263 CMU0110 -iii-c : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - CAPECITABINE (I) ; DAYS 1-14 - CAPECITABINE 750-1000MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE EVERY 28 DAYS; 1 CYCLE BEFORE AND 2 CYCLES AFTER CHEMORADIATION. MEDICAL ONCOLOGY 3300 3300 3300 3300 3300 3300 3300 3300
264 CMU0110 -iii-d : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - CAPECITABINE (II) ; DAYS 1-5 OR DAYS 1-7 - CAPECITABINE 625-825MG/M2 ORALLY TWICE DAILY; WEEKLY FOR 5 WEEKS. MEDICAL ONCOLOGY 1700 1700 1700 1700 1700 1700 1700 1700
265 CMU0110 -iii-e : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - FLUOROURACIL ; DAYS 1-5 OR DAYS 1-7 - 5-FU 200-250MG/M2 IV; ; WEEKLY FOR 5 WEEKS. MEDICAL ONCOLOGY 6900 6900 6900 6900 6900 6900 6900 6900
266 CMU0110 -iii-f : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - CISPLATIN + CAPECITABINE ; DAY 1 - CISPLATIN 60MG/M2 IV. ; DAYS 1-14 - CAPECITABINE 1000MG/M2 ORALLY TWICE DAILY ; REPEAT CYCLE EVERY 21 DAYS FOR 6 CYCLES. MEDICAL ONCOLOGY 4200 4200 4200 4200 4200 4200 4200 4200
267 CMU0110 -iii-h : GASTRIC CANCER - POSTOPERATIVE CHEMORADIATION (INCLUDING ESOPHAGOGASTRIC JUNCTION) - OXALIPLATIN + CAPECITABINE ; DAY 1 - OXALIPLATIN 130MG/M2 IV. ; DAYS 1-14 - CAPECITABINE 1000MG/M2 ORALLY TWICE DAILY ; REPEAT CYCLE EVERY 21 DAYS FOR 8 CYCLES.REPEAT CYCLE EVERY 21 DAYS FOR 8 CYCLES. MEDICAL ONCOLOGY 6300 6300 6300 6300 6300 6300 6300 6300
268 CMU0111 : COLORECTAL CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
269 CMU0111 -i : COLORECTAL CARCINOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
270 CMU0111 -i-a : COLORECTAL CARCINOMA - FOLFOX (STAGE - III) - (OXALIPLATIN, LEUCOVORIN, 5-FU) ; DAY 1 - OXALIPLATIN 85MG/M2 IV, LEUCOVORIN 400MG/M2 IV, 5-FU 400MG/M2 IV, FOLLOWED BY 5-FU 1, 200MG/M2/DAY IV X 2 DAYS (TOTAL 2, 400MG/M2) OVER 46-48-HOUR CONTINUOUS INFUSION. ; REPEAT CYCLE EVERY 2 WEEKS- UPTO 12 CYCLES MEDICAL ONCOLOGY 8400 8400 8400 8400 8400 8400 8400 8400
271 CMU0111 -i-b : COLORECTAL CARCINOMA - CAPEOX (STAGE - III) (OXALIPLATIN, CAPECITABINE) ; DAY 1 - OXALIPLATIN 130MG/M2 IV OVER 2 HOURS ; DAYS 1-14 - CAPECITABINE 1, 000MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE EVERY 3 WEEKS FOR 6 MONTHS MEDICAL ONCOLOGY 6900 6900 6900 6900 6900 6900 6900 6900
272 CMU0111 -i-c : COLORECTAL CARCINOMA - FLOX (STAGE - III) (5-FU, LEUCOVORIN, OXALIPLATIN) ; 5-FU 500MG/M2 IV BOLUS WEEKLY X 6, LEUCOVORIN 500MG/M2 IV WEEKLY X 6, EACH ; OXALIPLATIN 85MG/M2 IV ON WEEKS 1, 3, AND 5 ; 8-WEEK CYCLE X 3 CYCLES ; MEDICAL ONCOLOGY 31500 31500 31500 31500 31500 31500 31500 31500
273 CMU0111 -i-d : COLORECTAL CARCINOMA - CAPECITABINE ; CAPECITABINE 1, 250MG/M2 - BD / TDS D 1-14 ; EVERY 3 WEEKS * 24 WEEKSL CARCINOMA - CAPECITABINE ; CAPECITABINE 1, 250MG/M2 - BD / TDS D 1-14 ; EVERY 3 WEEKS * 24 WEEKS MEDICAL ONCOLOGY 4600 4600 4600 4600 4600 4600 4600 4600
274 CMU0111 -i-e : COLORECTAL CARCINOMA - FLUOROURACIL + LEUCOVORIN (I) ; LEUCOVORIN 500MG/M2 WEEKLY X 6 WEEKS, ; 5-FU 500MG/M2 WEEKLY X 6 WEEKS. ; REPEAT CYCLE EVERY 8 WEEKS FOR 4 CYCLES. MEDICAL ONCOLOGY 24900 24900 24900 24900 24900 24900 24900 24900
275 CMU0111 -i-f : COLORECTAL CARCINOMA - FLUOROURACIL + LEUCOVORIN (II)SIMPLIFIED BIWEEKLY INFUSION. ; LEUCOVORIN 400MG/M2 IV, 5-FU BOLUS 400MG/M2 AND THEN 1, 200MG/M2/DAY X 2 DAYS (TOTAL 2, 400MG/M2 OVER 46-48 HOURS) ; REPEAT CYCLE EVERY 2 WEEKS FOR 6 CYCLES. MEDICAL ONCOLOGY 5500 5500 5500 5500 5500 5500 5500 5500
276 CMU0111 -ii : COLORECTAL CARCINOMA - CONCURRENT MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
277 CMU0111 -ii-a : COLORECTAL CARCINOMA - CONCURRENT - 5FU - WITH XRT ; DAYS 1-5 OR 1-7 - 5-FU 225MG/M2 IV ; WITH EXTERNAL BEAM RADIOTHERAPY MEDICAL ONCOLOGY 4000 4000 4000 4000 4000 4000 4000 4000
278 CMU0111 -ii-b : COLORECTAL CARCINOMA - CONCURRENT - FLUOROURACIL + LEUCOVORIN - WITH XRT ; DAYS 1-4 - 5-FU 400MG/M2 IV + LEUCOVORIN 20MG/M2 IV. ; REPEAT CYCLE DURING WEEKS 1 AND 5 OF XRT. MEDICAL ONCOLOGY 6500 6500 6500 6500 6500 6500 6500 6500
279 CMU0111 -ii-c : COLORECTAL CARCINOMA - CONCURRENT - CAPECITABINE - WITH XRT ; CAPECITABINE TABLET 825MG / M2 TWICE DAILY ON DAYS 1-5 ; REPEAT CYCLE WEEKLY FOR 5 WEEKS. MEDICAL ONCOLOGY 1400 1400 1400 1400 1400 1400 1400 1400
280 CMU0112 : OSTEOSARCOMA/ BONE TUMORS MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
281 CMU0112 -i-a : OSTEOSARCOMA/ BONE TUMORS / DEDIFFERENTIATED CHONDROSARCOMA - CISPLATIN + DOXORUBICIN ; DAYS 1-3 - DOXORUBICIN 25MG/M2/DAY IV, ; DAY 1 - CISPLATIN 100MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS FOR 6 CYCLES MEDICAL ONCOLOGY 5900 5900 5900 5900 5900 5900 5900 5900
282 CMU0112 -i-b-1 : OSTEOSARCOMA/ BONE TUMORS / DEDIFFERENTIATED CHONDROSARCOMA - MAP (HIGH-DOSE METHOTREXATE + CISPLATIN + DOXORUBICIN) - PRE OPERATIVE ; DAYS 1 AND 28 - METHOTREXATE 8G/M2 IV ; DAYS 7-9 AND 34-36 - CISPLATIN 120MG/M2 BY INFUSION FOR 72 HOURS. ; DAYS 9 AND 36 - DOXORUBICIN 60MG/M2 IV MEDICAL ONCOLOGY 25500 25500 25500 25500 25500 25500 25500 25500
283 CMU0112 -i-b-2 : OSTEOSARCOMA/ BONE TUMORS / DEDIFFERENTIATED CHONDROSARCOMA - MAP (HIGH-DOSE METHOTREXATE + CISPLATIN + DOXORUBICIN) - POST OPERATIVE NECROSIS < 90% ; DAYS 1, 48, 96, AND 144 - DOXORUBICIN 45MG/M2/DAY FOR 2 CONSECUTIVE DAYS ; DAYS 21, 69, AND 117 - METHOTREXATE 8G/M2 IV ; DAYS 27, 75, AND 123 - CISPLATIN 120MG/M2 BY INFUSION FOR 72 HOURS. MEDICAL ONCOLOGY 42000 42000 42000 42000 42000 42000 42000 42000
284 CMU0112 -i-b-3 : OSTEOSARCOMA/ BONE TUMORS / DEDIFFERENTIATED CHONDROSARCOMA - MAP (HIGH-DOSE METHOTREXATE + CISPLATIN + DOXORUBICIN) - POST OPERATIVE NECROSIS > 90%POSTOPERATIVE CHEMOTHERAPY (NECROSIS MEDICAL ONCOLOGY 62000 62000 62000 62000 62000 62000 62000 62000
285 CMU0112 -i-c : DOXORUBICIN + CISPLATIN + IFOSFAMIDE + HIGH-DOSE METHOTREXATE (INCLUDING SURGERY COST) MEDICAL ONCOLOGY 117100 117100 117100 117100 117100 117100 117100 117100
286 CMU0112 -i-d : OSTEOSARCOMA/ BONE TUMORS / DEDIFFERENTIATED CHONDROSARCOMA - IFOSFAMIDE + CISPLATIN + EPIRUBICIN ; DAY 1 - EPIRUBICIN 90MG/M2 IV, CISPLATIN 100MG/M2 IV ; DAYS 2-4 - IFOSFAMIDE 2.0G/M2 WITH MESNA ; REPEAT CYCLE EVERY 21 DAYS. (3 CYCLES PREOPERATIVELY AND 3 CYCLES POSTOPERATIVELY). MEDICAL ONCOLOGY 8700 8700 8700 8700 8700 8700 8700 8700
287 CMU0112 -ii : OTHER BONE TUMORS - CHORDROMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
288 CMU0112 -ii-a : OTHER BONE TUMORS - CHORDROMA - IMATINIB ; IMATINIB 800 MG ONCE DAILY MEDICAL ONCOLOGY 4700 4700 4700 4700 4700 4700 4700 4700
289 CMU0112 -ii-b : OTHER BONE TUMORS - CHORDROMA - IMATINIB + CISPLATIN ; IMATINIB 400MG OD + CISPLATIN 25MG/M2 WEEKLY. MEDICAL ONCOLOGY 4700 4700 4700 4700 4700 4700 4700 4700
290 CMU0112 -ii-c : OTHER BONE TUMORS - CHORDROMA - IMATINIB + SIROLIMUS ; IMATINIB 400MG OD + SIROLIMUS 2MG OD MEDICAL ONCOLOGY 6300 6300 6300 6300 6300 6300 6300 6300
291 CMU0112 -ii-d : OTHER BONE TUMORS - CHORDROMA - ERLOTINIB ; ERLOTINIB 150MG OD MEDICAL ONCOLOGY 2300 2300 2300 2300 2300 2300 2300 2300
292 CMU0112 -ii-e : OTHER BONE TUMORS - CHORDROMA - SUNITINIB ; SUNITINIB 37.5MG OD MEDICAL ONCOLOGY 29900 29900 29900 29900 29900 29900 29900 29900
293 CMU0112 -iii : OTHER BONE TUMORS - GIANT CELL TUMOR OF BONE MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
294 CMU0112 -iii-a : OTHER BONE TUMORS - GIANT CELL TUMOR OF BONE - DENOSUMAB ; DENOSUMAB 120MG SUBCUTANEOUS ON WEEK 1, 2 AND 3 OF A 4 WEEK CYCLE MEDICAL ONCOLOGY 58800 58800 58800 58800 58800 58800 58800 58800
295 CMU0112 -iii-b : OTHER BONE TUMORS - GIANT CELL TUMOR OF BONE - INTERFERON ALFA ; INTERFERON ALFA- 2A THRICE WEEKLY MEDICAL ONCOLOGY 4800 4800 4800 4800 4800 4800 4800 4800
296 CMU0112 -iii-c : OTHER BONE TUMORS - GIANT CELL TUMOR OF BONE - PEGINTERFERON ; PEGINTERFERON ALFA-2A 1.0MCG/KG SQ INJECTION WEEKLY. MEDICAL ONCOLOGY 3700 3700 3700 3700 3700 3700 3700 3700
297 CMU0112 -iv : OTHER BONE TUMORS - MESENCHYMAL CHORDOSARCOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
298 CMU0112 -iv-a : VAC AND IE CYCLES MEDICAL ONCOLOGY 6800 6800 6800 6800 6800 6800 6800 6800
299 CMU0112 -iv-b : OTHER BONE TUMORS - MESENCHYMAL CHORDOSARCOMA VAIA ; DAY 1 - VINCRISTINE 1.5MG/M2 IV ; DAYS 1-3 - IFOSFAMIDE 2, 000MG/M2 IV + MESNA ; DAYS 1, 3, AND 5 - DACTINOMYCIN 0.5MG/M2 IV ; DAYS 2 AND 4 - DOXORUBICIN 30MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS. MEDICAL ONCOLOGY 8000 8000 8000 8000 8000 8000 8000 8000
300 CMU0112 -vi : OTHER BONE TUMORS - MESENCHYMAL CHORDOSARCOMA VIDE (VINCRISTINE + IFOSFAMIDE + DOXORUBICIN + ETOPOSIDE) ; DAY 1 - VINCRISTINE 1.4MG/M2 (MAX 2MG), ; DAYS 1-3 - DOXORUBICIN 20MG/M2 IV + IFOSFAMIDE 3MG/M2 IV + MESNA 3G/M2 + ETOPOSIDE 150MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR UP TO 6 CYCLES. MEDICAL ONCOLOGY 9700 9700 9700 9700 9700 9700 9700 9700
301 CMU0113 : WILMS TUMOR MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
302 CMU0113 -a : WILMS TUMOR - VINCRISTINE & ACTINOMYCIN D ; DACTINOMYCIN 45MCG/KG - WEEK - 0, 3, 6, 9, 12, 15, 18 ; VINCRISTINE 1.5 MG/M2 - WEEK - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 18 MEDICAL ONCOLOGY 20400 20400 20400 20400 20400 20400 20400 20400
303 CMU0113 -b : WILMS TUMOR - DACTINOMYCIN, VINCRISTINE & ADRIAMYCIN ; DACTINOMYCIN 1.35 MG /M2 - WEEK - 0, 6, 12, 18, 24 ; ADRIYAMYCIN 30-45 MG /M2- WEEK - 3, 9, 15, 21 ; VINCRISTINE 2MG MAX- WEEK - 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 18, 21, 24 MEDICAL ONCOLOGY 24400 24400 24400 24400 24400 24400 24400 24400
304 CMU0113 -c : WILMS TUMOR - ADRIAMYCIN, CYCLOPHOSPHAMIDE, ETOPOSIDE, VINCRISTINE ; CYCLOPHOSPHAMIDE 440MG/M2/DAY - WEEK 3, 9, 15, 21 FOR 5 DAYS, WEEK - 6, 12, 18, 24 FOR 3 DAYS ; ADRIYAMYCIN 30-45MG /M2- WEEK -0, 6, 12, 18, 24 ; VINCRISTINE 2MG (MAX)- WEEK - 1, 2, 4, 5, 6, 7, 8, 10, 11, 12, 13, 18, 24 ; ETOPOSIDE 100MG /M2- WEEK - 3, 9, 15, 21 MEDICAL ONCOLOGY 56400 56400 56400 56400 56400 56400 56400 56400
305 CMU0113 -d : WILMS TUMOR - CYCLOPHOSPHAMIDE, ETOPOSIDE, CARBOPLATIN ; CYCLOPHOSPHAMIDE 440MG/M2/DAY - WEEK 6, 15, 24 *5 DAYS / WEEK ; CARBOPLATIN 500MG/M2 - WEEK - 0, 3, 9, 12, 18, 21 *2 DAYS / WEEK ; ETOPOSIDE 100MG/M2 - WEEK - 0, 3, 9, 12, 18, 21 *5 DAYS / WEEK MEDICAL ONCOLOGY 88700 88700 88700 88700 88700 88700 88700 88700
306 CMU0114 : HEPATOBLASTOMA- OPERABLEHEPATOBLASTOMA- OPERABLE MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
307 CMU0114 -a : HEPATOBLASTOMA- OPERABLE - PLADO - CISPLATIN + DOXORUBICIN ; CISPLATIN (PLA) (80MG/M2 / IV), DOXORUBICIN (DO) (30 MG/M2 IV ; EVERY 21 DAYS FOR 6 CYCLES MEDICAL ONCOLOGY 3000 3000 3000 3000 3000 3000 3000 3000
308 CMU0114 -b : HEPATOBLASTOMA- OPERABLE - CISPLATIN + VINCRISTINE +5FU ; CISPLATIN (90 MG/M2), VINCRISTINE (1.5MG/M2), 5-FU(5-FLUROURACIL- 600 MG/M2) ; EVERY 21 DAYS FOR 6 CYCLES MEDICAL ONCOLOGY 2600 2600 2600 2600 2600 2600 2600 2600
309 CMU0115 : HEPATOCELLULAR CARCINOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
310 CMU0115 -a : HEPATOCELLULAR CARCINOMA - SORAFENIB ; SORAFENIB 400 MG PO BID MEDICAL ONCOLOGY 6100 6100 6100 6100 6100 6100 6100 6100
311 CMU0116 : NEUROBLASTOMA ALL STAGES MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
312 CMU0116 A : NEUROBLASTOMA ALL STAGES - VINCRISTINE/CISPLATIN/ETOPOSIDE/CYCLOPHOSPHAMIDE/CARBOPLATIN MEDICAL ONCOLOGY 8400 8400 8400 8400 8400 8400 8400 8400
313 CMU0116 B : NEUROBLASTOMA ALL STAGES - CYCLOPHOSPHAMIDE/ADRIAMYCIN/VINCRISTINE ; D1-D5 - CYCLOPHOSPHAMIDE 300MG/M2 ; ADRIAMYCIN 60MG/M2 ; VINCRISTINE 1.5MG/M2 MEDICAL ONCOLOGY 7500 7500 7500 7500 7500 7500 7500 7500
314 CMU0116 C : NEUROBLASTOMA ALL STAGES - CISPLATIN & ETOPOSIDE ; DAYS 1-5 - CISPLATIN - 20MG/M2 ; DAYS 1-5 - ETOPOSIDE - 70 MG/M2 MEDICAL ONCOLOGY 5200 5200 5200 5200 5200 5200 5200 5200
315 CMU0116 D : NEUROBLASTOMA ALL STAGES - CARBOPLATIN & ETOPOSIDE ; DAYS 1-2 - CARBOPLATIN - 500MG/M2 ; DAYS 1-5 - ETOPOSIDE 100MG/M2 MEDICAL ONCOLOGY 6900 6900 6900 6900 6900 6900 6900 6900
316 CMU0116 E : NEUROBLASTOMA ALL STAGES - FOR STAGE IV PALLIATIVE CHEMOTHERAPY ONLY MEDICAL ONCOLOGY 10500 10500 10500 10500 10500 10500 10500 10500
317 CMU0117 : RETINOBLASTOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
318 CMU0117 -a : RETINOBLASTOMA - MELPHALAN - INTRA-ARTERIAL ; MELPHALAN - 3-7.5MG - INTRA-ARTERIAL MEDICAL ONCOLOGY 10200 10200 10200 10200 10200 10200 10200 10200
319 CMU0117 -b : RETINOBLASTOMA - CARBOPLATIN - INTRA-ARTERIAL ; CARBOPLATIN 15-30 MG - INTRA-ARTERIAL MEDICAL ONCOLOGY 9400 9400 9400 9400 9400 9400 9400 9400
320 CMU0117 -c : RETINOBLASTOMA - TOPOTECAN - INTRA-ARTERIAL ; TOPOTECAN 0.15-1.5 MG - INTRA-ARTERIAL MEDICAL ONCOLOGY 10400 10400 10400 10400 10400 10400 10400 10400
321 CMU0117 -d : RETINOBLASTOMA - METHOTREXATE - INTRA-ARTERIAL ; METHOTREXATE 6-12 MG - INTRA-ARTERIAL MEDICAL ONCOLOGY 9100 9100 9100 9100 9100 9100 9100 9100
322 CMU0117 -e : RETINOBLASTOMA - CARBOPLATIN - PERI OCULAR ; CARBOPLATIN 20MG/M2 - PERI OCULAR MEDICAL ONCOLOGY 2000 2000 2000 2000 2000 2000 2000 2000
323 CMU0117 -f : RETINOBLASTOMA - TOPOTECAN - PERI OCULAR ; TOPOTECAN 0.09 - 0.27 - PERI OCULAR MEDICAL ONCOLOGY 4500 4500 4500 4500 4500 4500 4500 4500
324 CMU0117 -g : RETINOBLASTOMA - MELPHALAN - INTRA-VITREAL ; MELPHALAN 20-30 MCG / 0.1CC - INTRA-VITREAL MEDICAL ONCOLOGY 300 300 300 300 300 300 300 300
325 CMU0117 -h : RETINOBLASTOMA - CARBOPLATIN - INTRA-VITREAL ; CARBOPLATIN 3-6MCG / 0.05CC - INTRA-VITREAL MEDICAL ONCOLOGY 2000 2000 2000 2000 2000 2000 2000 2000
326 CMU0117 -i : RETINOBLASTOMA - METHOTREXATE - INTRA-VITREAL ; METHOTREXATE 400MCG/0.1CC - INTRA-VITREAL MEDICAL ONCOLOGY 1700 1700 1700 1700 1700 1700 1700 1700
327 CMU0117 -j : RETINOBLASTOMA - CARBOPLATIN + ETOPOSIDE + VINCRISTINE ; CARBOPLATIN 560MG/M2 ; ETOPOSIDE 150MG/M2 ; VINCRISTINE 1.5MG/M2 MEDICAL ONCOLOGY 7200 7200 7200 7200 7200 7200 7200 7200
328 CMU0118 : HISTIOCYTOSIS MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
329 CMU0118 -a : HISTIOCYTOSIS - PREDNISOLONE AND VINBLASTINE - 1; PREDNISOLONE AND VINBLASTINE - 1 ; PREDNISOLONE - 6 WEEKS ORAL ; VINBLASTINE 1, 2, 3, 4, 5, 6 MEDICAL ONCOLOGY 6500 6500 6500 6500 6500 6500 6500 6500
330 CMU0118 -b : HISTIOCYTOSIS - PREDNISOLONE AND VINBLASTINE - 2; PREDNISOLONE AND VINBLASTINE - 1 ; PREDNISOLONE - 6 WEEKS ORAL ; VINBLASTINE 1, 2, 3, 4, 5, 6 MEDICAL ONCOLOGY 7200 7200 7200 7200 7200 7200 7200 7200
331 CMU0118 -c : HISTIOCYTOSIS - PREDNISOLONE AND VINBLASTINE - CONTINUATION; PREDNISOLONE AND VINBLASTINE - CONTINUATION AFTER EITHER COURSE 1 OR BOTH 1 & 2 ; PREDNISOLONE - 5 DAYS A WEEK ORAL ; VINBLASTINE -IV ; REPEAT EVERY 3 WEEKS TILL 1 YEAR MEDICAL ONCOLOGY 1900 1900 1900 1900 1900 1900 1900 1900
332 CMU0119 : RHABDOMYOSARCOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
333 CMU0119 -a : RHABDOMYOSARCOMA - VAC (VINCRISTINE + DACTINOMYCIN + CYCLOPHOSPHAMIDE + MESNA ) ; DAY -1 - VINCRISTINE 1.5 MG /M2 IV (2 MG MAX), DOXORUBICIN 75 MG /M2 IV, CYCLOPHOSPHAMIDE 1200 MG /M2 IV + MESNA ; REPEAT AT 21 DAY INTERVALS FOR 4-6 CYCLES MEDICAL ONCOLOGY 4000 4000 4000 4000 4000 4000 4000 4000
334 CMU0119 -b : RHABDOMYOSARCOMA - IVA (VINCRISTINE + DACTINOMYCIN + IFOSFAMIDE + MESNA ) ; DAY 1, 2 - IFOSFAMIDE IV 3 G/M2 + MESNA ; DAY 1 - VINCRISTINE IV 1.5 MG/M2 (MAX 2 MG), ACTINOMYCIN-D IV 1.5 MG/M2 (MAX 2 MG) ; REPEAT AT 21 DAY INTERVALS FOR 6 CYCLES MEDICAL ONCOLOGY 5900 5900 5900 5900 5900 5900 5900 5900
335 CMU0119 -c : RHABDOMYOSARCOMA - IVAD (VINCRISTINE + DOXORUBICIN + IFOSFAMIDE + MESNA ) ; DAYS 1 AND 2 - IFOSFAMIDE 3 G/M2 + MESNA, DOXORUBICIN 30MG/M2 ; DAY 1 - VINCRISTINE 1.5 MG/M2, ACTINOMYCIN-D 1.5 MG/M2 ; REPEAT AT 21 DAY INTERVALS FOR 6 CYCLES MEDICAL ONCOLOGY 5800 5800 5800 5800 5800 5800 5800 5800
336 CMU0120 : EWINGS SARCOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
337 CMU0120 -i : EWINGS SARCOMA - INDUCTION TREATMENT I MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
338 CMU0120 -i-a : EWINGS SARCOMA - INDUCTION TREATMENT - VIDE ; DAY 1 - VINCRISTINE 1.5MG/M2(MAX 2MG) IV ; DAYS 1-3 - DOXORUBICIN 20MG/M2 IV, IFOSFAMIDE 3G/M2IV, MESNA CONTINUOUS IV, ETOPOSIDE 150MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS FOR UP TO 6 CYCLES MEDICAL ONCOLOGY 8800 8800 8800 8800 8800 8800 8800 8800
339 CMU0120 -i-b : EWINGS SARCOMA - INDUCTION TREATMENT - VAC/IE ; MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
340 CMU0120 -i-b-1 : EWINGS SARCOMA - INDUCTION TREATMENT - VAC/IE - VAC ; DAY 1 - VINCRISTINE 2MG/M2 (MAX 2MG) IV, DOXORUBICIN 75MG/M2 IV BOLUS, CYCLOPHOSPHAMIDE 1, 200MG/M2 IV, MESNA. ; DACTINOMYCIN 1.25MG/M2 IV CAN BE SUBSTITUTED FOR DOXORUBICIN WHEN A TOTAL DOXORUBICIN DOSE OF 375MG/M2 IS REACHED. MEDICAL ONCOLOGY 4800 4800 4800 4800 4800 4800 4800 4800
341 CMU0120 -i-b-2 : EWINGS SARCOMA - INDUCTION TREATMENT - VAC/IE - IE ; IE CYCLES ; DAYS 1-5 - IFOSFAMIDE 1, 800MG/M2 IV + MESNA + ETOPOSIDE 100MG/M2 IV. ; REPEAT EACH CYCLE EVERY 3 WEEKS FOR 17 CYCLES. MEDICAL ONCOLOGY 6300 6300 6300 6300 6300 6300 6300 6300
342 CMU0120 -i-c : EWINGS SARCOMA - INDUCTION TREATMENT - VAIA - 4 DAY REGIMEN ; DAY 1 - VINCRISTINE 1.5MG/M2IV ; DAYS 1-3 - IFOSFAMIDE 2, 000MG/M2 IV + MESNA ; DAYS 1, 3, AND 5 - DACTINOMYCIN 0.5MG/M2 IV ; DAYS 2 AND 4 - DOXORUBICIN 30MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 4 CYCLES, THEN LOCAL THERAPY, FOLLOWED BY 10 ADDITIONAL CYCLES OF VAIA FOR HIGH RISK AND ; 10 ADDITIONAL CYCLES OF VAIA OR 10 CYCLES OF VACA FOR STANDARD-RISK PATIENTS MEDICAL ONCOLOGY 8000 8000 8000 8000 8000 8000 8000 8000
343 CMU0120 -i-d : EWINGS SARCOMA - INDUCTION TREATMENT - VAIA - 24 DAY REGIMEN ; DAYS 1, 8, 15, AND 22 - VINCRISTINE 1.5MG/M2 IV ; DAYS 1, 2, 22, 23, 43, AND 44 - IFOSFAMIDE 3, 000MG/M2 IV + MESNA ; DAYS 1, 2, 43, AND 44 - DOXORUBICIN 30MG/M2 IV ; DAYS 22, 23, AND 24 - DACTINOMYCIN 0.5MG/M2 IV ; AFTER COMPLETION OF ONE 9-WEEK CYCLE, LOCAL THERAPY FOLLOWED BY 3 ADDITIONAL CYCLES. MEDICAL ONCOLOGY 18600 18600 18600 18600 18600 18600 18600 18600
344 CMU0120 -i-e : EWINGS SARCOMA - INDUCTION TREATMENT - VACA ; DAY 1 - VINCRISTINE 1.5MG/M2 IV + CYCLOPHOSPHAMIDE 1, 200MG/M2 IV + MESNA ; DAYS 1, 3, AND 5 - DACTINOMYCIN 0.5MG/M2 IV ; DAYS 2 AND 4 - DOXORUBICIN 30MG/M2 IV. ; REPEAT CYCLE EVERY 21 DAYS FOR 10 CYCLES. MEDICAL ONCOLOGY 4800 4800 4800 4800 4800 4800 4800 4800
345 CMU0120 -ii : EWINGS SARCOMA - MAINTENANCE TREATMENT MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
346 CMU0120 -ii-a : EWINGS SARCOMA - MAINTENANCE TREATMENT - ETOPOSIDE/IFOSFAMIDE ; DAYS 1-5 - IFOSFAMIDE 1, 800MG/M2/DAY IV + MESNA ; DAYS 1-5 - ETOPOSIDE 100MG/M2/DAY IV. MEDICAL ONCOLOGY 8700 8700 8700 8700 8700 8700 8700 8700
347 CMU0121 : PALLIATIVE CHEMOTHERAPY (ANY REGIMEN)- MAXIMUM PAYABLE MEDICAL ONCOLOGY 10500 10500 10500 10500 10500 10500 10500 10500
348 CMU0122 : CERVICAL CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
349 CMU0122 -a : CERVICAL CANCER - CISPLATIN ; CISPLATIN 40MG/M2 IV ONCE WEEKLY FOR UP TO 6 CYCLES MEDICAL ONCOLOGY 1900 1900 1900 1900 1900 1900 1900 1900
350 CMU0122 -b : CERVICAL CANCER - CISPLATIN & 5FU WITH RT ; DAYS 1-5 OF RADIOTHERAPY - CISPLATIN 75MG/M2 IV, 5-FU 4, 000MG/M2 IV OVER 96 HOURS ; REPEAT CYCLE EVERY 3 WEEKS FOR 3 MEDICAL ONCOLOGY 9700 9700 9700 9700 9700 9700 9700 9700
351 CMU0122 -c : CERVICAL CANCER - CISPLATIN & 5FU ; DAYS 1 AND 29 - CISPLATIN 50MG/M2 IV ; DAYS 2-5, AND 30-33 - 5-FU 1, 000MG/M2 IV MEDICAL ONCOLOGY 9400 9400 9400 9400 9400 9400 9400 9400
352 CMU0123 : VULVAL CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
353 CMU0123 -a : VULVAL CANCER - CISPLATIN ; DAY 1 - 40 MG/M 2 IV MEDICAL ONCOLOGY 1900 1900 1900 1900 1900 1900 1900 1900
354 CMU0123 -b : VULVAL CANCER - CISPLATIN + 5FU ; DAYS 1-5 OF RADIOTHERAPY - CISPLATIN 75MG/M2 IV, 5-FU 4, 000MG/M2 ; REPEAT CYCLE EVERY 3 WEEKS - TOTAL 3 CYCLES MEDICAL ONCOLOGY 5000 5000 5000 5000 5000 5000 5000 5000
355 CMU0123 -c : VULVAL CANCER - 5-FU + MITOMYCIN ; 5-FU + MITOMYCIN ; DAYS 1-4 AND 29-32 - 5-FU 1, 000MG/M2/DAY CONTINUOUS IV INFUSION ; DAYS 1 AND 29 - MITOMYCIN 10MG/M2 IV BOLUS (MAXIMUM 20MG PER COURSE), MEDICAL ONCOLOGY 12000 12000 12000 12000 12000 12000 12000 12000
356 CMU0123 -e : VULVAL CANCER - CISPLATIN + 5FU ; DAYS 1 AND 29 - CISPLATIN 50MG/M2 IV ; DAYS 2-5, AND 30-33 - 5-FU 1, 000MG/M2 IV MEDICAL ONCOLOGY 11700 11700 11700 11700 11700 11700 11700 11700
357 CMU0124 : VAGINAL CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
358 CMU0124 -a : VAGINAL CANCER - CISPLATIN ; CISPLATIN 75MG/M2 ; ONCE WEEKLY FOR UP TO 6 DOSES MEDICAL ONCOLOGY 1900 1900 1900 1900 1900 1900 1900 1900
359 CMU0125 : OVARIAN CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
360 CMU0125 -a : OVARIAN CANCER - PACLITAXEL + CISPLATIN ; DAY 1 - PACLITAXEL 135MG/M2 CONTINUOUS IV ; DAY 2 - CISPLATIN 75-100MG/M2 ; DAY 8 - PACLITAXEL 60MG/M2 ; REPEAT EVERY 3 WEEKS FOR 6 CYCLES. MEDICAL ONCOLOGY 9300 9300 9300 9300 9300 9300 9300 9300
361 CMU0125 -b : OVARIAN CANCER - PACLITAXEL + CARBOPLATIN ; DAY 1 - PACLITAXEL 175MG/M2 IV, CARBOPLATIN AUC 5-6 MG/MIN/ML IV ; REPEAT EVERY 3 WEEKS FOR 6 CYCLES MEDICAL ONCOLOGY 7400 7400 7400 7400 7400 7400 7400 7400
362 CMU0125 -c : OVARIAN CANCER - DOCETAXEL + CARBOPLATIN ; DAY 1 - DOCETAXEL 60-75MG/M2 IV, CARBOPLATIN AUC 5-6 MG/MIN/ML ; REPEAT EVERY 3 WEEKS FOR 6 CYCLES MEDICAL ONCOLOGY 9200 9200 9200 9200 9200 9200 9200 9200
363 CMU0126 : ENDOMETRIAL CANCER (PALLIATIVE CHEMOTHERAPY ONLY) MEDICAL ONCOLOGY 10500 10500 10500 10500 10500 10500 10500 10500
364 CMU0127 : OVARY- GERM CELL TUMOR MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
365 CMU0127 -a : OVARY- GERM CELL TUMOR - BEP (BLEOMYCIN + ETOPOSIDE + CISPLATIN) ; DAYS 1, 8, 15 - BLEOMYCIN 30 UNITS/WK IV, ETOPOSIDE 100 MG/M 2/DAY IV ; DAYS 1-5 - CISPLATIN 20 MG/M 2/DAY IV ; REPEAT EVERY 21 DAYS 3-4 CYCLES MEDICAL ONCOLOGY 11400 11400 11400 11400 11400 11400 11400 11400
366 CMU0127 -b : OVARY- GERM CELL TUMOR - EP ( ETOPOSIDE + CARBOPLATIN) ; DAY 1 - CARBOPLATIN 400 MG/M 2 IV ON DAYS 1-3 ; REPEAT EVERY 28 DAYS FOR THREE CYCLES MEDICAL ONCOLOGY 6800 6800 6800 6800 6800 6800 6800 6800
367 CMU0128 : GESTATIONAL TROPHOBLAST DISEASES MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
368 CMU0128 -a : GESTATIONAL TROPHOBLAST DISEASES - METHOTREXATE (5 DAYS REGIMEN) ; DAYS 1-5 - MTX 0.4 MG/KG/DAY IV OR IM FOR 5 DAYS, NOT TO EXCEED 25 MG/DAY ; REPEAT CYCLE EVERY 14 DAYS MEDICAL ONCOLOGY 2200 2200 2200 2200 2200 2200 2200 2200
369 CMU0128 -b : GESTATIONAL TROPHOBLAST DISEASES - METHOTREXATE (8-DAY ALTERNATING REGIMEN) ; DAYS 1, 3, 5, AND 7 - MTX 1 MG/KG IM, ; DAYS 2, 4, 6, AND 8 - FOLINIC ACID 15 MG ; REPEAT CYCLE EVERY 14 DAYS MEDICAL ONCOLOGY 3100 3100 3100 3100 3100 3100 3100 3100
370 CMU0128 -c : GESTATIONAL TROPHOBLAST DISEASES - METHOTREXATE + FOLINIC ACID ; DAY 1 - MTX 100 MG/M 2 IVP, THEN 200 MG/M 2 INFUSION ; DAY 2 - FOLINIC ACID 15 MG IM/PO Q12H FOR 4 DOSES ; REPEAT CYCLE EVERY 18 DAYS MEDICAL ONCOLOGY 2100 2100 2100 2100 2100 2100 2100 2100
371 CMU0128 -d : GESTATIONAL TROPHOBLAST DISEASES - METHOTREXATE - WEEKLY ; MTX 30-50 MG/M 2 IM WEEKLY MEDICAL ONCOLOGY 1400 1400 1400 1400 1400 1400 1400 1400
372 CMU0128 -e : GESTATIONAL TROPHOBLAST DISEASES - ACT-D ; ACT-D 10-13 MCG/KG OR 0.5-MG FLAT DOSE IV QD FOR 5D ; REPEAT CYCLE EVERY 14 DAYS MEDICAL ONCOLOGY 8200 8200 8200 8200 8200 8200 8200 8200
373 CMU0128 -f : GESTATIONAL TROPHOBLAST DISEASES - ACTINOMYCIN ; ACTINOMYCIN 1.25 MG/M 2 IV ; REPEAT EVERY 2 WEEKS MEDICAL ONCOLOGY 2300 2300 2300 2300 2300 2300 2300 2300
374 CMU0128 -g : GESTATIONAL TROPHOBLAST DISEASES - EMA-CO (COMPLETE) ; DAY 1 - ACT-D - 0.5 MG IV, ETOPOSIDE - 100 MG/M2 IV, MTX - 300 MG/M2 IV ; DAY 2 - ACT-D - 0.5 MG IV, ETOPOSIDE - 100 MG/M2 IV, LEUCOVORIN - 15 MG PO/IM Q12H 4 DOSES ; DAY 8 - VINCRISTINE - 0.8 MG/M2 IV, CYCLOPHOSPHAMIDE - 600 MG/M2 IV ; REPEAT CYCLE EVERY 14 DAYS MEDICAL ONCOLOGY 6700 6700 6700 6700 6700 6700 6700 6700
375 CMU0129 : TESTICULAR CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
376 CMU0129 -a : TESTICULAR CANCER - EP ; DAYS 1-5 - ETOPOSIDE 100MG/M2, CISPLATIN 20MG/M2 ; REPEAT CYCLE EVERY 3 WEEKS FOR 4 CYCLES. MEDICAL ONCOLOGY 5700 5700 5700 5700 5700 5700 5700 5700
377 CMU0129 -b : TESTICULAR CANCER - BEP ; DAYS 1-5 - CISPLATIN 20MG/M2, ETOPOSIDE 100MG/M2 ; DAYS 1, 8, AND 15 OR DAYS 2, 9, OR 16 - BLEOMYCIN 30 UNITS IV ; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES. MEDICAL ONCOLOGY 10500 10500 10500 10500 10500 10500 10500 10500
378 CMU0129 -c : TESTICULAR CANCER - VIP ; DAY 1 (BEFORE IFOSFAMIDE) - MESNA 120MG/M2 IV ; DAYS 1-5 - ETOPOSIDE 75MG/M2 IV, MESNA 1, 200MG/M2 IV, IFOSFAMIDE 1, 200MG/M2 IV + CISPLATIN 20MG/M2. ; REPEAT CYCLE EVERY 3 WEEKS FOR 4 CYCLES. MEDICAL ONCOLOGY 6600 6600 6600 6600 6600 6600 6600 6600
379 CMU0130 : PROSTATE CANCERPROSTATE CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
380 CMU0130 -a : PROSTATE CANCER - DOCETAXEL + PREDNISONE ; DAY 1 - DOCETAXEL 75MG/M2 IV, PREDNISONE 5MG ORALLY TWICE DAILY. ; ONCE EVERY 3 WEEKS, REPEAT FOR UP TO 10 CYCLES IF TOLERATED MEDICAL ONCOLOGY 3800 3800 3800 3800 3800 3800 3800 3800
381 CMU0130 -c : PROSTATE CANCER - ZOLEDRONIC ACID FOR SKELETAL METASTASIS MEDICAL ONCOLOGY 2900 2900 2900 2900 2900 2900 2900 2900
382 CMU0131 : FEBRILE NEUTROPENIA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
383 CMU0131 -a : FEBRILE NEUTROPENIA - FIRST-LINE MONOTHERAPY ; PIPERACILLIN-TAZOBACTAM 4.5 G ; CEFEPIME 2 G ; MEROPENEM 1 G ; IMIPENEM-CILASTATIN 500 MG MEDICAL ONCOLOGY 14200 14200 14200 14200 14200 14200 14200 14200
384 CMU0131 -b : FEBRILE NEUTROPENIA - SECOND-LINE DUAL THERAPY ; PIPERACILLIN-TAZOBACTAM 4.5 G IV PLUS AN AMINOGLYCOSIDE ; MEROPENEM 1 G IV PLUS AN AMINOGLYCOSIDE ; IMIPENEM-CILASTATIN 500 MG IV PLUS AN AMINOGLYCOSIDE MEDICAL ONCOLOGY 20500 20500 20500 20500 20500 20500 20500 20500
385 CMU0132 : THYROID CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
386 CMU0132 -a : THYROID CANCER - SORAFENIB ; SORAFENIB 400 MG PO BID MEDICAL ONCOLOGY 3100 3100 3100 3100 3100 3100 3100 3100
387 CMU0132 -b : THYROID CANCER - SUNITINIB ; SUNITINIB 50 MG MEDICAL ONCOLOGY 29900 29900 29900 29900 29900 29900 29900 29900
388 CMU0132 -c : THYROID CANCER - PAZOPANIB MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
389 CMU0132 -d : THYROID CANCER - DOXORUBICIN ; DOXORUBICIN 60 MG/M2 AS MONOTHERAPY OR IN COMBINATION WITH CISPLATIN 40 MG/M2 MEDICAL ONCOLOGY 4600 4600 4600 4600 4600 4600 4600 4600
390 CMU0133 : THYMOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
391 CMU0133 -a : THYMOMA - CAP ; DAY 1 - CISPLATIN 50MG/M2 IV, DOXORUBICIN 50MG/M2 IV, CYCLOPHOSPHAMIDE 500MG/M2 IV. ; REPEAT EVERY 21 DAYS FOR A MAX OF 8 CYCLES. MEDICAL ONCOLOGY 4800 4800 4800 4800 4800 4800 4800 4800
392 CMU0133 -b : THYMOMA - CAPP ; DAY 1 - CYCLOPHOSPHAMIDE 500MG/M2 IV ; DAYS 1-3 - CISPLATIN 30MG/M2 IV ; DAYS 1-3 - DOXORUBICIN 20MG/M2 ; DAYS 1-5 - PREDNISONE 100MG. ; REPEAT EVERY 3 WEEKS FOR 3 CYCLES. MEDICAL ONCOLOGY 7200 7200 7200 7200 7200 7200 7200 7200
393 CMU0133 -c : THYMOMA - ADOC ; DAY 1 - CISPLATIN 50MG/M2 IV, DOXORUBICIN 40MG/M2 IV ; DAY 3 - VINCRISTINE 0.6MG/M2 IV ; DAY 4 - CYCLOPHOSPHAMIDE 700MG/M2 IV. ; REPEAT EVERY 3 WEEKS FOR 5 CYCLES. MEDICAL ONCOLOGY 6200 6200 6200 6200 6200 6200 6200 6200
394 CMU0133 -d : THYMOMA - PE ; DAY 1 - CISPLATIN 60MG/M2 IV ; DAYS 1-3 - ETOPOSIDE 120MG/M2 IV ; REPEAT EVERY 3 WEEKS FOR A MAX OF 8 CYCLES. MEDICAL ONCOLOGY 5400 5400 5400 5400 5400 5400 5400 5400
395 CMU0133 -e : THYMOMA - VIP ; DAYS 1-4 - ETOPOSIDE 75MG/M2 IV, IFOSFAMIDE 1.2G/M2 IV, CISPLATIN 20MG/M2 IV. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES MEDICAL ONCOLOGY 8000 8000 8000 8000 8000 8000 8000 8000
396 CMU0133 -f : THYMOMA - CARBOPLATIN+PACLITAXEL ; DAY 1 - PACLITAXEL 225MG/M2 IV, CARBOPLATIN AUC = 6 IV ; REPEAT EVERY 3 WEEKS FOR A MAX OF 6 CYCLES. MEDICAL ONCOLOGY 9800 9800 9800 9800 9800 9800 9800 9800
397 CMU0134 : BRAIN CARCINOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
398 CMU0134 -i : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT LOW-GRADE INFILTRATIVE SUPRATENTORIAL ASTROCYTOMA/OLIGODENDROGLIOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
399 CMU0134 -i-a : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT LOW-GRADE INFILTRATIVE SUPRATENTORIAL ASTROCYTOMA/OLIGODENDROGLIOMA - COMBINATION PCV (LOMUSTINE + PROCARBAZINE + VINCRISTINE) ; DAY 1 - LOMUSTINE 110MG/M2 ORALLY. ; DAYS 8-21 - PROCARBAZINE 60MG/M2 ORALLY ONCE DAILY. ; DAYS 8 AND 29 - VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV. ; REPEAT EVERY 6 WEEKS. MEDICAL ONCOLOGY 4000 4000 4000 4000 4000 4000 4000 4000
400 CMU0134 -i-b : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT LOW-GRADE INFILTRATIVE SUPRATENTORIAL ASTROCYTOMA/OLIGODENDROGLIOMA - TEMOZOLOMIDE (7 WEEKS) ; DAYS 1-49 - TEMOZOLOMIDE 75MG/M2 ORALLY. ; REPEAT CYCLE EVERY 11 WEEKS (7 WEEKS ON/4 WEEKS OFF) FOR 6 CYCLES. MEDICAL ONCOLOGY 6800 6800 6800 6800 6800 6800 6800 6800
401 CMU0134 -i-c : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT LOW-GRADE INFILTRATIVE SUPRATENTORIAL ASTROCYTOMA/OLIGODENDROGLIOMA - TEMOZOLOMIDE MONTHLY 5-DAY COURSE ; TEMOZOLOMIDE MONTHLY 5-DAY COURSES AT DOSES OF 180 - 200MG/M2/DAY MEDICAL ONCOLOGY 2200 2200 2200 2200 2200 2200 2200 2200
402 CMU0134 -i-d : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT LOW-GRADE INFILTRATIVE SUPRATENTORIAL ASTROCYTOMA/OLIGODENDROGLIOMA - TEMOZOLOMIDE (3 WEEKS) ; DAYS 1-21 - TEMOZOLOMIDE 75MG/M2/DAY ORALLY. ; REPEAT CYCLE EVERY 28 DAYS. MEDICAL ONCOLOGY 3600 3600 3600 3600 3600 3600 3600 3600
403 CMU0134 -ii : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMASSYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
404 CMU0134 -ii-a : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - TEMOZOLOMIDE MONTHLY 5-DAY COURSE ; DAYS 1-5 - TEMOZOLOMIDE 200MG/M2/DAY ORALLY. ; REPEAT CYCLE EVERY 4 WEEKS UNTIL DISEASE PROGRESSION OR FOR UP TO 24 CYCLES. MEDICAL ONCOLOGY 2200 2200 2200 2200 2200 2200 2200 2200
405 CMU0134 -ii-b : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - PCV WITH DEFERRED RT (LOMUSTINE + PROCARBAZINE + VINCRISTINE) ; DAY 1 - LOMUSTINE 110MG/M2 ORALLY ; DAYS 8-21 - PROCARBAZINE 60MG/M2 ORALLY ONCE DAILY ; DAYS 8 AND 29 - VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV. ; REPEAT EVERY 6 WEEKS MEDICAL ONCOLOGY 4000 4000 4000 4000 4000 4000 4000 4000
406 CMU0134 -ii-c : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - CONCURRENT TEMOZOLOMIDE (WITH RT) - FOLLOWED BY ADJUVANT TEMOZOLOMIDE ; MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
407 CMU0134 -ii-c-1 : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - CONCURRENT TEMOZOLOMIDE (WITH RT) - FOLLOWED BY ADJUVANT TEMOZOLOMIDE ; DAILY ORAL TEMOZOLOMIDE (75MG/M2/DAY, 7 DAYS PER WEEK FROM THE FIRST TO THE LAST DAY OF RADIOTHERAPY) MEDICAL ONCOLOGY 7600 7600 7600 7600 7600 7600 7600 7600
408 CMU0134 -ii-c-2 : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - ADJUVANT TEMOZOLOMIDE - PRECEEDED BY CONCURRENT TEMOZOLOMIDE (WITH RT) ; TEMOZOLOMIDE 150-200MG/M2/DAY FOR 5 DAYS. ; REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLES MEDICAL ONCOLOGY 2200 2200 2200 2200 2200 2200 2200 2200
409 CMU0134 -ii-d : ADJUVANT TEMOZOLOMIDE MEDICAL ONCOLOGY 2200 2200 2200 2200 2200 2200 2200 2200
410 CMU0134 -ii-e : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ANAPLASTIC GLIOMAS - PCV FOR 1P19Q CO-DELETED (WITH RADIOTHERAPY) ; DAY 1 - LOMUSTINE 110MG/M2 ORALLY ; DAYS 8-21 - PROCARBAZINE 60MG/M2 ORALLY ONCE DAILY ; DAYS 8 AND 29 - VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV. ; REPEAT EVERY 6 WEEKS. FOR 6 CYCLES MEDICAL ONCOLOGY 4000 4000 4000 4000 4000 4000 4000 4000
411 CMU0134 -iii : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR GLIOBLASTOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
412 CMU0134 -iii-a : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR GLIOBLASTOMA - CONCURRENT TEMOZOLOMIDE (WITH RT) - FOLLOWED BY ADJUVANT TEMOZOLOMIDE ; DAILY ORAL TEMOZOLOMIDE (75MG/M2/DAY, 7 DAYS PER WEEK FROM THE FIRST TO THE LAST DAY OF RADIOTHERAPY) MEDICAL ONCOLOGY 7600 7600 7600 7600 7600 7600 7600 7600
413 CMU0134 -iii-b : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR GLIOBLASTOMA - ADJUVANT TEMOZOLOMIDE (PRECEEDED BY CONCURRENT TEMOZOLZMIDE) ; DAYS 1-5 - TEMOZOLOMIDE 150-200MG/M2/DAY ORALLY FOR 5 DAYS. ; REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLES. MEDICAL ONCOLOGY 2200 2200 2200 2200 2200 2200 2200 2200
414 CMU0134 -iii-c : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR GLIOBLASTOMA - TEMOZOLOMIDE (POST RT) ; DAYS 1-5 - TEMOZOLOMIDE 150-200MG/M2/DAY ORALLY FOR 5 DAYS. ; REPEAT CYCLE EVERY 28 DAYS MEDICAL ONCOLOGY 2200 2200 2200 2200 2200 2200 2200 2200
415 CMU0134 -iii-d : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR GLIOBLASTOMA - TEMOZOLOMIDE (200MG) WITH STANDARD RT ; DAYS 1-5 - TEMOZOLOMIDE 200MG/M2, ORALLY MEDICAL ONCOLOGY 2200 2200 2200 2200 2200 2200 2200 2200
416 CMU0134 -iv : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT MEDULLOBLASTOMA AND SUPRATENTORIAL PRIMITIVE NEUROECTODERMAL TUMOR (PNET) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
417 CMU0134 -iv-a : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT MEDULLOBLASTOMA AND SUPRATENTORIAL PRIMITIVE NEUROECTODERMAL TUMOR (PNET) - VINCRISTINE + CISPLATIN + LOMUSTINE ; DAY 1 - LOMUSTINE 75MG/M2 ORALLY ; DAY 2 - CISPLATIN 75MG/M2 IV ; DAYS 2, 8 AND 15 - VINCRISTINE 1.5MG/M2 IV BOLUS, MAX 2MG BOLUS; ; DURING CRANIO-SPINAL RT MEDICAL ONCOLOGY 4600 4600 4600 4600 4600 4600 4600 4600
418 CMU0134 -iv-b : BRAIN CARCINOMA - SYSTEMIC THERAPY FOR ADULT MEDULLOBLASTOMA AND SUPRATENTORIAL PRIMITIVE NEUROECTODERMAL TUMOR (PNET) - VINCRISTINE + CISPLATIN + CYCLOPHOSPHAMIDE ; DAY 1 - CISPLATIN 75MG/M2 IV ; DAYS 2, 8 AND 15 - VINCRISTINE 1.5MG/M2 IV BOLUS, MAX 2MG BOLUS ; DAYS 22, 23 - CYCLOPHOSPHAMIDE 1, 000MG/M2 IV. MEDICAL ONCOLOGY 5800 5800 5800 5800 5800 5800 5800 5800
419 CMU0134 -v : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMAPRIMARY CNS LYMPHOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
420 CMU0134 -v-a : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE COMBINED WITH THE FOLLOWING PLUS RADIATION THERAPYHIGH DOSE METHOTREXATE COMBINED WITH THE FOLLOWING PLUS RADIATION THERAPY MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
421 CMU0134 -v-a-1 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE + CYTARABINE ; DAY 1 - MTX 3.5G/M2 ; DAYS 2-3 - CYTARABINE 2G/M2 IV TWICE A DAY. MEDICAL ONCOLOGY 6900 6900 6900 6900 6900 6900 6900 6900
422 CMU0134 -v-a-2 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE + LEUCOVORIN + IFOSFAMIDE + MESNA ; DAY 1 - MTX 4GM/M2 IV, ; DAYS 2-5 - LEUCOVORIN 20-25MG IV (UPTO 40MG) ; DAYS 3-5 - IFOSFAMIDE 1.5GM/M2 IV + MESNA 400MG IV MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
423 CMU0134 -v-b : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE COMBINED WITH THE FOLLOWING PLUS RADIATION THERAPY HIGH DOSE METHOTREXATE (MTX 2.5-4.0MG/M2) + CHEMOTHERAPY MONOCLONAL ANTIBODY MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
424 CMU0134 -v-b-1 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - RITUXIMAB + MTX + VINCRISTINE +PROCARBAZINE ; DAY 1 - RITUXIMAB 500MG/M2 IV ; DAY 2 - MTX 3.5MG/M2 IV PLUS VINCRISTINE 1.4MG/M2 ; PROCARBAZINE 100MG/M2/DAY ADMINISTERED FOR 7 DAYS WITH ODD-NUMBERED CYCLES MEDICAL ONCOLOGY 44000 44000 44000 44000 44000 44000 44000 44000
425 CMU0134 -v-c : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE (MTX 8.0MG/M2) + CHEMOTHERAPY +/- MONOCLONAL ANTIBODY HIGH DOSE METHOTREXATE (MTX 8.0MG/M2) + CHEMOTHERAPY MONOCLONAL ANTIBODY MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
426 CMU0134 -v-c-1 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE INDUCTION ; MTX 8G/M2 IV ; REPEAT EVERY 2 WEEKS UNTIL COMPLETE RESPONSE ACHIEVED OR MAX OF 8 CYCLES REACHED. ; MEDICAL ONCOLOGY 8300 8300 8300 8300 8300 8300 8300 8300
427 CMU0134 -v-c-2 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE CONSOLIDATION ; MTX 8G/M2 IV ADMINISTERED ; REPEAT EVERY 2 WEEKS FOR 2 CYCLES. MEDICAL ONCOLOGY 8300 8300 8300 8300 8300 8300 8300 8300
428 CMU0134 -v-c-3-i : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE MAINTANANCE (CYCLES 1-4) ; DAY 1 - MTX 8G/M2 IV, RITUXIMAB 375MG/M2 IV. ; REPEAT EVERY 4 WEEKS FOR 4 CYCLES MEDICAL ONCOLOGY 27600 27600 27600 27600 27600 27600 27600 27600
429 CMU0134 -v-c-3-ii : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - HIGH DOSE METHOTREXATE MAINTANANCE (CYCLES 5-11) ; MTX 8G/M2 IV ADMINISTERED EVERY 4 WEEKS FOR 11 CYCLES. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES MEDICAL ONCOLOGY 8300 8300 8300 8300 8300 8300 8300 8300
430 CMU0134 -v-d : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - RITUXIMAB + TEMOZOLOMIDE REGIMEN MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
431 CMU0134 -v-d-1 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - RITUXIMAB + TEMOZOLOMIDE REGIMEN - INDUCTION ; DAY 1 - RITUXIMAB 375MG/M2 IV, FOLLOWED BY ; DAYS 1-5 - TEMOZOLOMIDE 150-200MG/M2 ORALLY DAILY, AFTER RITUXIMAB INFUSION. ; REPEAT CYCLE EVERY 4 WEEKS FOR 4 CYCLES. MEDICAL ONCOLOGY 22700 22700 22700 22700 22700 22700 22700 22700
432 CMU0134 -v-d-2 : BRAIN CARCINOMA - PRIMARY CNS LYMPHOMA - RITUXIMAB + TEMOZOLOMIDE REGIMEN - MAINTANANCEDAYS 1-5 - TEMOZOLOMIDE 150-200MG/M2 ORALLY DAILY. ; REPEAT CYCLE EVERY 4 WEEKS FOR 8 CYCLES. MEDICAL ONCOLOGY 1700 1700 1700 1700 1700 1700 1700 1700
433 CMU0134 -v-e : BRAIN CARCINOMA - MENINGIOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
434 CMU0134 -v-e-1 : BRAIN CARCINOMA - MENINGIOMA - INTERFERON-ALFAINTERFERON-ALFA ; ALPHA-IFN 106 UNITS/M2 SC EVERY OTHER DAY FOR 4 WEEKS. ; REPEAT CYCLE EVERY 4 WEEKS. ; MEDICAL ONCOLOGY 6300 6300 6300 6300 6300 6300 6300 6300
435 CMU0134 -v-e-2 : BRAIN CARCINOMA - MENINGIOMA -SOMATOSTATIN ANALOG ; SANDOSTATIN LAR DEPOT 10-30MG IM ; REPEAT EVERY 4 WEEKS. ; MEDICAL ONCOLOGY 5700 5700 5700 5700 5700 5700 5700 5700
436 CMU0134 -v-e-3 : BRAIN CARCINOMA - MENINGIOMA - SUNITINIB ; DAYS 1-28 - SUNITINIB 50MG ORALLY DAILY. ; REPEAT CYCLE EVERY 42 DAYS. MEDICAL ONCOLOGY 3100 3100 3100 3100 3100 3100 3100 3100
437 CMU0135 : HEAD AND NECK CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
438 CMU0135 -i : HEAD AND NECK CANCER - SQUAMOUS CELL CANCERS MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
439 CMU0135 -i-a : HEAD AND NECK CANCER - HIGH DOSE CISPLATIN ; CISPLATIN 100MG/M2 IV + CONCURRENT RADIOTHERAPY; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES MEDICAL ONCOLOGY 2100 2100 2100 2100 2100 2100 2100 2100
440 CMU0135 -i-b : HEAD AND NECK CANCER - CARBOPLATIN + INFUSIONAL 5-FU ; DAYS 1-4 - 5-FU 600MG/M2/DAY AS CONTINUOUS IV I, CARBOPLATIN 70MG/M2/DAY IV ; REPEAT EVERY 3 WEEKS FOR 3 CYCLES (GIVEN CONCURRENTLY WITH RADIOTHERAPY). MEDICAL ONCOLOGY 5000 5000 5000 5000 5000 5000 5000 5000
441 CMU0135 -i-c : HEAD AND NECK CANCER - 5-FU + HYDROXYUREA ; DAY 1 - HYDROXYUREA 1, 000MG ORALLY EVERY 12 HOURS (11 DOSES/CYCLE), 5-FU 800MG/M2/DAY ; REPEAT EVERY OTHER WEEK FOR 7 CYCLES. WITH CONCURRENT RADIOTHERAPY MEDICAL ONCOLOGY 2400 2400 2400 2400 2400 2400 2400 2400
442 CMU0135 -i-d : HEAD AND NECK CANCER - CISPLATIN + PACLITAXEL ; DAY 1 - PACLITAXEL 30MG/M2 IV (EVERY MONDAY), ; DAY 2 - CISPLATIN 20MG/M2 IV (EVERY TUESDAY). ; REPEAT CYCLE EVERY WEEK FOR 7 CYCLES, WITH CONCURRENT RADIOTHERAPY MEDICAL ONCOLOGY 3600 3600 3600 3600 3600 3600 3600 3600
443 CMU0135 -i-e : HEAD AND NECK CANCER - CISPLATIN + INFUSIONAL 5-FU ; DAY 1 - CISPLATIN 60MG/M2 OVER ; DAYS 1-5 - 5-FU 800MG/M2/DAY ; REPEAT EVERY OTHER WEEK FOR 7 CYCLES. WITH CONCURRENT RADIOTHERAPY MEDICAL ONCOLOGY 5600 5600 5600 5600 5600 5600 5600 5600
444 CMU0135 -i-f : HEAD AND NECK CANCER - CARBOPLATIN + PACLITAXEL ; DAY 1 - PACLITAXEL 40-45MG/M2, CARBOPLATIN 100MG/M2 ; REPEAT CYCLE EVERY WEEK FOR 8 CYCLES, WITH CONCURRENT RADIOTHERAPY MEDICAL ONCOLOGY 3700 3700 3700 3700 3700 3700 3700 3700
445 CMU0135 -i-g : HEAD AND NECK CANCER - WEEKLY CISPLATIN ; CISPLATIN 40MG/M2 IV PER WEEK MEDICAL ONCOLOGY 1900 1900 1900 1900 1900 1900 1900 1900
446 CMU0135 -i-h : HEAD AND NECK CANCER - CISPLATIN (FOR HIGH RISK OROPHARYNGEAL CARCINOMA) ; DAYS 1, 22, AND 43 - CISPLATIN 100MG/M2 IV + RADIOTHERAPY. MEDICAL ONCOLOGY 5600 5600 5600 5600 5600 5600 5600 5600
447 CMU0135 -ii : HEAD AND NECK CANCER - NASOPHARYNX CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
448 CMU0135 -i-i : HEAD AND NECK CANCER - DOCETAXEL + CISPLATIN + 5-FU ; DAY 1 - DOCETAXEL 75MG/M2 IV, CISPLATIN 75MG/M2 IV, ; DAYS 1-5 - 5-FU 750MG/M2/DAY IV. ; REPEAT EVERY 3 WEEKS FOR UP TO 4 CYCLES. MEDICAL ONCOLOGY 7100 7100 7100 7100 7100 7100 7100 7100
449 CMU0135 -ii-a : NASOPHARYNX CANCER - CONCURRENT CISPLATIN FOLLOWED BY CONCURRENT CISPLATIN +5FUC ; MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
450 CMU0135 -ii-a-1 : NASOPHARYNX CANCER - CONCURRENT CISPLATIN (FOLLOWED BY CONCURRENT CISPLATIN +5FU) ; DAY 1 - CISPLATIN 100MG/M2 IV; PLUS RADIOTHERAPY. ; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES; FOLLOWED BY CONCURRENT CISPLATIN +5FU MEDICAL ONCOLOGY 2100 2100 2100 2100 2100 2100 2100 2100
451 CMU0135 -ii-a-2 : NASOPHARYNX CANCER - CONCURRENT CISPLATIN +5FU - PRECEEDED BY (CONCURRENT CISPLATIN 3 CYCLES) ; DAYS 1-4 - CISPLATIN 80MG/M2/DAY, 5-FU 1, 000MG/M2/DAY IV ; REPEAT CYCLE EVERY 4 WEEKS FOR 3 CYCLES MEDICAL ONCOLOGY 7100 7100 7100 7100 7100 7100 7100 7100
452 CMU0135 -ii-b : NASOPHARYNX CANCER - CONCURRENT CARBOPLATIN FOLLOWED BY CONCURRENT CARBOPLATIN +5FU MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
453 CMU0135 -ii-b-1 : NASOPHARYNX CANCER - CONCURRENT CARBOPLATIN - (FOLLOWED BY CONCURRENT CARBOPLATIN +5FU) ; DAY 1 - CARBOPLATIN AUC 6MG/MIN/ML IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES; MEDICAL ONCOLOGY 4500 4500 4500 4500 4500 4500 4500 4500
454 CMU0135 -ii-b-2 : NASOPHARYNX CANCER - CONCURRENT CARBOPLATIN +5FU - PRECEEDED BY (CONCURRENT CARBOPLATIN ) ; DAY 1 - CARBOPLATIN AUC 5MG/MIN/ML IV ; DAYS 1-4 - 5-FU 1, 000MG/M2/DAY IV ; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES. MEDICAL ONCOLOGY 14200 14200 14200 14200 14200 14200 14200 14200
455 CMU0135 -ii-c : NASOPHARYNX CANCER - CONCURRENT CISPLATIN ; CISPLATIN 40MG/M2 ; REPEAT WEEKLY FOR 7 CYCLES MEDICAL ONCOLOGY 1900 1900 1900 1900 1900 1900 1900 1900
456 CMU0135 -ii-d : NASOPHARYNX CANCER - DOCETAXEL + CISPLATIN + 5-FU FOLLOWED BY CISPLATIN ; MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
457 CMU0135 -ii-d-1 : NASOPHARYNX CANCER - DOCETAXEL + CISPLATIN + 5-FU - FOLLOWED BY CISPLATIN AFTER 3 CYCLES ; DAY 1 - DOCETAXEL 70MG/M2 IV, CISPLATIN 75MG/M2 IV ; DAYS 1-4 - 5-FU 1, 000MG/M2/DAY IV ; REPEAT EVERY WEEK FOR 3 CYCLES MEDICAL ONCOLOGY 6500 6500 6500 6500 6500 6500 6500 6500
458 CMU0135 -ii-d-2 : NASOPHARYNX CANCER - CISPLATIN - WEEKLY - PRECEDED BY 3 CYCLES OF DOCETAXEL + 5-FU ; DAY 1 - CISPLATIN 100MG/M2; ; REPEAT EVERY 3 WEEKS, TILL RADIATION MEDICAL ONCOLOGY 3000 3000 3000 3000 3000 3000 3000 3000
459 CMU0135 -ii-e : NASOPHARYNX CANCER - DOCETAXEL + CISPLATIN MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
460 CMU0135 -ii-e-1 : NASOPHARYNX CANCER - DOCETAXEL + CISPLATIN - FOLLOWED BY CISPLATIN AFTER 2 CYCLES ; DAY 1 - DOCETAXEL 75MG/M2 IV + CISPLATIN 75MG/M2 IV ; REPEAT EVERY 3 WEEKS FOR TWO CYCLES MEDICAL ONCOLOGY 4100 4100 4100 4100 4100 4100 4100 4100
461 CMU0135 -ii-e-2 : NASOPHARYNX CANCER - CISPLATIN - WEEKLY - PRECEDED BY 2 CYCLES OF DOCETAXEL + CISPLATIN ; CISPLATIN 40MG/M2 IV ; WEEKLY CONCURRENT WITH RADIOTHERAPY. MEDICAL ONCOLOGY 2400 2400 2400 2400 2400 2400 2400 2400
462 CMU0135 -ii-f : NASOPHARYNX CANCER - CISPLATIN + 5-FU ; DAY 1 - CISPLATIN 100MG/M2/DAY IV. ; DAYS 1-4 - 5-FU 1, 000MG/M2/DAY CONTINUOUS IV INFUSION FOR 4 DAYS. ; REPEAT CYCLE EVERY 3 WEEKS FOR A MINIMUM OF 6 CYCLES MEDICAL ONCOLOGY 5400 5400 5400 5400 5400 5400 5400 5400
463 CMU0135 -i-j : HEAD AND NECK CANCER - PACLITAXEL + CISPLATIN+ INFUSIONAL 5-FU ; DAY 1 - PACLITAXEL 175MG/M2 ; DAY 2 - CISPLATIN 100MG/M2 ; DAY 2-6 - 5-FU 500MG/M2/DAY IV ; REPEAT EVERY 3 WEEKS FOR 3 CYCLES. MEDICAL ONCOLOGY 8300 8300 8300 8300 8300 8300 8300 8300
464 CMU0136 : RENAL CELL CARCINOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
465 CMU0136 -a : RENAL CELL CARCINOMA - PAZOPANIB MEDICAL ONCOLOGY 20000 20000 20000 20000 20000 20000 20000 20000
466 CMU0136 -b : RENAL CELL CARCINOMA - SUNITINIB MEDICAL ONCOLOGY 30500 30500 30500 30500 30500 30500 30500 30500
467 CMU0136 -c : RENAL CELL CARCINOMA - SORAFENIB MEDICAL ONCOLOGY 6100 6100 6100 6100 6100 6100 6100 6100
468 CMU0136 Ia : RENAL CELL CARCINOMA - FIRST-LINE THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL HISTOLOGY - PAZOPANIB ; PAZOPANIB 800MG ORALLY ONCE DAILY MEDICAL ONCOLOGY 20200 20200 20200 20200 20200 20200 20200 20200
469 CMU0136 Ib : RENAL CELL CARCINOMA - FIRST-LINE THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL HISTOLOGY - SUNITINIB ; SUNITINIB 50MG ORALLY DAILY FOR 4 WEEKS, FOLLOWED BY 2 WEEKS OFF. MEDICAL ONCOLOGY 30700 30700 30700 30700 30700 30700 30700 30700
470 CMU0136 Ic : RENAL CELL CARCINOMA - FIRST-LINE THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL HISTOLOGY - BEVACIZUMAB + IFN-ALPHA ; BEVACIZUMAB 10MG/KG IV EVERY 2 WEEKS + IFN-ALPHA. MEDICAL ONCOLOGY 70100 70100 70100 70100 70100 70100 70100 70100
471 CMU0136 Id : RENAL CELL CARCINOMA - FIRST-LINE THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL HISTOLOGY - SORAFENIB ; SORAFENIB 400MG ORALLY TWICE DAILY MEDICAL ONCOLOGY 3800 3800 3800 3800 3800 3800 3800 3800
472 CMU0136 IIa : RENAL CELL CARCINOMA - SUBSEQUENT THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL CARCINOMA - EVEROLIMUS ; EVEROLIMUS 10MG ORALLY ONCE DAILY MEDICAL ONCOLOGY 39100 39100 39100 39100 39100 39100 39100 39100
473 CMU0136 IIb : RENAL CELL CARCINOMA - SUBSEQUENT THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL CARCINOMA - PAZOPANIB ; PAZOPANIB 800MG ORALLY ONCE DAILY MEDICAL ONCOLOGY 20200 20200 20200 20200 20200 20200 20200 20200
474 CMU0136 IIc : RENAL CELL CARCINOMA - SUBSEQUENT THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL CARCINOMA - SORAFENIB ; SORAFENIB 400MG ORALLY TWICE DAILY MEDICAL ONCOLOGY 3800 3800 3800 3800 3800 3800 3800 3800
475 CMU0136 IId : RENAL CELL CARCINOMA - SUBSEQUENT THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL CARCINOMA - SUNITINIB ; SUNITINIB 50MG ORALLY DAILY FOR 4 WEEKS, FOLLOWED BY 2 WEEKS OFF. MEDICAL ONCOLOGY 30700 30700 30700 30700 30700 30700 30700 30700
476 CMU0136 IIe : RENAL CELL CARCINOMA - SUBSEQUENT THERAPY FOR PATIENTS WITH PREDOMINANTLY CLEAR CELL CARCINOMA - BEVACIZUMAB ; BEVACIZUMAB 10MG/KG IV EVERY 2 WEEKS. MEDICAL ONCOLOGY 69600 69600 69600 69600 69600 69600 69600 69600
477 CMU0136 IIIa : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - SUNITINIB ; SUNITINIB 50MG ORALLY DAILY FOR 4 WEEKS, FOLLOWED BY 2 WEEKS OFF. MEDICAL ONCOLOGY 30700 30700 30700 30700 30700 30700 30700 30700
478 CMU0136 IIIb : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - BEVACIZUMAB ; BEVACIZUMAB 10MG/KG IV EVERY 2 WEEKS. MEDICAL ONCOLOGY 69600 69600 69600 69600 69600 69600 69600 69600
479 CMU0136 IIIc : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - EVEROLIMUS ; EVEROLIMUS 10MG ORALLY ONCE DAILY MEDICAL ONCOLOGY 39100 39100 39100 39100 39100 39100 39100 39100
480 CMU0136 IIId : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - ERLOTINIB ; ERLOTINIB 150MG ORALLY ONCE DAILY MEDICAL ONCOLOGY 3600 3600 3600 3600 3600 3600 3600 3600
481 CMU0136 IIIe : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - PAZOPANIB ; PAZOPANIB 800MG ORALLY ONCE DAILY MEDICAL ONCOLOGY 20200 20200 20200 20200 20200 20200 20200 20200
482 CMU0136 IIIf : RENAL CELL CARCINOMA - SYSTEMIC THERAPY FOR PATIENTS WITH NON-CLEAR CELL HISTOLOGY - SORAFENIB ; SORAFENIB 400MG ORALLY TWICE DAILY MEDICAL ONCOLOGY 3800 3800 3800 3800 3800 3800 3800 3800
483 CMU0137 : UNKNOWN PRIMARY MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
484 CMU0137 -i : UNKNOWN PRIMARY - ADENOCARCINOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
485 CMU0137 -i-a : UNKNOWN PRIMARY - ADENOCARCINOMA - PACLITAXEL + CARBOPLATIN + ETOPOSIDE ; DAY 1 - PACLITAXEL 200 MG/M 2 IV, CARBOPLATIN AUC 6 ; DAYS 1-10 - ETOPOSIDE 50 MG PO ALTERNATING WITH 100 MG DAILY ; REPEAT EVERY 21DAYS FOR 2-3 CYCLES; RESTAGE, CAN BE TREATED UPTO 8 CYCLES MEDICAL ONCOLOGY 8400 8400 8400 8400 8400 8400 8400 8400
486 CMU0137 -i-b : UNKNOWN PRIMARY - ADENOCARCINOMA - PACLITAXEL + CARBOPLATIN ; DAY 1 - PACLITAXEL 200 MG/M 2, CARBOPLATIN AUC 6 ; REPEAT CYCLE EVERY 3 WEEKS, MAXIMUM 8 CYCLES MEDICAL ONCOLOGY 7600 7600 7600 7600 7600 7600 7600 7600
487 CMU0137 -i-c : UNKNOWN PRIMARY - ADENOCARCINOMA - DOCETAXEL + CARBOPLATIN ; DAY 1 - DOCETAXEL 65MG/M2 IV, CARBOPLATIN AUC 6 ; REPEAT CYCLE EVERY 3 WEEKS, MAXIMUM 8 CYCLES. MEDICAL ONCOLOGY 4000 4000 4000 4000 4000 4000 4000 4000
488 CMU0137 -i-d : UNKNOWN PRIMARY - ADENOCARCINOMA - GEMCITABINE + CISPLATIN ; DAY 1 - CISPLATIN 100MG/M2 IV ; DAY 1 AND 8 - GEMCITABINE 1250MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 4 CYCLES. MEDICAL ONCOLOGY 5600 5600 5600 5600 5600 5600 5600 5600
489 CMU0137 -i-e : UNKNOWN PRIMARY - ADENOCARCINOMA - GEMCITABINE + DOCETAXEL ; DAY 1 AND 8 - GEMCITABINE 1000MG/M2 IV OVER 30 MINUTES ; DAY 8 - DOCETAXEL 75MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS FOR A MAXIMUM OF 6 CYCLES MEDICAL ONCOLOGY 6100 6100 6100 6100 6100 6100 6100 6100
490 CMU0137 -i-f : UNKNOWN PRIMARY - ADENOCARCINOMA - GEMCITABINE + IRINOTECAN ; DAYS 1 AND 8 - IRINOTECAN 100MG/M2 IV, GEMCITABINE 1000MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 6 CYCLES.RESTAGE EVERY 2-3 CYCLES MEDICAL ONCOLOGY 5900 5900 5900 5900 5900 5900 5900 5900
491 CMU0137 -i-g : UNKNOWN PRIMARY - ADENOCARCINOMA - MFOLFOX ; DAY 1 - OXALIPLATIN 85MG/M2 IV OVER 2 HOURS + LEUCOVORIN 400MG/M2 IV OVER 2 HOURS + 5-FU 400MG/M2 IV BOLUS THEN ; DAYS 1 AND 2 - 5-FU 1200MG/M2 (TOTAL 2400MG/M2 OVER 46-48 HOURS) IV CONTINUOUS INFUSION. ; REPEAT CYCLE EVERY 2 WEEKS FOR 24 CYCLES MEDICAL ONCOLOGY 8400 8400 8400 8400 8400 8400 8400 8400
492 CMU0137 -i-h : UNKNOWN PRIMARY - ADENOCARCINOMA - CAPEOX ; DAY 1 - OXALIPLATIN 130MG/M2 IV OVER 2 HOURS ; DAY 1-14 - CAPECITABINE 850-1000MG/M2 ORALLY TWICE DAILY. ; REPEAT CYCLE EVERY 3 WEEKS FOR 16 CYCLES. MEDICAL ONCOLOGY 6800 6800 6800 6800 6800 6800 6800 6800
493 CMU0137 -ii : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
494 CMU0137 -i-i : UNKNOWN PRIMARY - ADENOCARCINOMA - IRINOTECAN + CARBOPLATIN ; DAY 1 - CARBOPLATIN AUC 5MG PER MIN/ML IV ; DAYS 1, 8, AND 15 - IRINOTECAN 60MG/M2 IV. ; REPEAT CYCLE EVERY 4 WEEKS FOR UP TO 6 CYCLES MEDICAL ONCOLOGY 8100 8100 8100 8100 8100 8100 8100 8100
495 CMU0137 -ii-a : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA - PACLITAXEL + CISPLATIN + 5-FU ; PACLITAXEL 175 MG/M 2 IV, ; DAY 2 - CISPLATIN 100 MG/M 2 IV, ; DAY 5-FU (5-FLUOROURACIL) 500 MG/M 2/DAY IV ; REPEAT EVERY 21D MEDICAL ONCOLOGY 6500 6500 6500 6500 6500 6500 6500 6500
496 CMU0137 -ii-b : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA - DOCETAXEL + CISPLATIN + 5-FU ; DAY 1 - DOCETAXEL 75MG/M2 IV, CISPLATIN 75MG/M2 IV. ; DAYS 1-5 - 5-FU 750MG/M2/DAY IV ; REPEAT CYCLE EVERY 3 WEEKS FOR 3 CYCLES. MEDICAL ONCOLOGY 7200 7200 7200 7200 7200 7200 7200 7200
497 CMU0137 -ii-c : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -PACLITAXEL + CARBOPLATIN ; DAY 1 - CARBOPLATIN AUC 6MG PER MIN/ML IV OVER 30 MINUTES + PACLITAXEL 200MG/M2 IV OVER 3 HOURS. ; REPEAT CYCLE EVERY 3 WEEKS FOR 8 CYCLES IN RESPONDING PATIENTS AND FOR 6 CYCLES MAXIMUM IN PATIENTS WITH STABLE DISEASE MEDICAL ONCOLOGY 7600 7600 7600 7600 7600 7600 7600 7600
498 CMU0137 -ii-d : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -CISPLATIN + GEMCITABINE ; DAY 1 - CISPLATIN 100MG/M2 IV ; DAY 1 AND 8 - GEMCITABINE 1250MG/M2 IV. ; REPEAT EVERY 3 WEEKS FOR 4 CYCLES. MEDICAL ONCOLOGY 5500 5500 5500 5500 5500 5500 5500 5500
499 CMU0137 -ii-e : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -MFOLFOX ; DAY 1 - OXALIPLATIN 85MG/M2 IV OVER 2 HOURS + LEUCOVORIN 400MG/M2 IV OVER 2 HOURS + 5-FU 400MG/M2 IV BOLUS THEN ; DAYS 1 AND 2 - 5-FU 1200MG/M2 (TOTAL 2400MG/M2 OVER 46-48 HOURS) IV CONTINUOUS INFUSION. ; REPEAT CYCLE EVERY 2 WEEKS FOR 24 CYCLES. MEDICAL ONCOLOGY 8400 8400 8400 8400 8400 8400 8400 8400
500 CMU0137 -ii-f : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -PACLITAXEL + CISPLATIN ; DAY 1 - PACLITAXEL 175MG/M2 IV + CISPLATIN 60MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS. MEDICAL ONCOLOGY 6800 6800 6800 6800 6800 6800 6800 6800
501 CMU0137 -ii-g : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -DOCETAXEL + CARBOPLATIN ; DAY 1 - DOCETAXEL 75MG/M2 IV OVER 30 MINUTES + CARBOPLATIN AUC 5MG PER MIN/ML IV OVER 30 MINUTES. ; REPEAT CYCLE EVERY 3 WEEKS FOR 8 CYCLES MEDICAL ONCOLOGY 9200 9200 9200 9200 9200 9200 9200 9200
502 CMU0137 -ii-h : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -DOCETAXEL + CISPLATIN ; DAY 1 - DOCETAXEL 60MG/M2 IV + CISPLATIN 80MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR 2 CYCLES AND AN ADDITIONAL 4 CYCLES UNTIL DISEASE PROGRESSION IS DEMONSTRATED MEDICAL ONCOLOGY 5300 5300 5300 5300 5300 5300 5300 5300
503 CMU0137 -iii : UNKNOWN PRIMARY - NEUROENDOCRINE TUMORS MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
504 CMU0137 -ii-i : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -DOCETAXEL + CISPLATIN ; DAY 1 - DOCETAXEL 75MG/M2 IV + CISPLATIN 75MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS FOR UP TO 6 CYCLES. MEDICAL ONCOLOGY 4000 4000 4000 4000 4000 4000 4000 4000
505 CMU0137 -iii-b : UNKNOWN PRIMARY - NEUROENDOCRINE TUMORS - ETOPOSIDE + CISPLATIN ; DAYS 1-3 - ETOPOSIDE 100 MG/M 2 ; DAYS 2-3 - CISPLATIN 45 MG/M 2 IV ; REPEAT EVERY 28 DAYS MEDICAL ONCOLOGY 5300 5300 5300 5300 5300 5300 5300 5300
506 CMU0137 -ii-j : UNKNOWN PRIMARY - SQUAMOUS CELL CARCINOMA -CISPLATIN + FLUOROURACIL ; DAYS 1-5 - CISPLATIN 20MG/M2 IV ; DAYS 1-5 - FLUOROURACIL 700MG/M2/DAY IV VIA CONTINUOUS INFUSION OVER 24 HOURS. ; REPEAT CYCLE EVERY 4 WEEKS FOR 3 CYCLES. MEDICAL ONCOLOGY 7400 7400 7400 7400 7400 7400 7400 7400
507 CMU0138 : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMACA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
508 CMU0138 -a : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - GEMCITABINE + CISPLATIN ; DAYS 1 AND 8 - CISPLATIN 25MG/M2 IV, GEMCITABINE 1, 000MG/M2 IV ; REPEAT EVERY 21 DAYS FOR 4 CYCLES, RE-EVALUATE AND CONTINUE AN ADDITIONAL 4 CYCLES IF WARRANTED MEDICAL ONCOLOGY 3900 3900 3900 3900 3900 3900 3900 3900
509 CMU0138 -b : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - 5-FU ; 5 - FU IV MEDICAL ONCOLOGY 4300 4300 4300 4300 4300 4300 4300 4300
510 CMU0138 -c : CA HEPATO BILIARY /CA COMMON BILE DUCT/CA GALLBLADDER/ CHOLANGIOCARCINOMA - CAPECITABINE ; CAPECITABINE ORAL ; REPEAT EVERY 21 DAYS MEDICAL ONCOLOGY 3800 3800 3800 3800 3800 3800 3800 3800
511 CMU0139 : PANCREAS CARCINOMAPANCREAS CARCINOMA - MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
512 CMU0139 -i : PANCREAS CARCINOMA - PATIENTS WITH RESECTABLE PANCREATIC CANCER - LOCALLY ADVANCED ; MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
513 CMU0139 -i-a : PANCREAS CARCINOMA - PATIENTS WITH RESECTABLE PANCREATIC CANCER - LOCALLY ADVANCED GEMCITABINE ; DAYS 1, 8, AND 15 - GEMCITABINE 1, 000MG/M2 IV ; REPEAT EVERY 4 WEEKS FOR SIX CYCLES MEDICAL ONCOLOGY 6900 6900 6900 6900 6900 6900 6900 6900
514 CMU0139 -ii : PANCREAS CARCINOMA - ADJUVANT CHEMOTHERAPY AND CHEMORADIATION MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
515 CMU0139 -ii-a : PANCREAS CARCINOMA - ADJUVANT CHEMOTHERAPY AND CHEMORADIATION - 5-FU + LEUCOVORIN ; DAYS 1-5 - LEUCOVORIN 20MG/M2 IV, 5-FU 425MG/M2 IV ; REPEAT CYCLE EVERY 4 WEEKS MEDICAL ONCOLOGY 5300 5300 5300 5300 5300 5300 5300 5300
516 CMU0139 -ii-b : PANCREAS CARCINOMA - ADJUVANT CHEMOTHERAPY AND CHEMORADIATION - GEMCITABINE & 5FU ; PRIOR TO CHEMORADIATION - ; DAYS 1, 8 AND 15 - GEMCITABINE 1, 000MG/M2 IV; INITIATE 1-2 WEEKS PRIOR TO CHEMORADIATION (50.4GY + 5-FU 250MG/M2/DAY). ; AFTER CHEMORADIATION - ; DAYS 1, 8 AND 15 - GEMCITABINE 1, 000MG/M2 IV; INITIATE 3-5 WEEKS FOLLOWING CHEMORADIATION. ; REPEAT CYCLE EVERY 4 WEEKS FOR 3 MONTHS. MEDICAL ONCOLOGY 7100 7100 7100 7100 7100 7100 7100 7100
517 CMU0139 -ii-c : PANCREAS CARCINOMA - ADJUVANT CHEMOTHERAPY AND CHEMORADIATION - CONTINUOUS INFUSION 5-FU (WITH RADIATION) ; PRIOR TO CHEMORADIATION - ; DAYS 1-21 - 5-FU 250MG/M2/DAY CONTINUOUS IV INFUSION; INITIATE 1-2 WEEKS PRIOR TO CHEMORADIATION (50.4GY + 5-FU 250MG/M2/DAY). ; AFTER CHEMORADIATION - ; DAYS 1-28 - 5-FU 250MG/M2/DAY CONTINUOUS IV INFUSION; INITIATE 3-5 WEEKS FOLLOWING CHEMORADIATION. ; REPEAT CYCLE EVERY 6 WEEKS FOR 3 MONTHS. MEDICAL ONCOLOGY 21800 21800 21800 21800 21800 21800 21800 21800
518 CMU0139 -iii : PANCREAS CARCINOMA - NEOADJUVANT THERAPY - NEOADJUVANT THERAPY MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
519 CMU0139 -iii-a : PANCREAS CARCINOMA - NEOADJUVANT THERAPY - CAPECITABINECAPECITABINE ; CAPECITABINE ; REPEAT CYCLE EVERY 3 WEEKS FOR UP TO 52 WEEKS. MEDICAL ONCOLOGY 3800 3800 3800 3800 3800 3800 3800 3800
520 CMU0140 : PERI AMPULLARY CARCINOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
521 CMU0140 -a : PERI AMPULLARY CARCINOMA - 5-FU ; FLUOROURACIL 425 MG/M2 ADMINISTERED ON DAYS 1 TO 5 AND 29-33 MEDICAL ONCOLOGY 5600 5600 5600 5600 5600 5600 5600 5600
522 CMU0141 : NEURO ENDOCRINE CARCINOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
523 CMU0141 -a : NEURO ENDOCRINE CARCINOMA - ALL NECS ARE COVERED UNDER ORGAN CANCERS. IF UNCOVERED - UNLISTED ONLY. MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
524 CMU0142 : SARCOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
525 CMU0142 -i : SARCOMA - GASTROINTESTINAL STROMAL TUMOR - GIST MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
526 CMU0142 -i-a : SARCOMA - GASTROINTESTINAL STROMAL TUMOR - GIST - IMATINIB ; IMATINIB 400MG ORALLY ONCE DAILY TO TWICE DAILY MEDICAL ONCOLOGY 3200 3200 3200 3200 3200 3200 3200 3200
527 CMU0142 -ii : SARCOMA - SOFT TISSUE SARCOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
528 CMU0142 -ii-a : SARCOMA - SOFT TISSUE SARCOMA - DOXORUBICIN + DACARBAZINE (AD) ; DAYS 1-4 - DOXORUBICIN 60MG/M2 + DACARBAZINE 750MG/M2 ; REPEAT CYCLE EVERY 3 WEEKS MEDICAL ONCOLOGY 12100 12100 12100 12100 12100 12100 12100 12100
529 CMU0142 -ii-b : SARCOMA - SOFT TISSUE SARCOMA - DOXORUBICIN + IFOSFAMIDE + MESNA ; DAYS 1 AND 2 - DOXORUBICIN 30MG/M2/DAY IV, IFOSFAMIDE 3, 750MG/M2/DAY IV, MESNA 750MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS MEDICAL ONCOLOGY 9700 9700 9700 9700 9700 9700 9700 9700
530 CMU0142 -ii-c : SARCOMA - SOFT TISSUE SARCOMA - MESNA + DOXORUBICIN + IFOSFAMIDE + DACARBAZINE (MAID) ; DAYS 1-3 - DOXORUBICIN 20MG/M2/DAY, IFOSFAMIDE 2, 500MG/M2/DAY, DACARBAZINE 300MG/M2/DAY IV ; DAYS 1-4 - MESNA 2, 500MG/M2/DAY IV FOR 84 TO 96 HOURS. ; REPEAT CYCLE EVERY 3 WEEKS. MEDICAL ONCOLOGY 11300 11300 11300 11300 11300 11300 11300 11300
531 CMU0142 -ii-d : SARCOMA - SOFT TISSUE SARCOMA - IFOSFAMIDE + EPIRUBICIN + MESNA ; DAYS 1 AND 2 - EPIRUBICIN 60MG/M2/DAY IV ; DAYS 1-5 - IFOSFAMIDE 1.8G/M2/DAY IV + MESNA. ; REPEAT CYCLE EVERY 3 WEEKS FOR 5 CYCLES. MEDICAL ONCOLOGY 13500 13500 13500 13500 13500 13500 13500 13500
532 CMU0142 -ii-e : SARCOMA - SOFT TISSUE SARCOMA - GEMCITABINE + DOCETAXEL ; DAYS 1 AND 8 - GEMCITABINE 900MG/M2 IV ; DAY 8 - DOCETAXEL 100MG/M2 IV. ; REPEAT CYCLE EVERY 3 WEEKS MEDICAL ONCOLOGY 5400 5400 5400 5400 5400 5400 5400 5400
533 CMU0142 -ii-f : SARCOMA - SOFT TISSUE SARCOMA - GEMCITABINE + VINORELBINE ; DAYS 1 AND 8 - VINORELBINE 25MG/M2 IV, GEMCITABINE 800MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS MEDICAL ONCOLOGY 15500 15500 15500 15500 15500 15500 15500 15500
534 CMU0142 -ii-g : SARCOMA - SOFT TISSUE SARCOMA - GEMCITABINE + DACARBAZINE ; DAY 1 - GEMCITABINE 1, 800MG/M2 IV + DACARBAZINE 500MG/M2 IV. ; REPEAT CYCLE EVER 2 WEEKS FOR A TOTAL OF 12 CYCLES; MEDICAL ONCOLOGY 3500 3500 3500 3500 3500 3500 3500 3500
535 CMU0142 -ii-h : SARCOMA - SOFT TISSUE SARCOMA - DOXORUBICIN ; DOXORUBICIN 60-75MG/M2 IV ; ONCE EVERY 3 WEEKS MEDICAL ONCOLOGY 3100 3100 3100 3100 3100 3100 3100 3100
536 CMU0142 -ii-i : SARCOMA - SOFT TISSUE SARCOMA - IFOSFAMIDE ; DAYS 1-3 - IFOSFAMIDE 2, 000-3, 000MG/M2/DAY IV FOR 3 TO 4 DAYS + MESNA ; REPEAT EVERY 3 WEEKS. MEDICAL ONCOLOGY 10500 10500 10500 10500 10500 10500 10500 10500
537 CMU0142 -ii-j : SARCOMA - SOFT TISSUE SARCOMA - IFOSFAMIDE ; DAY 1 - IFOSFAMIDE 5, 000MG/M2 + MESNA 5, 000MG/M2 IV ; DAY 2 - MESNA 400-600MG/M2 IV ; IFOSFAMIDE, MESNA ; REPEAT EVERY 3 WEEKS MEDICAL ONCOLOGY 2000 2000 2000 2000 2000 2000 2000 2000
538 CMU0142 -ii-k : SARCOMA - SOFT TISSUE SARCOMA - EPIRUBICIN ; EPIRUBICIN 160MG/M2 IV ; REPEAT EVERY 3 WEEKS MEDICAL ONCOLOGY 6200 6200 6200 6200 6200 6200 6200 6200
539 CMU0142 -ii-l : SARCOMA - SOFT TISSUE SARCOMA - GEMCITABINE ; DAYS 1 AND 8 - GEMCITABINE 1, 200MG/M2 IV ; REPEAT CYCLE EVERY 3 WEEKS. MEDICAL ONCOLOGY 3800 3800 3800 3800 3800 3800 3800 3800
540 CMU0142 -ii-m : SARCOMA - SOFT TISSUE SARCOMA - DACARBAZINE (I) ; DACARBAZINE 250MG/M2/DAY IV FOR 5 DAYS ; REPEAT EVERY 3 WEEKS. MEDICAL ONCOLOGY 6500 6500 6500 6500 6500 6500 6500 6500
541 CMU0142 -ii-n : SARCOMA - SOFT TISSUE SARCOMA - DACARBAZINE (II) ; DACARBAZINE 800-1, 000MG/M2 IV ; REPEAT EVERY 3 WEEKS. MEDICAL ONCOLOGY 2500 2500 2500 2500 2500 2500 2500 2500
542 CMU0142 -ii-o : SARCOMA - SOFT TISSUE SARCOMA - LIPOSOMAL DOXORUBICIN ; LIPOSOMAL DOXORUBICIN 30-50MG/M2 IV ; REPEAT EVERY 4 WEEKS. MEDICAL ONCOLOGY 8300 8300 8300 8300 8300 8300 8300 8300
543 CMU0142 -ii-p : SARCOMA - SOFT TISSUE SARCOMA - TEMOZOLOMIDE ; TEMOZOLOMIDE 200MG/M2 ORALLY TWICE DAILY FOR 5 DAYS, FOLLOWED BY 9 DOSES OF 90MG/M2 ORALLY ; REPEAT EVERY 4 WEEKS MEDICAL ONCOLOGY 4400 4400 4400 4400 4400 4400 4400 4400
544 CMU0143 : PRIMITIVE NEURO ECTODERMAL TUMOR MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
545 CMU0143 -a : PRIMITIVE NEURO ECTODERMAL TUMOR - WEEKLY VINCRISTINE ; VINCRISTINE 1.5MG/M2 IV, MAX 2MG ; FOR 5 TO 6 WEEKS MEDICAL ONCOLOGY 1800 1800 1800 1800 1800 1800 1800 1800
546 CMU0143 -b : PRIMITIVE NEURO ECTODERMAL TUMOR - VINCRISTINE + CISPLATIN + LOMUSTINE ; DURING CRANIOSPINAL RADIOTHERAPY (RT) ; DAY 1 - LOMUSTINE 75MG/M2 ORALLY ; DAY 2 - CISPLATIN 75MG/M2 IV ; DAYS 2, 8 AND 15 - VINCRISTINE 1.5MG/M2 IV BOLUS, MAX 2MG BOLUS; UP TO MAX 8 DOSES MEDICAL ONCOLOGY 4600 4600 4600 4600 4600 4600 4600 4600
547 CMU0143 -c : PRIMITIVE NEURO ECTODERMAL TUMOR - VINCRISTINE + CISPLATIN + CYCLOPHOSPHAMIDE ; DAY 1 - CISPLATIN 75MG/M2 IV ; DAYS 2, 8 AND 15 - VINCRISTINE 1.5MG/M2 IV, MAX 2MG ; DAYS 22, 23 - CYCLOPHOSPHAMIDE 1, 000MG/M2 IV MEDICAL ONCOLOGY 8000 8000 8000 8000 8000 8000 8000 8000
548 CMU0144 : ANAL CANAL CANCER MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
549 CMU0144 -a : ANAL CANAL CANCER - 5-FU + MITOMYCIN ; DAYS 1-4 AND 29-32 - 5-FU 1, 000MG/M2/DAY IV ; DAYS 1 AND 29 - MITOMYCIN 10MG/M2 IV BOLUS (MAXIMUM 20MG PER COURSE), WITH CONCURRENT RADIOTHERAPY MEDICAL ONCOLOGY 12000 12000 12000 12000 12000 12000 12000 12000
550 CMU0144 -b : ANAL CANAL CANCER - CAPECITABINE + MITOMYCIN (I) ; DAYS 1-5 - CAPECITABINE 825MG/M2 ORALLY TWICE DAILY WEEKLY FOR 6 WEEKS, ; DAYS 1 AND 29 - MITOMYCIN 10MG/M2 IV BOLUS, WITH CONCURRENT RADIOTHERAPY. MEDICAL ONCOLOGY 8500 8500 8500 8500 8500 8500 8500 8500
551 CMU0144 -c : ANAL CANAL CANCER - CAPECITABINE + MITOMYCIN (II) ; DAYS 1-5 - CAPECITABINE 825MG/M2 ORALLY TWICE DAILY WEEKLY FOR 6 WEEKS, ; DAY 1 - MITOMYCIN 12MG/M2 IV BOLUS, WITH CONCURRENT RADIOTHERAPY MEDICAL ONCOLOGY 7200 7200 7200 7200 7200 7200 7200 7200
552 CMU0144 -d : ANAL CANAL CANCER - CISPLATIN + 5-FU ; DAYS 1-5 - 5-FU 1, 000MG/M2/DAY IV ; DAY 2 - CISPLATIN 100MG/M2 IV ; REPEAT CYCLE EVERY 4 WEEKS, WITH CONCURRENT RADIOTHERAPY MEDICAL ONCOLOGY 7100 7100 7100 7100 7100 7100 7100 7100
553 CMU0145 : CA-PENIS MEDICAL ONCOLOGY 6000 6000 6000 6000 6000 6000 6000 6000
2361 CMU0975 : SURGERY/CHEMOTHERAPY/RADIOTHERAPY FOR ALL LEUKEMIAS MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2362 CMU0975 A : ALL LEUKEMIA( CHEMOTHERAPHY) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2363 CMU0975 A-I : CHRONIC MYELOID LEUKEMIA (CML) - CHRONIC MYELOID LEUKEMIA (CML) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2364 CMU0975 A-II : ACUTE MYELOID LEUKEMIA (AML) - ACUTE MYELOID LEUKEMIA (AML) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2365 CMU0975 A-II-a : ACUTE MYELOID LEUKEMIA (AML) - DAUNORUBICIN + CYTARABINE 1 - AGE MEDICAL ONCOLOGY 12900 12900 12900 12900 12900 12900 12900 12900
2366 CMU0975 A-I-i-a : CHRONIC MYELOID LEUKEMIA (CML) - IMATINIB - LOW TO INTERMEDIATE RISK - IMATINIB 400MG ORALLY DAILY MEDICAL ONCOLOGY 1600 1600 1600 1600 1600 1600 1600 1600
2367 CMU0975 A-II-b : ACUTE MYELOID LEUKEMIA (AML) - IDARUBICIN + CYTARABINE - AGE MEDICAL ONCOLOGY 24400 24400 24400 24400 24400 24400 24400 24400
2368 CMU0975 A-I-i-b : CHRONIC MYELOID LEUKEMIA (CML) - NILOTINIB - LOW TO INTERMEDIATE RISK - NILOTINIB 300MG ORALLY TWICE DAILY MEDICAL ONCOLOGY 18700 18700 18700 18700 18700 18700 18700 18700
2369 CMU0975 A-II-c : ACUTE MYELOID LEUKEMIA (AML) - DAUNORUBICIN + CYTARABINE 2 - AGE MEDICAL ONCOLOGY 10900 10900 10900 10900 10900 10900 10900 10900
2370 CMU0975 A-II-d : ACUTE MYELOID LEUKEMIA (AML) - DAUNORUBICIN + CYTARABINE (HIGH DOSE) - AGE MEDICAL ONCOLOGY 17600 17600 17600 17600 17600 17600 17600 17600
2371 CMU0975 A-II-e : ACUTE MYELOID LEUKEMIA (AML) - IDARUBICIN + CYTARABINE (HIGH DOSE) - AGE MEDICAL ONCOLOGY 31100 31100 31100 31100 31100 31100 31100 31100
2372 CMU0975 A-II-f : ACUTE MYELOID LEUKEMIA (AML) - DAUNORUBICIN (90MG) + CYTARABINE - AGE ?60 YEARS, DAYS 1-3; DAUNORUBICIN 45-90MG/M2 IV, DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV. MEDICAL ONCOLOGY 12900 12900 12900 12900 12900 12900 12900 12900
2373 CMU0975 A-II-g : ACUTE MYELOID LEUKEMIA (AML) - IDARUBICIN + CYTARABINE - AGE ?60 YEARS, DAYS 1-3; IDARUBICIN 12MG/M2 IV, DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV. MEDICAL ONCOLOGY 24400 24400 24400 24400 24400 24400 24400 24400
2374 CMU0975 A-II-h : ACUTE MYELOID LEUKEMIA (AML) - MITOXANTRONE + CYTARABINE - AGE ?60 YEARS, DAYS 1-3; MITOXANTRONE 12MG/M2 IV), DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV. MEDICAL ONCOLOGY 10800 10800 10800 10800 10800 10800 10800 10800
2375 CMU0975 A-III : CHRONICLYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2376 CMU0975 A-II-i : ACUTE MYELOID LEUKEMIA (AML) - CYTARABINE - AGE ?60 YEARS, LOW-INTENSITY THERAPY, DAYS 1-10; CYTARABINE 20MG SC TWICE DAILY MEDICAL ONCOLOGY 7200 7200 7200 7200 7200 7200 7200 7200
2377 CMU0975 A-I-ii : CHRONICMYELOID LEUKEMIA (CML) - BLAST PHASE-LYMPHOID ALL TYPE INDUCTION + TKI MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2378 CMU0975 A-I-ii-a : CML - BLAST PHASE-LYMPHOID ALL TYPE INDUCTION + TKI - INDUCTION - 4 WEEKS OF STANDARD INDUCTION CHEMOTHERAPY - CYCLOPHOSPHAMIDE 1200 MG/M 2 (800 MG/M2 - OLDER THAN 60 Y) IV ON DAY 1 +DAUNORUBICIN 45 MG/M 2/DAY (30 MG/M 2/DAY - OLDER THAN 60 Y) IV ON DAYS 1-3 +VINCRISTINE 2 MG IV ON DAYS 1, 8, 15, AND 22 +PREDNISONE 60 MG/M 2/DAY PO ON DAYS 1-21 (DAYS 1-7- OLDER THAN 60 Y) + L-ASPARAGINASE 6000 U/M 2 SC ON DAYS 5, 8, 11, 15, 18, AND 22 MEDICAL ONCOLOGY 13500 13500 13500 13500 13500 13500 13500 13500
2379 CMU0975 A-III-a-i : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - RITUXIMAB + CHLORAMBUCIL CYCLE 1 - DAYS 1-7; CHLORAMBUCIL 8MG/M2/DAY ORALLY MEDICAL ONCOLOGY 1200 1200 1200 1200 1200 1200 1200 1200
2380 CMU0975 A-III-a-ii : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - RITUXIMAB + CHLORAMBUCIL CYCLE 3 - DAY 1; RITUXIMAB 375MG/M2 IV, DAYS 1-7; CHLORAMBUCIL 8MG/M2/DAY ORALLY MEDICAL ONCOLOGY 21800 21800 21800 21800 21800 21800 21800 21800
2381 CMU0975 A-III-a-iii : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - RITUXIMAB + CHLORAMBUCIL CYCLE 4-8 - DAY 1; RITUXIMAB 500MG/M2 IV, DAYS 1-7; CHLORAMBUCIL 8MG/M2/DAY ORALLY. MEDICAL ONCOLOGY 28100 28100 28100 28100 28100 28100 28100 28100
2382 CMU0975 A-III-a-iv : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - MAINTANANCE - RITUXIMAB - RITUXIMAB AT DOSE OF 375MG/M2 IV EVERY 2 MONTHS FOR 2 YEARS MEDICAL ONCOLOGY 21700 21700 21700 21700 21700 21700 21700 21700
2383 CMU0975 A-III-b : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - RITUXIMAB DAY 1, 8, 15, AND 22 - DAY 1, 8, 15, AND 22; RITUXIMAB 375MG/M2/DAY IV. MEDICAL ONCOLOGY 85500 85500 85500 85500 85500 85500 85500 85500
2384 CMU0975 A-I-ii-b : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-LYMPHOID ALL TYPE INDUCTION + TKI - IMATINIB - IMATINIB 400MG ORALLY DAILY MEDICAL ONCOLOGY 1600 1600 1600 1600 1600 1600 1600 1600
2385 CMU0975 A-III-c : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - CHLORAMBUCIL - DAYS 1-28; CHLORAMBUCIL 0.4MG/KG/DAY WITH AN INCREASE TO 0.8MG/KG ORALLY DAILY. REPEAT CYCLE EVERY 28 DAYS FOR 12 CYCLES MEDICAL ONCOLOGY 2500 2500 2500 2500 2500 2500 2500 2500
2386 CMU0975 A-I-ii-c : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-LYMPHOID ALL TYPE INDUCTION + TKI - NILOTINIB - NILOTINIB 300MG ORALLY TWICE DAILY MEDICAL ONCOLOGY 18700 18700 18700 18700 18700 18700 18700 18700
2387 CMU0975 A-III-d-i : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - BENDAMUSTINE + RITUXIMAB (CYCLE -1) - DAY 0; RITUXIMAB 375MG/M2 IV, DAYS 1 AND 2; BENDAMUSTINE 70MG/M2 IV. REPEAT NEXT CYCLE AFTER 28 DAYS MEDICAL ONCOLOGY 31100 31100 31100 31100 31100 31100 31100 31100
2388 CMU0975 A-III-d-ii : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - BENDAMUSTINE + RITUXIMAB (CYCLES 2-6) - RITUXIMAB 500MG/M2 ON DAY 1 AND BENDAMUSTINE - 90MG/M2. REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLE MEDICAL ONCOLOGY 32300 32300 32300 32300 32300 32300 32300 32300
2389 CMU0975 A-III-d-iii : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - BENDAMUSTINE (70MG) (CYCLE -1) - DAYS 1 AND 2; BENDAMUSTINE 70MG/M2 IV. REPEAT NEXT CYCLE AFTER 28 DAYS MEDICAL ONCOLOGY 13100 13100 13100 13100 13100 13100 13100 13100
2390 CMU0975 A-III-d-iv : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - BENDAMUSTINE (90 MG) (CYCLES 2-6) - DAY 1 - BENDAMUSTINE 90MG/M2. REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLE MEDICAL ONCOLOGY 6800 6800 6800 6800 6800 6800 6800 6800
2391 CMU0975 A-III-e : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - FLUDARABINE + CYCLOPHOSPHAMIDE + RITUXIMAB (FCR) - DAY 1; RITUXIMAB 375MG OR 500/M2 IV, DAYS 1-3; FLUDARABINE 25MG/M2/DAY IV PLUS CYCLOPHOSPHAMIDE 250MG/M2/DAY IV. REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLE MEDICAL ONCOLOGY 27200 27200 27200 27200 27200 27200 27200 27200
2392 CMU0975 A-III-f : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - FLUDARABINE + RITUXIMAB (FR) - DAYS 1-5; FLUDARABINE 25MG/M2 IV, DAY 1; RITUXIMAB 50MG/M2 IV, DAY 3; RITUXIMAB 325MG/M2 IV, DAY 5; RITUXIMAB 375MG/M2 IV. REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLES WITH RITUXIMAB GIVEN AT A DOSE OF 375MG/M2 ON DAY 1 OF SUBSEQUENT CYCLES. MEDICAL ONCOLOGY 57800 57800 57800 57800 57800 57800 57800 57800
2393 CMU0975 A-III-g : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - ALEMTUZUMAB + RITUXIMAB - DAY 1; ALEMTUZUMAB 3MG IV, DAY 2; ALEMTUZUMAB 10MG IV, DAY 3, 10, 12, 17, 19, 24, AND 26; ALEMTUZUMAB 30MG IV MEDICAL ONCOLOGY 92700 92700 92700 92700 92700 92700 92700 92700
2394 CMU0975 A-III-h : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - ALEMTUZUMAB WITHOUT RITUXIMAB - DAY 1; ALEMTUZUMAB 3MG IV, DAY 2; ALEMTUZUMAB 10MG IV, DAY 3, 10, 12, 17, 19, 24, AND 26; ALEMTUZUMAB 30MG IV MEDICAL ONCOLOGY 12000 12000 12000 12000 12000 12000 12000 12000
2395 CMU0975 A-III-i : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - HIGH-DOSE METHYLPREDNISOLONE + RITUXIMAB - DAYS 1-3; METHYLPREDNISOLONE 1G/M2 IV, DAYS 1, 8, 15, AND 22; RITUXIMAB 375MG/M2 IV. REPEAT CYCLE EVERY 28 DAYS FOR 3 CYCLES MEDICAL ONCOLOGY 88400 88400 88400 88400 88400 88400 88400 88400
2396 CMU0975 A-I-iii : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2397 CMU0975 A-I-iii-a : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - DAUNORUBICIN (90MG/M2)+ CYTARABINE - < 60 YEARS, DAYS 1-3; DAUNORUBICIN 90MG/M2 IV, DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV MEDICAL ONCOLOGY 12900 12900 12900 12900 12900 12900 12900 12900
2398 CMU0975 A-I-iii-b : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - DAUNORUBICIN + CYTARABINE + CLADRIBINE - AGE MEDICAL ONCOLOGY 10900 10900 10900 10900 10900 10900 10900 10900
2399 CMU0975 A-I-iii-c : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - DAUNORUBICIN + CYTARABINE (HIGH DOSE) - AGE MEDICAL ONCOLOGY 17600 17600 17600 17600 17600 17600 17600 17600
2400 CMU0975 A-I-iii-d : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - DAUNORUBICIN (90MG) + CYTARABINE - AGE >60 YEARS - DAYS 1-3; DAUNORUBICIN 45-90MG/M2 IV, DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV. MEDICAL ONCOLOGY 12900 12900 12900 12900 12900 12900 12900 12900
2401 CMU0975 A-I-iii-e : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - IDARUBICIN + CYTARABINE (HIGH DOSE) - DAYS 1-3; IDARUBICIN 12MG/M2, DAYS 1-6; HIGH-DOSE CYTARABINE 2G/M2 IV EVERY 12 HOURS, OR DAYS 1-4; HIGH-DOSE CYTARABINE 3G/M2 IV EVERY 12 HOURS MEDICAL ONCOLOGY 31100 31100 31100 31100 31100 31100 31100 31100
2402 CMU0975 A-I-iii-f : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - IDARUBICIN + CYTARABINE - AGE ?60 YEARS, DAYS 1-3; IDARUBICIN 12MG/M2 IV, DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV. MEDICAL ONCOLOGY 24400 24400 24400 24400 24400 24400 24400 24400
2403 CMU0975 A-I-iii-g : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - MITOXANTRONE + CYTARABINE - AGE ?60 YEARS, DAYS 1-3; MITOXANTRONE 12MG/M2 IV), DAYS 1-7; CYTARABINE 100-200MG/M2 CONTINUOUS IV. MEDICAL ONCOLOGY 11400 11400 11400 11400 11400 11400 11400 11400
2404 CMU0975 A-I-iii-h : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - IMATINIB - IMATINIB 400MG ORALLY DAILY MEDICAL ONCOLOGY 1600 1600 1600 1600 1600 1600 1600 1600
2405 CMU0975 A-I-iii-i : CHRONIC MYELOID LEUKEMIA (CML) - BLAST PHASE-MYELOID AML TYPE INDUCTION + TKI - NILOTINIB - NILOTINIB 300MG ORALLY TWICE DAILY MEDICAL ONCOLOGY 18700 18700 18700 18700 18700 18700 18700 18700
2406 CMU0975 A-III-j : CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL / SLL) - HIGH-DOSE METHYLPREDNISOLONE - DAYS 1-3; METHYLPREDNISOLONE 1G/M2 IV. REPEAT CYCLE EVERY 28 DAYS FOR 3 CYCLES MEDICAL ONCOLOGY 6800 6800 6800 6800 6800 6800 6800 6800
2407 CMU0975 A-II-j : ACUTE MYELOID LEUKEMIA (AML) - DECITABINE - AGE ?60 YEARS, LOW-INTENSITY THERAPY, DAYS 1-5; DECITABINE 20MG/M2 IV FOR A 4-WEEK CYCLE. MEDICAL ONCOLOGY 26300 26300 26300 26300 26300 26300 26300 26300
2408 CMU0975 A-II-k : ACUTE MYELOID LEUKEMIA (AML) - AZACYTIDINE - AGE ?60 YEARS, LOW-INTENSITY THERAPY, DAYS 1-7; 5-AZACYTIDINE 75MG/M2 IV EVERY 28 DAYS MEDICAL ONCOLOGY 81400 81400 81400 81400 81400 81400 81400 81400
2409 CMU0975 A-II-l : ACUTE MYELOID LEUKEMIA (AML) - HYDROXYUREA - AGE ?60 YEARS, HYDROXYUREA 10-70MG/KG/DAY ORALLY IN DIVIDED DOSES. MEDICAL ONCOLOGY 1700 1700 1700 1700 1700 1700 1700 1700
2410 CMU0975 A-II-m : ACUTE MYELOID LEUKEMIA (AML) - CYTARABINE - HIGH DOSE - AGE MEDICAL ONCOLOGY 10200 10200 10200 10200 10200 10200 10200 10200
2411 CMU0975 A-II-n : ACUTE MYELOID LEUKEMIA (AML) - CLADRIBINE + CYTARABINE + IDARUBICIN + GCSF - DAYS 1-5; CLADRIBINE 5MG/M2 IV, DAYS 1-5; CYTARABINE 2G/M2 IV, DAYS 0-5; GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) 300MCG SC, DAYS 1-3; IDARUBICIN 10MG/M2 IV. MEDICAL ONCOLOGY 89400 89400 89400 89400 89400 89400 89400 89400
2412 CMU0975 A-II-o : ACUTE MYELOID LEUKEMIA (AML) - CLADRIBINE + CYTARABINE + MITOXANTRONE + GCSF - DAYS 1-5; CLADRIBINE 5MG/M2 IV, DAYS 1-5; CYTARABINE 2G/M2 IV, DAYS 0-5; GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) 300MCG SC, DAYS 1-3; MITOXANTRONE 10MG/M2 IV. MEDICAL ONCOLOGY 42700 42700 42700 42700 42700 42700 42700 42700
2413 CMU0975 A-II-p : ACUTE MYELOID LEUKEMIA (AML) - FLUDARABINE + CYTARABINE + IDARUBICIN + GCSF -DAYS 1-5; FLUDARABINE 30MG/M2 IV OVER 0.5 HOURS, DAYS 1-5; CYTARABINE 2G/M2 IV OVER 4 HOURS, DAYS 0 TO POLYMORPHONUCLEAR RECOVERY (>0.5 X 109/L); G-CSF 5MCG/KG OR 300MCG/M2. (G-CSF MAY ALSO START ON DAY +6 UNTIL ENGRAFTMENT.) + DAYS 1-3; IDARUBICIN 10MG/M2 IV. MEDICAL ONCOLOGY 70100 70100 70100 70100 70100 70100 70100 70100
2414 CMU0975 A-II-q : ACUTE MYELOID LEUKEMIA (AML) - ETOPOSIDE +CYTARABINE+MITOXANTRONE - ETOPOSIDE +CYTARABINE+MITOXANTRONE, DAYS 1-6; ETOPOSIDE 80MG/M2 IV OVER 1 HOUR, DAYS 1-6; CYTARABINE 1G/M2 IV OVER 6 HOURS + DAYS 1-6; MITOXANTRONE 6MG/M2 IV BOLUS MEDICAL ONCOLOGY 13900 13900 13900 13900 13900 13900 13900 13900
2415 CMU0975 A-II-r : ACUTE MYELOID LEUKEMIA (AML) - CYTARABINE SC - DAYS 1-10; CYTARABINE 20MG SC TWICE DAILY MEDICAL ONCOLOGY 3000 3000 3000 3000 3000 3000 3000 3000
2416 CMU0975 A-II-s : ACUTE MYELOID LEUKEMIA (AML) - AZACYTIDINE - DAYS 1-7; 5-AZACYTIDINE 75MG/M2 IV EVERY 28 DAYS MEDICAL ONCOLOGY 81400 81400 81400 81400 81400 81400 81400 81400
2417 CMU0975 A-II-t : ACUTE MYELOID LEUKEMIA (AML) - DECITABINE - DAYS 1-5; DECITABINE 20MG/M2 IV EVERY 28 DAYS. MEDICAL ONCOLOGY 26800 26800 26800 26800 26800 26800 26800 26800
2418 CMU0975 A-IV : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2419 CMU0975 A-IV-i : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2420 CMU0975 A-IV-i-a-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - CHILDRENS ONCOLOGY GROUP (COG) AALL-0031 INDUCTION PHASE; INDUCTION; 4 WEEKS OF STANDARD INDUCTION CHEMOTHERAPY; CYCLOPHOSPHAMIDE 1200 MG/M 2 (800 MG/M 2 IF PATIENTS OLDER THAN 60 Y) IV ON DAY 1 +DAUNORUBICIN 45 MG/M 2/DAY (30 MG/M 2/DAY IF PATIENTS OLDER THAN 60 Y) IV ON DAYS 1 - 3 +VINCRISTINE 2 MG IV ON DAYS 1, 8, 15, AND 22 +PREDNISONE 60 MG/M 2/DAY PO ON DAYS 1 - 21 (DAYS 1 - 7 IF PATIENTS OLDER THAN 60 Y); MEDICAL ONCOLOGY 14000 14000 14000 14000 14000 14000 14000 14000
2421 CMU0975 A-IV-i-a-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - CHILDRENS ONCOLOGY GROUP (COG) AALL-0031 CONSOLIDATION PHASE - BLOCK 1 - (3 WEEKS); DAY 1 - METHOTREXATE (MTX) INTRATHECALLY (IT), ETOPOSIDE 100MG/M2/DAY INTRAVENOUSLY (IV), IFOSFAMIDE 3.4G/M2/DAY IV; DAYS 1 - 21 - IMATINIB 340MG/M2/DAY ORALLY; DAYS 6 - 15 - FILGRASTIM 5G/KG/DAY SUBCUTANEOUSLY (SC) +/- IMATINIB; DAYS 8 AND 15 - CNS LEUKEMIA ONLY - MTX IT, HYDROCORTISONE IT, CYTARABINE IT; MEDICAL ONCOLOGY 18000 18000 18000 18000 18000 18000 18000 18000
2422 CMU0975 A-IV-i-a-3 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - CHILDRENS ONCOLOGY GROUP (COG) AALL-0031 CONSOLIDATION PHASE - BLOCK 2 (3 WEEKS); DAY 1 - AGE ADJUSTED - MTX IT, HYDROCORTISONE IT, CYTARABINE IT + MTX 5G/M2 IV OVER 24 HOURS; DAYS 1 - 21 - IMATINIB 340MG/M2/DAY ORALLY (HOLD IMATINIB IF PATIENT DOES NOT ACHIEVE COUNT RECOVERY WITHIN 2 WEEKS OF LAST DOSE OF PREVIOUS COURSE); DAYS 2 - 3 - LEUCOVORIN 75MG/M2 36 HOURS AFTER MTX, FOLLOWED BY 15MG/M2 IV OR ORALLY EVERY 6 HOURS FOR 6 DOSES + CYTARABINE 3G/M2/DOSE IV EVERY 12 HOURS FOR 4 DOSES; DAYS 4 - 13 - FILGRASTIM 5G/KG/DAY SC MEDICAL ONCOLOGY 20200 20200 20200 20200 20200 20200 20200 20200
2423 CMU0975 A-IV-i-a-4 : ALL - PH(+) AYA - COG AALL-0031 REINDUCTION ; DAY 1 - VINCRISTINE 1.5MG/M2 IV + AGE ADJUSTED - MTX IT, HYDROCORTISONE IT, CYTARABINE IT; DAYS 1 - 2 - DAUNORUBICIN 45MG/M2/DAY IV BOLUS; DAYS 1 - 21 - DEXAMETHASONE 6MG/M2/DAY ORALLY +/- IMATINIB 340MG/M2/DAY ORALLY (HOLD IMATINIB IF NEEDED); DAYS 3 - 4 - CYCLOPHOSPHAMIDE 250MG/M2/DOSE IV EVERY 12 HOURS FOR 4 DOSES + MESNA 125MG/M2/DOSE IV EVERY 12 HOURS FOR 4 DOSES; DAYS 4, 6, 8, 10, 12, 15, 17, 19, AND 21 - L - ASPARAGINASE 6, 000 IU/M2 INTRAMUSCULARLY (IM); DAYS 5 - 14 - FILGRASTIM 5G/KG/DAY SC; DAYS 8 AND 15 - VINCRISTINE 1.5MG/M2 IV; DAY 15 - MTX IT, HYDROCORTISONE IT, CYTARABINE IT. MEDICAL ONCOLOGY 26600 26600 26600 26600 26600 26600 26600 26600
2424 CMU0975 A-IV-i-a-5 : ALL - PH(+) AYA - COG AALL-0031 INTENSIFICATION; DAY 1 - MTX, HYDROCORTISONE, CYTARABINE - IT + MTX IV; DAYS 1-63 - IMATINIB ORAL; DAYS 2-3 - LEUCOVORIN ; DAY 8 - MTX IV; DAYS 9-10 - LEUCOVORIN; DAY 15 - MTX , HYDROCORTISONE , CYTARABINE - IT; DAYS 15-19 - ETOPOSIDE + CYCLOPHOSPHAMIDE + MESNA - IV; DAYS 20-29 - FILGRASTIM SC; DAYS 36-37 - CYTARABINE; DAY 37 - L - ASPARAGINASE IM +/- IMATINIB; DAYS 43-44 - CYTARABINE IV; DAY 44 - L - ASPARAGINASE IM +/- IMATINIB; MEDICAL ONCOLOGY 43500 43500 43500 43500 43500 43500 43500 43500
2425 CMU0975 A-IV-i-a-6 : ALL - PH(+) AYA - COG AALL-0031 MAINTENANCE CYCLES 1-4 (8 WEEKS); DAY 1 - MTX, HYDROCORTISONE, CYTARABINE - IT + VINCRISTINE + MTX IV; DAYS 1 - 5 - DEXA; DAYS 1 - 56 - IMATINIB; DAY 2 - LEUCOVORIN 36 HOURS AFTER MTX; DAYS 8, 15, AND 22 - MTX ORAL; DAYS 8 - 28 - 6-MP; DAY 29 - MTX, HYDROCORTISONE, CYTARABINE - IT + VINCRISTINE IV; DAYS 29 - 33 - DEXA; DAYS 29 - 40 - IMATINIB; DAYS 36 - 40 - ETOPOSIDE + CYCLOPHOSPHAMIDE IV; DAYS 41 - 50 - FILGRASTIM SC; MEDICAL ONCOLOGY 37400 37400 37400 37400 37400 37400 37400 37400
2426 CMU0975 A-IV-i-a-7 : ALL - PH(+) AYA -COG AALL-0031 MAINTENANCE CYCLES 5-12 (8 WEEKS); CYCLE 5 ONLY - CRANIAL IRRADIATION 12 GY; DAY 1 - VINCRISTINE 1.5MG/M2 IV; DAYS 1 - 5 - DEXAMETHASONE 6MG/M2/DAY ORALLY; DAYS 1 - 14 - IMATINIB 340MG/M2/DAY ORALLY (HOLD IMATINIB IF NEEDED); DAYS 8, 15, AND 22 - MTX 20MG/M2/WEEK ORALLY; DAYS 8 - 28 - 6 - MP 75MG/M2/DAY; DAY 29 - VINCRISTINE 1.5MG/M2 IV; DAYS 29 - 33 - DEXAMETHASONE 6MG/M2/DAY ORALLY; DAYS 29 - 42 - IMATINIB 340MG/M2/DAY ORALLY (HOLD IMATINIB IF NEEDED); DAY 36 - MTX 20MG/M2/WEEK ORALLY; DAYS 36 - 56 - 6 - MP 75MG/M2/DAY; DAYS 43 AND 50 - MTX 20MG/M2/WEEK ORALLY; MEDICAL ONCOLOGY 13500 13500 13500 13500 13500 13500 13500 13500
2427 CMU0975 A-IV-i-b-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 1 AND 3) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY DAYS 1 AND 11 (CYCLES 1 AND 3 ONLY) - RITUXIMAB 375MG/M2 IV. MEDICAL ONCOLOGY 62400 62400 62400 62400 62400 62400 62400 62400
2428 CMU0975 A-IV-i-b-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 2 AND 4); HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES DAYS 2 AND 8 - RITUXIMAB 375MG/M2 IV MEDICAL ONCOLOGY 65500 65500 65500 65500 65500 65500 65500 65500
2429 CMU0975 A-IV-i-b-3 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 5 & 7) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY MEDICAL ONCOLOGY 12000 12000 12000 12000 12000 12000 12000 12000
2430 CMU0975 A-IV-i-b-4 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 6 & 8) DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES DAYS 2 AND 8 MEDICAL ONCOLOGY 14100 14100 14100 14100 14100 14100 14100 14100
2431 CMU0975 A-IV-i-b-5 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) INDUCTION II - DAY 1 - CYCLOPHOSPHAMIDE 1, 200MG/M2 IV OVER 3 HOURS; DAYS 1 - 3 - DAUNORUBICIN 60MG/M2 IV OVER 1 HOUR; DAYS 1 - 21 - PREDNISOLONE 60MG/M2 ORALLY; DAYS 1, 8, 15, AND 22 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 8 - 63 - IMATINIB 600MG ORALLY; DAY 29 - MTX 15MG IT, CYTARABINE 40MG IT, DEXAMETHASONE 4MG IT MEDICAL ONCOLOGY 15900 15900 15900 15900 15900 15900 15900 15900
2432 CMU0975 A-IV-i-b-6 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) INDUCTION III - PRETREATMENT FOR 7 DAYS - PREDNISONE AT INCREASING DOSES FROM 10 - 40MG/M2/DAY; DAYS 1 - 45 - IMATINIB 800MG ORALLY DAILY + PREDNISONE 40MG/M2 DAILY MEDICAL ONCOLOGY 5800 5800 5800 5800 5800 5800 5800 5800
2433 CMU0975 A-IV-i-b-7 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) MAINTENANCE - MTX WEEKLY + 6 - MP DAILY + VINCRISTINE PULSE MONTHLY + PREDNISONE PULSE MONTHLY FOR 2 TO 3 YEARS. MEDICAL ONCOLOGY 10400 10400 10400 10400 10400 10400 10400 10400
2434 CMU0975 A-IV-i-c-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS INDUCTION PHASE - DAY 1 - CYCLOPHOSPHAMIDE 1, 200MG/M2 IV OVER 3 HOURS; DAYS 1 - 3 - DAUNORUBICIN 60MG/M2 IV OVER 1 HOUR; DAYS 1, 8, 15, AND 22 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 1 - 21 - PREDNISOLONE 60MG/M2 ORALLY DAILY; DAYS 8 - 63 - IMATINIB 600MG ORALLY DAILY; DAY 29 - MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT. MEDICAL ONCOLOGY 15900 15900 15900 15900 15900 15900 15900 15900
2435 CMU0975 A-IV-i-c-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS CONSOLIDATION I - DAY 1 - MTX 1G/M2 IV OVER 24 HOURS + MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT; DAYS 1 - 3 - METHYLPREDNISOLONE 50MG IV OVER 1 HOUR × 2 DOSES; DAYS 2 AND 3 - CYTARABINE 2G/M2 IV OVER 3 HOURS; REPEAT FOR 4 CYCLES. MEDICAL ONCOLOGY 8900 8900 8900 8900 8900 8900 8900 8900
2436 CMU0975 A-IV-i-c-3 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS CONSOLIDATION II - DAY 1 - MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT; REPEAT FOR 4 CYCLES; DAY 1 - 28 - IMATINIB 600MG ORALLY DAILY. MEDICAL ONCOLOGY 3900 3900 3900 3900 3900 3900 3900 3900
2437 CMU0975 A-IV-i-c-4 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS MAINTENANCE - DAY 1 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 1 - 5 - PREDNISOLONE 60MG/M2 ORALLY DAILY; DAY 1 - 28 - IMATINIB 600MG ORALLY DAILY; REPEAT EVERY 4 WEEKS UP TO 2 YEARS FROM THE DATE OF COMPLETE REMISSION. MEDICAL ONCOLOGY 3600 3600 3600 3600 3600 3600 3600 3600
2438 CMU0975 A-IV-i-c-5 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - IMATINIB - IMATINIB 400MG ORALLY DAILY MEDICAL ONCOLOGY 1600 1600 1600 1600 1600 1600 1600 1600
2439 CMU0975 A-IV-i-c-6 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - NILOTINIB - NILOTINIB 300MG ORALLY TWICE DAILY MEDICAL ONCOLOGY 18700 18700 18700 18700 18700 18700 18700 18700
2440 CMU0975 A-IV-ii : ACUTELYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2441 CMU0975 A-IV-ii-a-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 1 AND 3) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY DAYS 1 AND 11 - RITUXIMAB 375MG/M2 IV MEDICAL ONCOLOGY 62400 62400 62400 62400 62400 62400 62400 62400
2442 CMU0975 A-IV-ii-a-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 2 AND 4) - HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES DAYS 2 AND 8 - RITUXIMAB 375MG/M2 IV MEDICAL ONCOLOGY 65500 65500 65500 65500 65500 65500 65500 65500
2443 CMU0975 A-IV-ii-a-3 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 5 & 7) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY MEDICAL ONCOLOGY 12000 12000 12000 12000 12000 12000 12000 12000
2444 CMU0975 A-IV-ii-a-4 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 6 & 8) - HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES MEDICAL ONCOLOGY 14100 14100 14100 14100 14100 14100 14100 14100
2445 CMU0975 A-IV-ii-a-5 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) INDUCTION II - DAY 1 - CYCLOPHOSPHAMIDE 1, 200MG/M2 IV OVER 3 HOURS; DAYS 1 - 3 - DAUNORUBICIN 60MG/M2 IV OVER 1 HOUR; DAYS 1 - 21 - PREDNISOLONE 60MG/M2 ORALLY; DAYS 1, 8, 15, AND 22 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 8 - 63 - IMATINIB 600MG ORALLY; DAY 29 - MTX 15MG IT, CYTARABINE 40MG IT, DEXAMETHASONE 4MG IT. MEDICAL ONCOLOGY 15900 15900 15900 15900 15900 15900 15900 15900
2446 CMU0975 A-IV-ii-a-6 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) INDUCTION III - PRETREATMENT FOR 7 DAYS - PREDNISONE AT INCREASING DOSES FROM 10 - 40MG/M2/DAY; DAYS 1 - 45 - IMATINIB 800MG ORALLY DAILY + PREDNISONE 40MG/M2 DAILY MEDICAL ONCOLOGY 5800 5800 5800 5800 5800 5800 5800 5800
2447 CMU0975 A-IV-ii-a-7 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) MAINTENANCE - MTX WEEKLY + 6 - MP DAILY + VINCRISTINE PULSE MONTHLY + PREDNISONE PULSE MONTHLY FOR 2 TO 3 YEARS. MEDICAL ONCOLOGY 10400 10400 10400 10400 10400 10400 10400 10400
2448 CMU0975 A-IV-ii-b-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS INDUCTION PHASE - DAY 1 - CYCLOPHOSPHAMIDE 1, 200MG/M2 IV OVER 3 HOURS; DAYS 1 - 3 - DAUNORUBICIN 60MG/M2 IV OVER 1 HOUR; DAYS 1, 8, 15, AND 22 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 1 - 21 - PREDNISOLONE 60MG/M2 ORALLY DAILY; DAYS 8 - 63 - IMATINIB 600MG ORALLY DAILY; DAY 29 - MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT. MEDICAL ONCOLOGY 16400 16400 16400 16400 16400 16400 16400 16400
2449 CMU0975 A-IV-ii-b-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS CONSOLIDATION I - DAY 1 - MTX 1G/M2 IV OVER 24 HOURS + MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT; DAYS 1 - 3 - METHYLPREDNISOLONE 50MG IV OVER 1 HOUR × 2 DOSES; DAYS 2 AND 3 - CYTARABINE 2G/M2 IV OVER 3 HOURS; REPEAT FOR 4 CYCLES. MEDICAL ONCOLOGY 12700 12700 12700 12700 12700 12700 12700 12700
2450 CMU0975 A-IV-ii-b-3 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS CONSOLIDATION II - DAY 1 - MTX 15MG IT + CYTARABINE 40MG IT + DEXAMETHASONE 4MG IT; REPEAT FOR 4 CYCLES; DAY 1 - 28 - IMATINIB 600MG ORALLY DAILY. MEDICAL ONCOLOGY 3400 3400 3400 3400 3400 3400 3400 3400
2451 CMU0975 A-IV-ii-b-4 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - MULTIAGENT CHEMOTHERAPY + TKIS MAINTENANCE - DAY 1 - VINCRISTINE 1.3MG/M2 IV BOLUS; DAYS 1 - 5 - PREDNISOLONE 60MG/M2 ORALLY DAILY; DAY 1 - 28 - IMATINIB 600MG ORALLY DAILY; REPEAT EVERY 4 WEEKS UP TO 2 YEARS FROM THE DATE OF COMPLETE REMISSION. MEDICAL ONCOLOGY 6700 6700 6700 6700 6700 6700 6700 6700
2452 CMU0975 A-IV-ii-b-5 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - IMATINIB - IMATINIB 400MG ORALLY DAILY MEDICAL ONCOLOGY 1600 1600 1600 1600 1600 1600 1600 1600
2453 CMU0975 A-IV-ii-b-6 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - NILOTINIB - NILOTINIB 300MG ORALLY TWICE DAILY MEDICAL ONCOLOGY 18700 18700 18700 18700 18700 18700 18700 18700
2454 CMU0975 A-IV-ii-c : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(+) AYA - CORTICOSTEROIDS + TKIS - PRETREATMENT MEDICAL ONCOLOGY 9500 9500 9500 9500 9500 9500 9500 9500
2455 CMU0975 A-IV-iii : ACUTELYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2456 CMU0975 A-IV-iii-a-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - GRAALL-2003 INDUCTION - CORTICOSTEROID PRE-PHASE - 1-7 DAYS BEFORE INDUCTION THERAPY; PREDNISONE 60MG/M2/DAY, 4-7 DAYS BEFORE INDUCTION THERAPY; MTX 15MG IT. INDUCTION I - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2/DAY + VINCRISTINE 2MG IV, DAYS 1-3; DAUNORUBICIN 50MG/M2/DAY, DAYS 1-14; PREDNISONE 60MG/M2/DAY, DAY 8; VINCRISTINE 2MG IV + L-ASPARAGINASE 6, 000IU/M2/DAY, DAYS 10 AND 12; L-ASPARAGINASE 6, 000IU/M2/DAY, DAY 15; VINCRISTINE 2MG IV, DAY 15; FOR GOOD EARLY RESPONDERS; CYCLOPHOSPHAMIDE 750MG/M2/DAY. MEDICAL ONCOLOGY 16500 16500 16500 16500 16500 16500 16500 16500
2457 CMU0975 A-IV-iii-a-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - GRAALL-2003 SALVAGE - DAYS 1-3; IDARUBICIN 12MG/M2/DAY, DAYS 1-4; CYTARABINE 2G/M2/12 HOURS, DAY 9; FILGRASTIM TO MYELOID RECOVERY. MEDICAL ONCOLOGY 30200 30200 30200 30200 30200 30200 30200 30200
2458 CMU0975 A-IV-iii-a-3 : ALL - PH(-) AYA - GRAALL-2003 CONSOLIDATION - BLOCKS 1, 4, AND 7; - DAYS 1 AND 2; CYTARABINE 2G/M2/12 HOURS + DEXAMETHASONE 10MG/12 HOURS, DAY 3; L-ASPARAGINASE 10, 000IU/M2/DAY, DAYS 7-13; FILGRASTIM TO MYELOID RECOVERY. BLOCKS 2, 5, AND 8 - DAY 15; MTX 3G/M2 CONTINUOUS INFUSION + VINCRISTINE 2MG IV + 6-MP 60MG/M2/DAY, DAY 16; L-ASPARAGINASE 10, 000IU/M2/DAY, DAYS 16-21; 6-MP 60MG/M2/DAY, DAYS 22-27; FILGRASTIM TO MYELOID RECOVERY. BLOCKS 3, 6, AND 9 - DAY 29; MTX 25MG/M2/DAY, DAYS 29 AND 30; CYCLOPHOSPHAMIDE 500MG/M2/DAY + ETOPOSIDE 75MG/M2/DAY, DAY 31; FILGRASTIM TO MYELOID RECOVERY. TO BE APPROVED 3 TIMES (BLOCKS - 1, 2, 3; BLOCKS - 4, 5, 6; BLOCKS - 7, 8, 9 MEDICAL ONCOLOGY 32300 32300 32300 32300 32300 32300 32300 32300
2459 CMU0975 A-IV-iii-a-4 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - GRAALL-2003 LATE INTENSIFICATION BETWEEN CONSOLIDATION BLOCKS 6 AND 7 (FOR PATIENTS IN COMPLETE REMISSION [CR] AFTER THE FIRST INDUCTION COURSE) - DAY 1; VINCRISTINE 2MG IV, DAYS 1-3; DAUNORUBICIN 30MG/M2/DAY, DAYS 1-14; PREDNISONE 60MG/M2/DAY MEDICAL ONCOLOGY 16300 16300 16300 16300 16300 16300 16300 16300
2460 CMU0975 A-IV-iii-a-5 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - GRAALL-2003 LATE INTENSIFICATION BETWEEN CONSOLIDATION BLOCKS 6 AND 7 (FOR PATIENTS IN CR AFTER SALVAGE COURSE) - DAYS 1-3; IDARUBICIN 9MG/M2/DAY, DAYS 1-4; CYTARABINE 2G/M2/12 HOURS, DAY 9; FILGRASTIM TO MYELOID RECOVERY. MEDICAL ONCOLOGY 28600 28600 28600 28600 28600 28600 28600 28600
2461 CMU0975 A-IV-iii-a-6 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - GRAALL-2003 MAINTENANCE MEDICAL ONCOLOGY 59800 59800 59800 59800 59800 59800 59800 59800
2462 CMU0975 A-IV-iii-b : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - CNS THERAPY-TREATMENT OF PATIENTS WITH INITIAL CNS INVOLVEMENT MEDICAL ONCOLOGY 22200 22200 22200 22200 22200 22200 22200 22200
2463 CMU0975 A-IV-iii-v : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - CCG-1961 MEDICAL ONCOLOGY 19200 19200 19200 19200 19200 19200 19200 19200
2464 CMU0975 A-IV-iv : ACUTELYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2465 CMU0975 A-IV-iv-a-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - CALGB 8811 (LARSON REGIMEN) INDUCTION MEDICAL ONCOLOGY 19000 19000 19000 19000 19000 19000 19000 19000
2466 CMU0975 A-IV-iv-a-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - CALGB 8811 (LARSON REGIMEN) CONSOLIDATION MEDICAL ONCOLOGY 17500 17500 17500 17500 17500 17500 17500 17500
2467 CMU0975 A-IV-iv-b-1 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - HYPER-CVAD WITH OR WITHOUT RITUXIMAB CYCLE 1, 3, 5, 7 - DAYS 1 - 3 - CYCLOPHOSPHAMIDE IV EVERY 12 HOURS + MESNA CONTINUOUS IV INFUSION STARTING 1 HOUR BEFORE CYCLOPHOSPHAMIDE UNTIL 12 HOURS AFTER COMPLETION OF CYCLOPHOSPHAMIDE; DAYS 1 - 4 AND 11 - 14 - DEXAMETHASONE ORALLY DAILY, +/-; DAYS 1 AND 8 - RITUXIMABIV; DAY 4 - DOXORUBICIN IV OVER 24 HOURS; DAYS 4 AND 11 - VINCRISTINE IV MEDICAL ONCOLOGY 64000 64000 64000 64000 64000 64000 64000 64000
2468 CMU0975 A-IV-iv-b-2 : ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) - PH(-) AYA - HYPER-CVAD WITH OR WITHOUT RITUXIMAB CYCLE 2, 4, 6, 8 - DAY 1 - METHOTREXATE IV OVER 2 HOURS FOLLOWED BY CONTINUOUS IV INFUSION OVER 22 HOURS FOLLOWED BY LEUCOVORIN IV EVERY 6 HOURS STARTING 12 HOURS AFTER COMPLETION OF MTX; DAYS 2 - 3 - CYTARABINE (IV OVER 2 HOURS EVERY 12 HOURS, +/-; DAYS 1 AND 8 - RITUXIMAB 375MG/M2 IV; CNS PROPHYLAXIS; DAY 2 - METHOTREXATE 12MG IT; DAY 8 - CYTARABINE 100MG IT. MEDICAL ONCOLOGY 59700 59700 59700 59700 59700 59700 59700 59700
2469 CMU0976 A : ALL LYMPHOMACHEMOTHERAPHY MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2470 CMU0976 A-I : HODGKINS LYMPHOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2471 CMU0976 A-I-a : HODGKINSLYMPHOMA - ABVD - DAYS 1 AND 15; DOXORUBICIN 25MG/M2 IV PUSH + BLEOMYCIN 10UNITS/M2 IV PUSH + VINBLASTINE 6MG/M2 IV OVER 5-10 MINUTES + DACARBAZINE 375MG/M2 IV OVER 60 MINUTES. REPEAT CYCLE EVERY 4 WEEKS FOR 2-4 CYCLES OR UPTO 6 CYCLES - MAY BE FOLLOWED BY ESCALATED BEACOPP MEDICAL ONCOLOGY 4700 4700 4700 4700 4700 4700 4700 4700
2472 CMU0976 A-I-b : HODGKINSLYMPHOMA - ESCALATED BEACOPP - DAY 1; CYCLOPHOSPHAMIDE 1, 250MG/M2 IV OVER 60 MINUTES + DOXORUBICIN 35MG/M2 IV PUSH, DAYS 1-3; ETOPOSIDE 200MG/M2 IV OVER 2 HOURS MEDICAL ONCOLOGY 7500 7500 7500 7500 7500 7500 7500 7500
2473 CMU0976 A-I-c : HODGKINSLYMPHOMA - ABVD + RITUXIMAB (CYLED EVERY 4 WEEKS) - MEDICAL ONCOLOGY 24300 24300 24300 24300 24300 24300 24300 24300
2474 CMU0976 A-I-d-i : HODGKINS LYMPHOMA - ABVD + RITUXIMAB (1 CYCLE - WEEKLY RITUXIMAB 4 DOSES) FOLLOWED BY ABVD - DAYS 1 AND 15; DOXORUBICIN 25MG/M2 IV PUSH + BLEOMYCIN 10UNITS/M2 IV PUSH + VINBLASTINE 6MG/M2 IV OVER 5-10 MINUTES + DACARBAZINE 375MG/M2 IV OVER 60 MINUTES, DAYS 1, 8, 15, AND 22; RITUXIMAB 375MG/M2 IV FOR CYCLE 1 ONLY. REPEAT ABVD CYCLE EVERY 4 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION (OR ) 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION MEDICAL ONCOLOGY 87200 87200 87200 87200 87200 87200 87200 87200
2475 CMU0976 A-I-d-ii : HODGKINS LYMPHOMA - ABVD - DAYS 1 AND 15; DOXORUBICIN 25MG/M2 IV PUSH + BLEOMYCIN 10UNITS/M2 IV PUSH + VINBLASTINE 6MG/M2 IV OVER 5-10 MINUTES + DACARBAZINE 375MG/M2 IV OVER 60 MINUTES. REPEAT CYCLE EVERY 4 WEEKS FOR 2-4 CYCLES OR UPTO 6 CYCLES - MAY BE FOLLOWED BY ESCALATED BEACOPP MEDICAL ONCOLOGY 4700 4700 4700 4700 4700 4700 4700 4700
2476 CMU0976 A-I-e-i : HODGKINS LYMPHOMA - CHOP + RITUXIMAB - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) +/- RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES, DAYS 1-5; PREDNISONE 100MG ORALLY DAILY, DAY 1; RITUXIMAB 375MG/M2 IV, REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION. MEDICAL ONCOLOGY 22800 22800 22800 22800 22800 22800 22800 22800
2477 CMU0976 A-I-e-ii : HODGKINS LYMPHOMA - CHOP - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) +/- RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES, DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION. MEDICAL ONCOLOGY 3000 3000 3000 3000 3000 3000 3000 3000
2478 CMU0976 A-I-f-i : HODGKINS LYMPHOMA - CVP +/- RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OR 1, 000MG/M2 OVER 60 MINUTES + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES, DAYS 1-5; PREDNISONE 100MG ORALLY DAILY, DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6 CYCLES WITHOUT SUBSEQUENT RADIATION. MEDICAL ONCOLOGY 22000 22000 22000 22000 22000 22000 22000 22000
2479 CMU0976 A-I-f-ii : HODGKINS LYMPHOMA - CVP - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OR 1, 000MG/M2 OVER 60 MINUTES + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES, DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6 CYCLES WITHOUT SUBSEQUENT RADIATION. MEDICAL ONCOLOGY 1900 1900 1900 1900 1900 1900 1900 1900
2480 CMU0976 A-I-g : HODGKINSLYMPHOMA - RITUXIMAB - DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT CYCLE EVERY 7 DAYS FOR 4 WEEKS WITH OR WITHOUT MAINTENANCE RITUXIMAB (375MG/M2 IV ONCE WEEKLY FOR 4 WEEKS EVERY 6 MONTHS FOR UP TO 2 YEARS) MEDICAL ONCOLOGY 21700 21700 21700 21700 21700 21700 21700 21700
2481 CMU0976 A-II : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2482 CMU0976 A-II-a : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - BORTEZOMIB + DEXAMETHASONE - DAYS 1, 4, 8, AND 11; BORTEZOMIB 1.3MG/M2 IV, DAYS 1, 4, 8, AND 11; DEXAMETHASONE 40MG IV. REPEAT FOR 4 CONSECUTIVE CYCLES AS INDUCTION THERAPY AND FOLLOW WITH 4 MAINTENANCE CYCLES, EACH GIVEN 3 MONTHS APART. MEDICAL ONCOLOGY 57900 57900 57900 57900 57900 57900 57900 57900
2483 CMU0976 A-II-b : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE + RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 IV + DOXORUBICIN 50MG/M2 IV + VINCRISTINE 1.4MG/M2 (MAX 2MG) IV + RITUXIMAB 375MG/M2 IV, DAYS 1-5; PREDNISONE 100MG ORALLY. REPEAT EVERY 3 WEEKS FOR 6 CYCLES MEDICAL ONCOLOGY 22800 22800 22800 22800 22800 22800 22800 22800
2484 CMU0976 A-II-c : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - RITUXIMAB - DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT EVERY 7 DAYS FOR 4 WEEKS MEDICAL ONCOLOGY 21700 21700 21700 21700 21700 21700 21700 21700
2485 CMU0976 A-II-d : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - RITUXIMAB + CYCLOPHOSPHAMIDE + PREDNISONE - DAY 1; RITUXIMAB 375MG/M2 IV + CYCLOPHOSPHAMIDE 1, 000MG/M2 IV, DAYS 1-5; PREDNISONE 100MG ORALLY. REPEAT EVERY 21 DAYS FOR 6 CYCLES MEDICAL ONCOLOGY 21900 21900 21900 21900 21900 21900 21900 21900
2486 CMU0976 A-II-e : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - RITUXIMAB + CYCLOPHOSPHAMIDE + DEXAMETHASONE - DAY 1; DEXAMETHASONE 20MG IV FOLLOWED BY RITUXIMAB 375MG/M2 IV, DAYS 1-5; CYCLOPHOSPHAMIDE 100MG/M2 ORALLY TWICE DAILY. REPEAT EVERY 21 DAYS FOR 6 MONTHS MEDICAL ONCOLOGY 21700 21700 21700 21700 21700 21700 21700 21700
2487 CMU0976 A-II-f-i : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - THALIDOMIDE WITH OR WITHOUT RITUXIMAB (WEEKS 1 AND 2) - THALIDOMIDE 200MG ORALLY DAILY MEDICAL ONCOLOGY 2700 2700 2700 2700 2700 2700 2700 2700
2488 CMU0976 A-II-f-ii : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - THALIDOMIDE WITH OR WITHOUT RITUXIMAB (WEEKS 3-50) - THALIDOMIDE 400MG ORALLY DAILY MEDICAL ONCOLOGY 6300 6300 6300 6300 6300 6300 6300 6300
2489 CMU0976 A-II-f-iii : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - THALIDOMIDE WITH OR WITHOUT RITUXIMAB (WEEKS 50-52) - THALIDOMIDE 400MG ORALLY DAILY MEDICAL ONCOLOGY 6300 6300 6300 6300 6300 6300 6300 6300
2490 CMU0976 A-II-f-iv : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - THALIDOMIDE WITH OR WITHOUT RITUXIMAB WEEKS 2-5 AND 13-16 - RITUXIMAB 375MG/M2 IV ONCE WEEKLY FOR A TOTAL OF 8 INFUSIONS AS ADD-ON MEDICAL ONCOLOGY 20400 20400 20400 20400 20400 20400 20400 20400
2491 CMU0976 A-II-g-i : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - BENDAMUSTINE WITH OR WITHOUT RITUXIMAB DAYS 1-2; BENDAMUSTINE 90MG/M2 IV, DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT EVERY 4 WEEKS FOR 4 CYCLES. MEDICAL ONCOLOGY 31100 31100 31100 31100 31100 31100 31100 31100
2492 CMU0976 A-II-g-ii : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - BENDAMUSTINE - RITUXIMAB - DAYS 1-2; BENDAMUSTINE 90MG/M2 IV, REPEAT EVERY 4 WEEKS FOR 4 CYCLES. MEDICAL ONCOLOGY 13100 13100 13100 13100 13100 13100 13100 13100
2493 CMU0976 A-II-h-i : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - CLADRIBINE WITH OR WITHOUT RITUXIMAB - DAYS 1-5; CLADRIBINE 0.1MG/KG SUBCUTANEOUS INJECTION, DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT EVERY 4 WEEKS FOR 4 CYCLES MEDICAL ONCOLOGY 27500 27500 27500 27500 27500 27500 27500 27500
2494 CMU0976 A-II-h-ii : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - CLADRIBINE - RITUXIMAB - DAYS 1-5; CLADRIBINE 0.1MG/KG SUBCUTANEOUS INJECTION. REPEAT EVERY 4 WEEKS FOR 4 CYCLES MEDICAL ONCOLOGY 8700 8700 8700 8700 8700 8700 8700 8700
2495 CMU0976 A-III : NON HODGKINS LYMPHOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2496 CMU0976 A-II-i : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - BENDAMUSTINE - DAYS 1-2; BENDAMUSTINE 90MG/M2 IV MEDICAL ONCOLOGY 13100 13100 13100 13100 13100 13100 13100 13100
2497 CMU0976 A-III-i : NON HODGKINS LYMPHOMA - BURKITT LYMPHOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2498 CMU0976 A-III-i-a-1 : NON HODGKINS LYMPHOMA - BURKITT LYMPHOMA - CALGB 10002 CYCLE 1 - DAY 1; TRIPLE INTRATHECAL THERAPY FOR CNS, DAYS 1-5; CYCLOPHOSPHAMIDE 200MG/M2 IV, DAYS 1-7; PREDNISONE 60MG/M2 ORALLY. MEDICAL ONCOLOGY 9400 9400 9400 9400 9400 9400 9400 9400
2499 CMU0976 A-III-i-a-2 : NON HODGKINS LYMPHOMA - BURKITT LYMPHOMA - CALGB 10002 CYCLES 2 (BEGINNING DAY 8) - DAY 1; TRIPLE INTRATHECAL THERAPY FOR CNS PROPHYLAXIS - DAYS 1-5; IFOSFAMIDE 800MG/M2 IV + DEXAMETHASONE 10MG/M2 IV MEDICAL ONCOLOGY 69400 69400 69400 69400 69400 69400 69400 69400
2500 CMU0976 A-III-i-a-3 : NON HODGKINS LYMPHOMA - BURKITT LYMPHOMA - CALGB 10002 CYCLES 3, 5, AND 7 - DAY 1; TRIPLE INTRATHECAL THERAPY FOR CNS PROPHYLAXIS, DAYS 1-5; CYCLOPHOSPHAMIDE 200MG/M2 IV + DEXAMETHASONE 10MG/M2 IV MEDICAL ONCOLOGY 34800 34800 34800 34800 34800 34800 34800 34800
2501 CMU0976 A-III-i-a-4 : NON HODGKINS LYMPHOMA - BURKITT LYMPHOMA - CALGB 10002 CYCLES 4, AND 6. DAY 1; TRIPLE INTRATHECAL THERAPY FOR CNS PROPHYLAXIS, DAYS 1-5; IFOSFAMIDE 800MG/M2 IV + DEXAMETHASONE 10MG/M2 IV, DAY 1; METHOTREXATE 1.5G/M2 IV (WITH LEUCOVORIN RESCUE) + VINCRISTINE 2MG IV, DAYS 4 AND 5; CYTARABINE 1G/M2 IV + ETOPOSIDE 80MG/M2 IV, DAY 8; 375MG/M2 IV. DELIVER CYCLES EVERY 21 DAYS. MEDICAL ONCOLOGY 38200 38200 38200 38200 38200 38200 38200 38200
2502 CMU0976 A-III-i-b : NHL - BURKITT LYMPHOMA - CODOX-M (ORIGINAL OR MODIFIED) (CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE WITH INTRATHECAL MTX + CYTARABINE, FOLLOWED BY SYSTEMIC MTX AND CYTARABINE) WITH OR WITHOUT RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE + DOXORUBICIN, DAYS 2-5; CYCLOPHOSPHAMIDE IV, DAYS 1, 3; CYTARABINE INTRATHECAL, DAYS 1, 8; VINCRISTINE IV, DAY 10; MTX IV 1 HOUR, THEN INFUSION OVER 23 HOURS, DAY 11; LEUCOVORIN IV, EVERY 6 HOURS, DAY 13; G-CSF SC DAILY, DAY 15; MTX INTRATHECAL MEDICAL ONCOLOGY 39800 39800 39800 39800 39800 39800 39800 39800
2503 CMU0976 A-III-i-c-1 : NHL - BURKITT LYMPHOMA - DOSE-ADJUSTED EPOCH (ETOPOSIDE + PREDNISONE + VINCRISTINE + CYCLOPHOSPHAMIDE + DOXORUBICIN) + INTRATHECAL MTX + RITUXIMAB (CYCLES 1 & 2) - DAY 1; RITUXIMAB 375MG/M2 IV DAYS 1-4; ETOPOSIDE 50MG/M2 IV INFUSION + DOXORUBICIN 10MG/M2 IV INFUSION + VINCRISTINE 0.4MG/M2 IV INFUSION, DAYS 1-5; PREDNISONE 60MG/M2 ORAL BD, DAY 5; CYCLOPHOSPHAMIDE 750MG/M2 IV, DAY 6; G-CSF 300uG ADMINISTERED UNTIL ANC >5, 000CELLS/uL MEDICAL ONCOLOGY 28100 28100 28100 28100 28100 28100 28100 28100
2504 CMU0976 A-III-i-c-2 : NHL - BURKITT LYMPHOMA - DOSE-ADJUSTED EPOCH (ETOPOSIDE + PREDNISONE + VINCRISTINE + CYCLOPHOSPHAMIDE + DOXORUBICIN) + MTX - IT+ RITUXIMAB (CYCLES 3-6) - DAY 1; RITUXIMAB 375MG/M2 IV DAYS 1-4; ETOPOSIDE 50MG/M2 IV INFUSION + DOXORUBICIN 10MG/M2 IV INFUSION + VINCRISTINE 0.4MG/M2 IV INFUSION, DAYS 1-5; PREDNISONE 60MG/M2 ORAL BD. DAY 5; CYCLOPHOSPHAMIDE 750MG/M2 IV, DAY 6; G-CSF 300uG UNTIL ANC >5, 000/uL, DAYS 1 AND 5 ; MTX 12MG - IT REPEAT EVERY 3 WEEKS FOR 6 CYCLES MEDICAL ONCOLOGY 27700 27700 27700 27700 27700 27700 27700 27700
2505 CMU0976 A-III-i-d-1 : NON HODGKINS LYMPHOMA - BURKITT LYMPHOMA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 1 AND 3) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY DAYS 1 AND 11 - RITUXIMAB 375MG/M2 IV MEDICAL ONCOLOGY 62400 62400 62400 62400 62400 62400 62400 62400
2506 CMU0976 A-III-i-d-2 : NON HODGKINS LYMPHOMA - BURKITT LYMPHOMA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 2 AND 4) - HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES DAYS 2 AND 8 - RITUXIMAB 375MG/M2 IV MEDICAL ONCOLOGY 65000 65000 65000 65000 65000 65000 65000 65000
2507 CMU0976 A-III-i-d-3 : NON HODGKINS LYMPHOMA - BURKITT LYMPHOMA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 5 & 7) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY MEDICAL ONCOLOGY 11500 11500 11500 11500 11500 11500 11500 11500
2508 CMU0976 A-III-i-d-4 : NON HODGKINS LYMPHOMA - BURKITT LYMPHOMA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 6 & 8) - HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES MEDICAL ONCOLOGY 13600 13600 13600 13600 13600 13600 13600 13600
2509 CMU0976 A-III-i-e-1 : NHL - BURKITT LYMPHOMA - CODOX-M ALTERNATED WITH IVAC- CODOX-M (ORIGINAL OR MODIFIED) - DAY 1- CYCLOPHOSPHAMIDE + DOXORUBICIN - IV, DAYS 2-5- CYCLOPHOSPHAMIDE IV, DAYS 1, 3- CYTARABINE IT, DAYS 1, 8; VINCRISTINE IV, DAY 10; MTX IV 1 HOUR, THEN INFUSION FOR 23 HOURS, DAY 11; LEUCOVORIN IV - 6TH HOURLY; DAY 13- G-CSF SC DAILY, DAY 15; MTX - IT DAY 16- LEUCOVORIN ORAL G, +/- DAY 1; RITUXIMAB IV. REPEAT FOR 4 CYCLES ALTERNATE BETWEEN CODOX-M AND IVAC MEDICAL ONCOLOGY 39800 39800 39800 39800 39800 39800 39800 39800
2510 CMU0976 A-III-i-e-2 : NHL - BURKITT LYMPHOMA - CODOX-M ALTERNATED WITH IVAC - IVAC (IFOSFAMIDE + CYTARABINE + ETOPOSIDE) AND IT MTX +/- RITUXIMAB - DAY 1; CYTARABINE 2G/M2 IV EVERY 12 HOURS FOR 4 DOSES. DAYS 1-5; ETOPOSIDE 60MG/M2 IV + IFOSFAMIDE 1, 500MG/M2 IV, + MESNA 360MG/M2, DAY 5; MTX 12MG IT DAY 6; LEUCOVORIN 15MG ORAL - MTX, DAY 7; G-CSF 5uG/KG SC DAILY UNTIL GRANULOCYTE COUNT >/=1 X 109/L, +/- DAY 1; RITUXIMAB 375 MG/M2 IV. REPEAT FOR 4 CYCLES ALTERNATE BETWEEN CODOX-M AND IVAC. MEDICAL ONCOLOGY 36500 36500 36500 36500 36500 36500 36500 36500
2511 CMU0976 A-III-i-f : NONHODGKINS LYMPHOMA - BURKITT LYMPHOMA - RICE (RITUXIMAB + IFOSFAMIDE + CARBOPLATIN + ETOPOSIDE) - DAY 1; RITUXIMAB 375MG/M2 IV, DAY 2; IFOSFAMIDE 5, 000MG/M2 AND MESNA 5, 000MG/M2 IV + CARBOPLATIN AUC 5 MG / MIN/ML (MAXIMUM 800MG) IV, DAY 1-3; ETOPOSIDE 100MG/M2 IV. REPEAT CYCLE EVERY 3 WEEKS. MEDICAL ONCOLOGY 28100 28100 28100 28100 28100 28100 28100 28100
2512 CMU0976 A-III-i-g : NONHODGKINS LYMPHOMA - BURKITT LYMPHOMA - RIVAC (RITUXIMAB + IFOSFAMIDE + CYTARABINE + ETOPOSIDE) - DAY 1; RITUXIMAB 375MG/M2 IV, DAY 1; CYTARABINE 2G/M2 IV EVERY 12 HOURS FOR 4 DOSES, DAYS 1-5; ETOPOSIDE 60MG/M2 IV + IFOSFAMIDE 1, 500MG/M2 IV, +MESNA 360MG/M2, DAY 5; METHOTREXATE 12MG INTRATHECALLY MEDICAL ONCOLOGY 37400 37400 37400 37400 37400 37400 37400 37400
2513 CMU0976 A-III-i-h : NONHODGKINS LYMPHOMA - BURKITT LYMPHOMA - RGDP (RITUXIMAB + GEMCITABINE + DEXAMETHASONE + CISPLATIN) - DAY 1; RITUXIMAB 375MG/M2 IV, DAY 1 AND 8; GEMCITABINE 1, 000MG/M2 IV, DAY 1-3; CISPLATIN 25MG/M2 IV, DAY 1-4; DEXAMETHASONE 40MG IV. REPEAT CYCLE EVERY 3 WEEKS. MEDICAL ONCOLOGY 27500 27500 27500 27500 27500 27500 27500 27500
2514 CMU0976 A-III-ii : NON HODGKINS LYMPHOMA - ADULT T-CELL LEUKEMIA / LYMPHOMA - NON HODGKIN LYMPHOMA -- ADULT T-CELL LEUKEMIA / LYMPHOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2515 CMU0976 A-III-i-i : NONHODGKINS LYMPHOMA - BURKITT LYMPHOMA - HDAC + RITUXIMAB - DAYS 1, 3, AND 5; HIGH-DOSE CYTARABINE 3G/M2 IV EVERY 12 HOURS, DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT FOR 4 CYCLES MEDICAL ONCOLOGY 23700 23700 23700 23700 23700 23700 23700 23700
2516 CMU0976 A-III-ii-a-1 : NON HODGKINS LYMPHOMA - ADULT T-CELL LEUKEMIA / LYMPHOMA - ZIDOVUDINE + ALPHA-INTERFERON (INDUCTION) - ZIDOVUDINE 1G ORALLY DAILY + ALPHA-INTERFERON 9 MILLION UNITS SC DAILY FOR 2 MONTHS, FOLLOWED BY MAINTENANCE THERAPY MEDICAL ONCOLOGY 4800 4800 4800 4800 4800 4800 4800 4800
2517 CMU0976 A-III-ii-a-2 : NON HODGKINS LYMPHOMA - ADULT T-CELL LEUKEMIA / LYMPHOMA - ZIDOVUDINE + ALPHA-INTERFERON (MAINTENANCE THERAPY) - ZIDOVUDINE 600MG ORALLY DAILY + ALPHA-INTERFERON 4.5 MILLION UNITS SC DAILY FOR 1 MONTH, REPEAT 12 MONTHS MEDICAL ONCOLOGY 2200 2200 2200 2200 2200 2200 2200 2200
2518 CMU0976 A-III-ii-b : NONHODGKINS LYMPHOMA - ADULT T-CELL LEUKEMIA / LYMPHOMA - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION. MEDICAL ONCOLOGY 3000 3000 3000 3000 3000 3000 3000 3000
2519 CMU0976 A-III-ii-c : NONHODGKINS LYMPHOMA - ADULT T-CELL LEUKEMIA / LYMPHOMA - CHOEP - DAYS 1-4; ETOPOSIDE 50MG/M2/DAY CONTINUOUS IV INFUSION + DOXORUBICIN 10MG/M2/DAY CONTINUOUS IV INFUSION + VINCRISTINE 0.4MG/M2/DAY CONTINUOUS IV INFUSION, DAYS 1-5; PREDNISONE 60MG/M2 ORALLY DAILY, DAY 5; CYCLOPHOSPHAMIDE 750MG/M2 IV OVER 15 MINUTES. REPEAT CYCLE EVERY 3 WEEKS FOR 6-8 CYCLES. MEDICAL ONCOLOGY 9100 9100 9100 9100 9100 9100 9100 9100
2520 CMU0976 A-III-ii-d : NONHODGKINS LYMPHOMA - ADULT T-CELL LEUKEMIA / LYMPHOMA - DOSE-ADJUSTED EPOCH (ETOPOSIDE + PREDNISONE + VINCRISTINE + CYCLOPHOSPHAMIDE + DOXORUBICIN) - DAYS 1-4 - ETOPOSIDE 50MG/M2/DAY CONTINUOUS IV INFUSION + DOXORUBICIN 10MG/M2/DAY CONTINUOUS IV INFUSION + VINCRISTINE 0.4MG/M2/DAY CONTINUOUS IV INFUSION, DAYS 1-5- PREDNISONE 60MG/M2 ORAL DAILY, DAY 5; CYCLOPHOSPHAMIDE 750MG/M2 IV OVER 15 MINUTES. REPEAT CYCLE EVERY 3 WEEKS FOR 6-8 CYCLES. ADJUST DOSES BASED ON ANC. MEDICAL ONCOLOGY 7300 7300 7300 7300 7300 7300 7300 7300
2521 CMU0976 A-III-iii : NONHODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2522 CMU0976 A-III-iii-a : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - CDE (CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE) + RITUXIMAB - DAYS 1-4; CYCLOPHOSPHAMIDE 187.5-200MG/M2 IV + DOXORUBICIN 12.5MG/M2 IV + ETOPOSIDE 60MG/M2 IV, DAY 1; RITUXIMAB 375MG/M2 IV JUST BEFORE CDE REGIMEN. REPEAT CYCLE EVERY 4 WEEKS FOR A MAXIMUM OF 6 CYCLES. MEDICAL ONCOLOGY 2600 2600 2600 2600 2600 2600 2600 2600
2523 CMU0976 A-III-iii-b-1 : NHL - DIFFUSE LARGE B CELL LYMPHOMA - CODOX-M ALTERNATED WITH IVAC (CODOX-M) CODOX-M (MODIFIED) (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + HIGH-DOSE MTX ALTERNATING WITH IFOSFAMIDE + ETOPOSIDE + HIGH-DOSE CYTARABINE) - DAY 1; CYCLOPHOSPHAMIDE + DOXORUBICIN IV, DAYS 2-5; CYCLOPHOSPHAMIDE IV, DAYS 1, 3; CYTARABINE -IT, DAYS 1, 8-VINCRISTINE IV, DAY 10; MTX IV, DAY 11; LEUCOVORIN, DAY 13; G-CSF SC DAILY, DAY 15; MTX -IT, DAY 16; LEUCOVORIN ORAL, +/- DAY 1; RITUXIMAB IV. REPEAT FOR 4 CYCLES ALTERNATING BETWEEN CODOX-M AND IVAC REGIMENS. MEDICAL ONCOLOGY 49100 49100 49100 49100 49100 49100 49100 49100
2524 CMU0976 A-III-iii-b-2 : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - CODOX-M ALTERNATED WITH IVAC (IVAC) CODOX-M/IVAC (MODIFIED) (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + HIGH-DOSE METHOTREXATE ALTERNATING WITH IFOSFAMIDE + ETOPOSIDE + HIGH-DOSE CYTARABINE) - DAY 1; CYTARABINE 2G/M2 IV EVERY 12 HOURS FOR 4 DOSES. DAYS 1-5; ETOPOSIDE 60MG/M2 IV + IFOSFAMIDE 1, 500MG/M2 IV, +MESNA 360MG/M2, DAY 5; METHOTREXATE 12MG INTRATHECALLY, DAY 6; LEUCOVORIN 15MG ORALLY 24 HOURS AFTER INTRATHECAL MTX, DAY 7; G-CSF 5uG/KG SC DAILY UNTIL ABSOLUTE GRANULOCYTE COUNT >/=1 X 109/L, +/- DAY 1; RITUXIMAB 375 MG/M2 IV. REPEAT FOR 4 CYCLES ALTERNATING BETWEEN CODOX-M AND IVAC REGIMENS. MEDICAL ONCOLOGY 45000 45000 45000 45000 45000 45000 45000 45000
2525 CMU0976 A-III-iii-c-1 : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - DOSE-ADJUSTED EPOCH (ETOPOSIDE + PREDNISONE + VINCRISTINE + CYCLOPHOSPHAMIDE + DOXORUBICIN) + INTRATHECAL MTX + RITUXIMAB (CYCLES 1&2) - DAY 1; RITUXIMAB 375MG/M2 IV, DAYS 1-4; ETOPOSIDE 50MG/M2 CONTINUOUS IV INFUSION + DOXORUBICIN 10MG/M2 CONTINUOUS IV INFUSION + VINCRISTINE 0.4MG/M2 CONTINUOUS IV INFUSION, DAYS 1-5; PREDNISONE 60MG/M2 ORALLY TWICE DAILY. DAY 5; CYCLOPHOSPHAMIDE 750MG/M2 IV, DAY 6; G-CSF 300uG ADMINISTERED UNTIL ANC >5, 000CELLS/uL MEDICAL ONCOLOGY 28100 28100 28100 28100 28100 28100 28100 28100
2526 CMU0976 A-III-iii-c-2 : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - DOSE-ADJUSTED EPOCH (ETOPOSIDE + PREDNISONE + VINCRISTINE + CYCLOPHOSPHAMIDE + DOXORUBICIN) + INTRATHECAL MTX + RITUXIMAB (CYCLES 3-6) - DAY 1; RITUXIMAB 375MG/M2 IV, DAYS 1-4; ETOPOSIDE 50MG/M2 CONTINUOUS IV INFUSION + DOXORUBICIN 10MG/M2 CONTINUOUS IV INFUSION + VINCRISTINE 0.4MG/M2 CONTINUOUS IV INFUSION, DAYS 1-5; PREDNISONE 60MG/M2 ORALLY TWICE DAILY. DAY 5; CYCLOPHOSPHAMIDE 750MG/M2 IV, DAY 6; G-CSF 300uG ADMINISTERED UNTIL ANC >5, 000CELLS/uL, DAYS 1 AND 5; METHOTREXATE 12MG INTRATHECALLY. REPEAT CYCLE EVERY 3 WEEKS FOR 6 CYCLES MEDICAL ONCOLOGY 27700 27700 27700 27700 27700 27700 27700 27700
2527 CMU0976 A-III-iii-d-1 : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 1 AND 3) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY DAYS 1 AND 11 - RITUXIMAB 375MG/M2 IV MEDICAL ONCOLOGY 62400 62400 62400 62400 62400 62400 62400 62400
2528 CMU0976 A-III-iii-d-2 : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 2 AND 4) - HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES DAYS 2 AND 8 - RITUXIMAB 375MG/M2 IV MEDICAL ONCOLOGY 65000 65000 65000 65000 65000 65000 65000 65000
2529 CMU0976 A-III-iii-d-3 : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 5 & 7) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY MEDICAL ONCOLOGY 11500 11500 11500 11500 11500 11500 11500 11500
2530 CMU0976 A-III-iii-d-4 : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 6 & 8) - HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES MEDICAL ONCOLOGY 13600 13600 13600 13600 13600 13600 13600 13600
2531 CMU0976 A-III-iii-e-1 : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (R-CHOP) RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES DAYS 1-5; PREDNISONE 100MG ORALLY DAILY, +/- DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION. MEDICAL ONCOLOGY 22800 22800 22800 22800 22800 22800 22800 22800
2532 CMU0976 A-III-iii-e-2 : NON HODGKINS LYMPHOMA - DIFFUSE LARGE B CELL LYMPHOMA - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION. MEDICAL ONCOLOGY 3000 3000 3000 3000 3000 3000 3000 3000
2533 CMU0976 A-III-iv : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2534 CMU0976 A-III-iv-a : NONHODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - CDE (CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE) + RITUXIMAB - CDE (CYCLOPHOSPHAMIDE + DOXORUBICIN + ETOPOSIDE) + RITUXIMAB - DAYS 1-4; CYCLOPHOSPHAMIDE 187.5-200MG/M2 IV + DOXORUBICIN 12.5MG/M2 IV + ETOPOSIDE 60MG/M2 IV, DAY 1; RITUXIMAB 375MG/M2 IV JUST BEFORE CDE REGIMEN. REPEAT CYCLE EVERY 4 WEEKS FOR A MAXIMUM OF 6 CYCLES. MEDICAL ONCOLOGY 2600 2600 2600 2600 2600 2600 2600 2600
2535 CMU0976 A-III-iv-b-1 : NHL - AIDS-RELATED B-CELL LYMPHOMAS - CODOX-M ALTERNATED WITH IVAC (CODOX-M) (MODIFIED) (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + HIGH-DOSE MTX ALTERNATING WITH IFOSFAMIDE + ETOPOSIDE + HIGH-DOSE CYTARABINE) - DAY 1; CYCLOPHOSPHAMIDE IV + DOXORUBICIN IV, DAYS 2-5; CYCLOPHOSPHAMIDE IV, DAYS 1 AND 3; CYTARABINE IT, DAYS 1 AND 8; VINCRISTINE IV, DAY 10; MTX IV OVER 1 HOUR, THEN IV INFUSION FOR 23 HOURS, DAY 11; LEUCOVORIN IV, FOLLOWED BY EVERY 6 HOURS, DAY 13; G-CSF SC DAILY UNTIL ABSOLUTE GRANULOCYTE COUNT >/=1 X 109/L, DAY 15; MTX IT, DAY 16; LEUCOVORIN 15MG ORAL, +/- DAY 1; RITUXIMAB IV. REPEAT FOR 4 CYCLES ALTERNATING BETWEEN CODOX-M AND IVAC REGIMENS. MEDICAL ONCOLOGY 49100 49100 49100 49100 49100 49100 49100 49100
2536 CMU0976 A-III-iv-b-2 : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - CODOX-M ALTERNATED WITH IVAC (IVAC) CODOX-M/IVAC (MODIFIED) (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + HIGH-DOSE METHOTREXATE ALTERNATING WITH IFOSFAMIDE + ETOPOSIDE + HIGH-DOSE CYTARABINE) - DAY 1; CYTARABINE 2G/M2 IV EVERY 12 HOURS FOR 4 DOSES. DAYS 1-5; ETOPOSIDE 60MG/M2 IV + IFOSFAMIDE 1, 500MG/M2 IV, +MESNA 360MG/M2, DAY 5; METHOTREXATE 12MG INTRATHECALLY, DAY 6; LEUCOVORIN 15MG ORALLY 24 HOURS AFTER INTRATHECAL MTX, DAY 7; G-CSF 5uG/KG SC DAILY UNTIL ABSOLUTE GRANULOCYTE COUNT >/=1 X 109/L, +/- DAY 1; RITUXIMAB 375 MG/M2 IV. REPEAT FOR 4 CYCLES ALTERNATING BETWEEN CODOX-M AND IVAC REGIMENS. MEDICAL ONCOLOGY 45000 45000 45000 45000 45000 45000 45000 45000
2537 CMU0976 A-III-iv-c-1 : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - DOSE-ADJUSTED EPOCH (ETOPOSIDE + PREDNISONE + VINCRISTINE + CYCLOPHOSPHAMIDE + DOXORUBICIN) + INTRATHECAL MTX + RITUXIMAB (CYCLES 1&2) - DAY 1; RITUXIMAB 375MG/M2 IV, DAYS 1-4; ETOPOSIDE 50MG/M2 CONTINUOUS IV INFUSION + DOXORUBICIN 10MG/M2 CONTINUOUS IV INFUSION + VINCRISTINE 0.4MG/M2 CONTINUOUS IV INFUSION, DAYS 1-5; PREDNISONE 60MG/M2 ORALLY TWICE DAILY. DAY 5; CYCLOPHOSPHAMIDE 750MG/M2 IV, DAY 6; G-CSF 300uG ADMINISTERED UNTIL ANC >5, 000CELLS/uL MEDICAL ONCOLOGY 28100 28100 28100 28100 28100 28100 28100 28100
2538 CMU0976 A-III-iv-c-2 : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - DOSE-ADJUSTED EPOCH (ETOPOSIDE + PREDNISONE + VINCRISTINE + CYCLOPHOSPHAMIDE + DOXORUBICIN) + INTRATHECAL MTX + RITUXIMAB (CYCLES 3-6) - DAY 1; RITUXIMAB 375MG/M2 IV, DAYS 1-4; ETOPOSIDE 50MG/M2 CONTINUOUS IV INFUSION + DOXORUBICIN 10MG/M2 CONTINUOUS IV INFUSION + VINCRISTINE 0.4MG/M2 CONTINUOUS IV INFUSION, DAYS 1-5; PREDNISONE 60MG/M2 ORALLY TWICE DAILY. DAY 5; CYCLOPHOSPHAMIDE 750MG/M2 IV, DAY 6; G-CSF 300uG ADMINISTERED UNTIL ANC >5, 000CELLS/uL DAYS 1 AND 5; METHOTREXATE 12MG INTRATHECALLY. REPEAT CYCLE EVERY 3 WEEKS FOR 6 CYCLES MEDICAL ONCOLOGY 27700 27700 27700 27700 27700 27700 27700 27700
2539 CMU0976 A-III-iv-d-1 : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 1 AND 3) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY DAYS 1 AND 11 - RITUXIMAB 375MG/M2 IV MEDICAL ONCOLOGY 62400 62400 62400 62400 62400 62400 62400 62400
2540 CMU0976 A-III-iv-d-2 : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 2 AND 4) - HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES DAYS 2 AND 8 - RITUXIMAB 375MG/M2 IV MEDICAL ONCOLOGY 65000 65000 65000 65000 65000 65000 65000 65000
2541 CMU0976 A-III-iv-d-3 : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 5 & 7) - DAYS 1 - 3 - CYCLOPHOSPHAMIDE 300MG/M2 IV EVERY 12 HOURS FOR 6 DOSES + MESNA 600MG/M2 CONTINUOUS IV INFUSION DAYS 4 AND 11 - VINCRISTINE 2MG IV DAY 4 - DOXORUBICIN 50MG/M2 IV DAYS 1 - 4 AND DAYS 11 - 14 - DEXAMETHASONE 40MG IV DAILY MEDICAL ONCOLOGY 11500 11500 11500 11500 11500 11500 11500 11500
2542 CMU0976 A-III-iv-d-4 : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - HYPERCVAD (CYCLOPHOSPHAMIDE + VINCRISTINE + DOXORUBICIN + DEXAMETHASONE ALTERNATING WITH HIGH-DOSE METHOTREXATE AND CYTARABINE) (CYCLES 6 & 8) - HIGH - DOSE MTX AND CYTARABINE DAY 1 - MTX 1G/M2 IV OVER 24 HOURS DAYS 2 AND 3 - CYTARABINE 3G/M2 IV EVERY 12 HOURS FOR 4 DOSES MEDICAL ONCOLOGY 13600 13600 13600 13600 13600 13600 13600 13600
2543 CMU0976 A-III-iv-e-1 : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) WITH OR WITHOUT RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES DAYS 1-5; PREDNISONE 100MG ORALLY DAILY, +/- DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION. MEDICAL ONCOLOGY 22800 22800 22800 22800 22800 22800 22800 22800
2544 CMU0976 A-III-iv-e-2 : NON HODGKINS LYMPHOMA - AIDS-RELATED B-CELL LYMPHOMAS - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION. MEDICAL ONCOLOGY 3000 3000 3000 3000 3000 3000 3000 3000
2545 CMU0976 A-III-v : NON HODGKINS LYMPHOMA - PRIMARY CUTANEOUS MARGINAL ZONE OR FOLLICLE CENTER LYMPHOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2546 CMU0976 A-III-v-a-1 : NON HODGKINS LYMPHOMA - PRIMARY CUTANEOUS MARGINAL ZONE OR FOLLICLE CENTER LYMPHOMA - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) WITH OR WITHOUT RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION. MEDICAL ONCOLOGY 22800 22800 22800 22800 22800 22800 22800 22800
2547 CMU0976 A-III-v-a-2 : NON HODGKINS LYMPHOMA - PRIMARY CUTANEOUS MARGINAL ZONE OR FOLLICLE CENTER LYMPHOMA - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION. MEDICAL ONCOLOGY 3000 3000 3000 3000 3000 3000 3000 3000
2548 CMU0976 A-III-v-b : NONHODGKINS LYMPHOMA - PRIMARY CUTANEOUS MARGINAL ZONE OR FOLLICLE CENTER LYMPHOMA - RITUXIMAB - DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT EVERY 7 DAYS FOR 4 WEEKS MEDICAL ONCOLOGY 21700 21700 21700 21700 21700 21700 21700 21700
2549 CMU0976 A-III-vi : NON HODGKINS LYMPHOMA - FOLLICULAR LYMPHOMA (GRADE 1-2) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2550 CMU0976 A-III-vi-a-1 : NON HODGKINS LYMPHOMA - FOLLICULAR LYMPHOMA (GRADE 1-2) - BENDAMUSTINE WITH OR WITHOUT RITUXIMAB - DAY 1; RITUXIMAB 375MG/M2 IV, DAYS 1 AND 2; BENDAMUSTINE 90MG/M2 IV. REPEAT CYCLE EVERY 28 DAYS FOR 6 TO 8 CYCLES MEDICAL ONCOLOGY 31100 31100 31100 31100 31100 31100 31100 31100
2551 CMU0976 A-III-vi-a-2 : NON HODGKINS LYMPHOMA - FOLLICULAR LYMPHOMA (GRADE 1-2) - BENDAMUSTINE (-) RITUXIMAB DAYS 1 AND 2; BENDAMUSTINE 90MG/M2 IV. REPEAT CYCLE EVERY 28 DAYS FOR 6 TO 8 CYCLES MEDICAL ONCOLOGY 13100 13100 13100 13100 13100 13100 13100 13100
2552 CMU0976 A-III-vi-b-1 : NON HODGKINS LYMPHOMA - FOLLICULAR LYMPHOMA (GRADE 1-2) - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) WITH OR WITHOUT RITUXIMAB - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION. MEDICAL ONCOLOGY 22800 22800 22800 22800 22800 22800 22800 22800
2553 CMU0976 A-III-vi-b-2 : NON HODGKINS LYMPHOMA - FOLLICULAR LYMPHOMA (GRADE 1-2) - CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE + PREDNISONE (CHOP) - DAY 1; CYCLOPHOSPHAMIDE 750MG/M2 OVER 60 MINUTES + DOXORUBICIN 50MG/M2 IV PUSH + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES DAYS 1-5; PREDNISONE 100MG ORALLY DAILY. REPEAT CYCLE EVERY 3 WEEKS FOR 3-4 CYCLES WITH SUBSEQUENT RADIATION OR 6-8 CYCLES WITHOUT SUBSEQUENT RADIATION. MEDICAL ONCOLOGY 3000 3000 3000 3000 3000 3000 3000 3000
2554 CMU0976 A-III-vi-c : NONHODGKINS LYMPHOMA - FOLLICULAR LYMPHOMA (GRADE 1-2) - CYCLOPHOSPHAMIDE + VINCRISTINE + PREDNISONE + RITUXIMAB (RCVP) - DAY 1;RITUXIMAB 375MG/M2 IV, CYCLOPHOSPHAMIDE 750MG/M2 OR 1, 000MG/M2 OVER 60 MINUTES + VINCRISTINE 1.4MG/M2 (MAXIMUM 2MG) IV OVER 5-10 MINUTES, DAYS 1-5; PREDNISONE 40MG/M2 ORALLY DAILY, REPEAT CYCLE EVERY 3 WEEKS FOR 8 CYCLES MEDICAL ONCOLOGY 22000 22000 22000 22000 22000 22000 22000 22000
2555 CMU0976 A-III-vi-d : NONHODGKINS LYMPHOMA - FOLLICULAR LYMPHOMA (GRADE 1-2) - RITUXIMAB - DAY 1; RITUXIMAB 375MG/M2 IV. REPEAT EVERY 7 DAYS FOR 4 WEEKS MEDICAL ONCOLOGY 21700 21700 21700 21700 21700 21700 21700 21700
2556 CMU0976 A-III-vi-e : NONHODGKINS LYMPHOMA - FOLLICULAR LYMPHOMA (GRADE 1-2) - LENALIDOMIDE + RITUXIMAB - DAYS 1-21; LENALIDOMIDE 25MG ORALLY DAILY, RITUXIMAB -APPLIED SEPARATELY ON DAYS 1, 8, 15, AND 22 AS AN ADDON MEDICAL ONCOLOGY 5800 5800 5800 5800 5800 5800 5800 5800
2557 CMU0976 A-III-vii : NONHODGKINS LYMPHOMA - EXTRANODAL NK/T-CELL LYMPHOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2558 CMU0976 A-III-vii-a : NON HODGKINS LYMPHOMA - EXTRANODAL NK/T-CELL LYMPHOMA - SMILE - DAY 1; METHOTREXATE 2G/M2 IV, DAYS 2-4; DEXAMETHASONE 40MG IV OR ORALLY + LEUCOVORIN 15MG × 4 DOSES/DAY IV OR ORALLY + IFOSFAMIDE 1500MG/M2 IV + ETOPOSIDE 100MG/M2 IV, DAYS 8, 10, 12, 14, 16, 18, AND 20; L-ASPARAGINASE 6000U/M2 IV. REPEAT EVERY 21 DAYS FOR 3 CYCLES. MEDICAL ONCOLOGY 28900 28900 28900 28900 28900 28900 28900 28900
2559 CMU0976 A-III-vii-b : NON HODGKINS LYMPHOMA - EXTRANODAL NK/T-CELL LYMPHOMA - DEVIC +RT - DAY 1; CARBOPLATIN 300MG/M2, DAYS 1-3; DEXAMETHASONE 40MG IV + ETOPOSIDE 100MG/M2 IV + IFOSFAMIDE 1.5MG/M2. REPEAT CHEMOTHERAPY EVERY 3 WEEKS FOR 3 CYCLES. RADIATION 50GY AND 3 COURSES OF DEVIC MEDICAL ONCOLOGY 9600 9600 9600 9600 9600 9600 9600 9600
2560 CMU0976 A-III-vii-c : NON HODGKINS LYMPHOMA - EXTRANODAL NK/T-CELL LYMPHOMA - VIPID - DAYS 1-3; ETOPOSIDE 100MG/M2 IV OVER 90 MINUTES + IFOSFAMIDE 1200MG/M2 IV OVER 1 HOUR + CISPLATIN 33MG/M2 IV OVER 1 HOUR + DEXAMETHASONE 40MG ORALLY OR IV. REPEAT CHEMOTHERAPY EVERY 3 WEEKS FOR 3 CYCLES MEDICAL ONCOLOGY 7000 7000 7000 7000 7000 7000 7000 7000
2561 CMU0976 A-II-j : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - CHLORAMBUCIL - DAYS 1-7; CHLORAMBUCIL 0.1MG/KG ORALLY DAILY OR 0.3MG/KG ORALLY DAILY. REPEAT EVERY 6 WEEKS. MEDICAL ONCOLOGY 1100 1100 1100 1100 1100 1100 1100 1100
2562 CMU0976 A-II-k : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - FLUDARABINE - DAYS 1-5; FLUDARABINE 25MG/M2 IV DAILY. REPEAT EVERY 4 WEEKS FOR 5-6 CYCLES MEDICAL ONCOLOGY 12700 12700 12700 12700 12700 12700 12700 12700
2563 CMU0976 A-II-l : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - FLUDARABINE + CYCLOPHOSPHAMIDE + RITUXIMAB (FCR) - DAY 1; RITUXIMAB 375MG/M2 IV, DAYS 2-4; FLUDARABINE 25MG/M2/DAY IV +CYCLOPHOSPHAMIDE 250MG/M2/DAY IV. REPEAT CYCLE EVERY 28 DAYS FOR 6 CYCLES WITH MEDICAL ONCOLOGY 27600 27600 27600 27600 27600 27600 27600 27600
2564 CMU0976 A-II-m : WALDENSTROM'S MACROGLOBULINEMIA/ LYMPHOPLASMACYTIC LYMPHOMA - ALEMTUZUMAB - ALEMTUZUMAB DOSES GRADUALLY ESCALATED OVER 1 WEEK (3, 10, AND 30 MG), FOLLOWED BY 36 ADDITIONAL TREATMENT-PHASE INFUSIONS AT 30-MG IV 3 TIMES WEEKLY FOR 12 WEEKS. MEDICAL ONCOLOGY 2800 2800 2800 2800 2800 2800 2800 2800
2565 CMU0977 : MYELODYSPLASTIC SYNDROMES TREATMENT REGIMENS MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2566 CMU0977 -i : SYMPTOMATICANEMIA WITH DEL(5Q) WITH OR WITHOUT OTHER CYTOGENETIC ABNORMALITIES MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2567 CMU0977 -i-a : SYMPTOMATIC ANEMIA WITH DEL(5Q) WITH OR WITHOUT OTHER CYTOGENETIC ABNORMALITIES - LENALIDOMIDE MEDICAL ONCOLOGY 2700 2700 2700 2700 2700 2700 2700 2700
2568 CMU0977 -ii : SYMPTOMATICANEMIA WITHOUT DEL(5Q) AND SERUM ERYTHROPOIETIN =500MU/ML MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2569 CMU0977 -ii-a-1 : SYMPTOMATIC ANEMIA WITHOUT DEL(5Q) AND SERUM ERYTHROPOIETIN =500MU/ML - RHU-EPO WITH OR WITHOUT G-CSF MEDICAL ONCOLOGY 26300 26300 26300 26300 26300 26300 26300 26300
2570 CMU0977 -ii-a-2 : SYMPTOMATIC ANEMIA WITHOUT DEL(5Q) AND SERUM ERYTHROPOIETIN =500MU/ML - RHU-EPO (-) G-CSF MEDICAL ONCOLOGY 26000 26000 26000 26000 26000 26000 26000 26000
2571 CMU0977 -ii-b-1 : SYMPTOMATIC ANEMIA WITHOUT DEL(5Q) AND SERUM ERYTHROPOIETIN =500MU/ML - DARBEPOETIN ALFA WITH OR WITHOUT G-CSF MEDICAL ONCOLOGY 9800 9800 9800 9800 9800 9800 9800 9800
2572 CMU0977 -ii-b-2 : SYMPTOMATIC ANEMIA WITHOUT DEL(5Q) AND SERUM ERYTHROPOIETIN =500MU/ML - DARBEPOETIN ALFA (-) G-CSF MEDICAL ONCOLOGY 9500 9500 9500 9500 9500 9500 9500 9500
2573 CMU0977 -iii : SYMPTOMATIC ANEMIA WITHOUT DEL(5Q), SERUM ERYTHROPOIETIN >500MU/ML, UNLIKELY TO RESPOND TO IST MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2574 CMU0977 -iii-a-1 : SYMPTOMATIC ANEMIA WITHOUT DEL(5Q), SERUM ERYTHROPOIETIN >500MU/ML, UNLIKELY TO RESPOND TO IST - DECITABINE (15MG/M2) MEDICAL ONCOLOGY 16300 16300 16300 16300 16300 16300 16300 16300
2575 CMU0977 -iii-a-2 : SYMPTOMATIC ANEMIA WITHOUT DEL(5Q), SERUM ERYTHROPOIETIN >500MU/ML, UNLIKELY TO RESPOND TO IST - DECITABINE (20MG/M2) MEDICAL ONCOLOGY 17300 17300 17300 17300 17300 17300 17300 17300
2576 CMU0977 -iii-b : SYMPTOMATIC ANEMIA WITHOUT DEL(5Q), SERUM ERYTHROPOIETIN >500MU/ML, UNLIKELY TO RESPOND TO IST - LENALIDOMIDE MEDICAL ONCOLOGY 2700 2700 2700 2700 2700 2700 2700 2700
2577 CMU0978 : MULTIPLE MYELOMA MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2578 CMU0978 -a : MULTIPLE MYELOMA - LENALIDOMIDE (28 DAYS) + DEXAMETHASONE MEDICAL ONCOLOGY 7000 7000 7000 7000 7000 7000 7000 7000
2579 CMU0978 -b : MULTIPLE MYELOMA - LENALIDOMIDE (21 DAYS) + DEXAMETHASONE MEDICAL ONCOLOGY 5300 5300 5300 5300 5300 5300 5300 5300
2580 CMU0978 -c : MULTIPLE MYELOMA - LENALIDOMIDE MEDICAL ONCOLOGY 2700 2700 2700 2700 2700 2700 2700 2700
2581 CMU0978 -d : MULTIPLE MYELOMA - BENDAMUSTINE + LENALIDOMIDE + DEXAMETHASONE MEDICAL ONCOLOGY 14300 14300 14300 14300 14300 14300 14300 14300
2582 CMU0978 -e : MULTIPLE MYELOMA - BENDAMUSTINE MEDICAL ONCOLOGY 23100 23100 23100 23100 23100 23100 23100 23100
2583 CMU0978 -f : MULTIPLE MYELOMA - CYCLOPHOSPHAMIDE + LENALIDOMIDE + DEXAMETHASONE MEDICAL ONCOLOGY 5400 5400 5400 5400 5400 5400 5400 5400
2584 CMU0978 -g : MULTIPLE MYELOMA - DEXAMETHASONE + CYCLOPHOSPHAMIDE + ETOPOSIDE + CISPLATIN (DCEP) MEDICAL ONCOLOGY 6000 6000 6000 6000 6000 6000 6000 6000
2585 CMU0978 -h : MULTIPLE MYELOMA - DEXAMETHASONE + THALIDOMIDE + CISPLATIN + DOXORUBICIN + CYCLOPHOSPHAMIDE + ETOPOSIDE (DT-PACE) MEDICAL ONCOLOGY 8100 8100 8100 8100 8100 8100 8100 8100
2586 CMU0978 -i : MULTIPLE MYELOMA - HIGH-DOSE CYCLOPHOSPHAMIDE MEDICAL ONCOLOGY 5400 5400 5400 5400 5400 5400 5400 5400
2587 CMU0978 -j : MULTIPLE MYELOMA - VAD / VAMP MEDICAL ONCOLOGY 6400 6400 6400 6400 6400 6400 6400 6400
2588 CMU0978 -k : MULTIPLE MYELOMA - MELPHALAN MEDICAL ONCOLOGY 4100 4100 4100 4100 4100 4100 4100 4100
2589 CMU0978 -l : MULTIPLE MYELOMA - MELPHALAN + PREDNISOLONE MEDICAL ONCOLOGY 1200 1200 1200 1200 1200 1200 1200 1200
2590 CMU0978 -m : MULTIPLE MYELOMA - THALIDOMIDE + DEXAMETHASONE MEDICAL ONCOLOGY 2500 2500 2500 2500 2500 2500 2500 2500
2591 CMU0978 -n : MULTIPLE MYELOMA - MELPHALAN / PREDNISOLONE/THALIDOMIDE(MPT) MEDICAL ONCOLOGY 2400 2400 2400 2400 2400 2400 2400 2400
2592 CMU0978 -O : MULTIPLE MYELOMA - ZOLEDRONIC ACID MEDICAL ONCOLOGY 2900 2900 2900 2900 2900 2900 2900 2900
2593 CMU0979 : ALL LYMPHOMA SALVAGE CHEMO (PACKAGE 953 TO BE UTILISED) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2594 CMU0980 : CHILDHOOD B CELL LYMPHOMA VARIABLE REGIMEN (PACKAGE 953 TO BE UTILISED) MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
2637 CMU1010 : HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY MEDICAL ONCOLOGY 100000 100000 100000 100000 100000 100000 100000 100000
2638 CMU1011 : HYPERTHERMIC INTRAPERITONEAL CATHETER INSERTION MEDICAL ONCOLOGY 10000 10000 10000 10000 10000 10000 10000 10000
2645 CMU1018 : CHEMOPORT - DEVICE WITH ACESSORIES AND MAINTENCE MEDICAL ONCOLOGY 30000 30000 30000 30000 30000 30000 30000 30000
2647 CMU1020 : HEMATOLOGICAL AND ONCOLOGICAL EMERGENCIES ( SUPERIOR MEDIASTINAL SYNDROME, SUPERIOR VENA CAVA SYNDROME, HYPER LEUCOCYTOSIS, HYPERVISCOSITY DUE TO DYSPROTEINEMIA, VASO-OCCLUSIVE CRISIS) MEDICAL ONCOLOGY 30000 30000 30000 30000 30000 30000 30000 30000
2648 CMU1021 : TUMOURLYSIS SYNDROME ( DRUGS AND MANAGEMENT WITHOUT DIALYSIS) MEDICAL ONCOLOGY 20000 20000 20000 20000 20000 20000 20000 20000
2655 CMU1028 : INTRATHECAL CHEMOTHERAPY MEDICAL ONCOLOGY 5000 5000 5000 5000 5000 5000 5000 5000
3295 CM1419 : Acute lymphoblastic leukemia: Supportive care/ rehabilitation MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3296 CM1420 : Acute myeloid leukemia: Supportive care/ rehabilitation MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3297 CM1421 : Hodgkin Lymphoma (Favorable group): Supportive care/ rehabilitation MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3298 CM1422 : Hodgkin Lymphoma (unfavorable group): Supportive care/ rehabilitation MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3299 CM1423 : Non-Hodgkin Lymphoma: Supportive care/ rehabilitation MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3300 CM1424 : Retinoblastoma (Intraocular): supportive care/ rehabilitation MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3301 CM1425 : Retinoblastoma (extraocular): supportive care/ rehabilitation MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3302 CM1426 : Brain tumors: supportive care/ rehabilitation MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3303 CM1427 : Histiocytosis: supportive care/ rehabilitation MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3304 CM1428 : Bone tumors/soft tissue sarcomas : supportive care/ rehabilitation MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3305 CM1429 : Chronic Myeloid Leukemia : supportive care/ rehabilitation MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3306 CM1430 : Terminally IllPalliative And Supportive Therapy - Per month MEDICAL ONCOLOGY 0 0 0 0 0 0 0 0
3376 CM1419 A : Acute lymphoblastic leukemia: Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN MEDICAL ONCOLOGY 20000 20000 20000 20000 20000 20000 20000 20000
3377 CM1420 A : Acute myeloid leukemia: Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage MEDICAL ONCOLOGY 30000 30000 30000 30000 30000 30000 30000 30000
3378 CM1421 A : Hodgkin Lymphoma (Favorable group): Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN MEDICAL ONCOLOGY 15000 15000 15000 15000 15000 15000 15000 15000
3379 CM1422 A : Hodgkin Lymphoma (unfavorable group): Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN MEDICAL ONCOLOGY 25000 25000 25000 25000 25000 25000 25000 25000
3380 CM1423 A : Non-Hodgkin Lymphoma: Supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN MEDICAL ONCOLOGY 50000 50000 50000 50000 50000 50000 50000 50000
3381 CM1429 A : Chronic Myeloid Leukemia : supportive care/ rehabilitation - Blood & Blood Product transfusions / granulocyte colony-stimulating factor (G-CSF) / Granulocyte-macrophage colony-stimulating factor (GM-CSF) / TPN MEDICAL ONCOLOGY 20000 20000 20000 20000 20000 20000 20000 20000
3382 CM1430 A : Terminally Ill - Pain management (Opioid therapy / Neural Blocks / epidural or Intrathecal infusions / Antero-lateral spinal cordotomy (tractotomy) by RFA) / TPN - Per month MEDICAL ONCOLOGY 3000 3000 3000 3000 3000 3000 3000 3000

Say hello to us , Toll-Free

1800 425 3993

Write to us

[email protected]
[email protected]

Reach us At

The Project Director

Tamil Nadu Health Systems Project (TNHSP)
3rd Floor, DMS Annex New Building
259 Anna Salai, Teynampet
Chennai - 600 006, Tamil Nadu.

CMCHIS Project Office

Chief Minister's Comprehensive Health Insurance Scheme
No.226,Om Sakthi Towers,
Kilpauk Garden Road, Kilpauk,
Chennai-600010, Tamil Nadu

Scan QR Code or Click Here to Download the Mobile app for Beneficiary

Visitors Count : 26873 / 36268246